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General Introduction
Within the mammalian body, communication is essential for the regulation of all
physiological functions. Signaling from the extracellular environment to the cell’s
interior is conducted in most cases by cell surface receptors. The largest class of
membrane bound receptors consists of the Guanylyl-nucleotide-binding Protein-
Coupled Receptors, also known as the G protein-coupled receptors or GPCRs.
These GPCRs can be activated by a wide variety of ligands, such as ions, peptides,
hormones1, neurotransmitters, chemokines or odorants2. Not surprisingly, GPCRs
are currently the largest group of drug targets3. Membrane bound receptors consist of
a single polypeptide, arranged in 7 transmembrane (7TM) helices that are oriented
perpendicular to the membrane (Figure 1.1). Upon activation of the receptor by
agonist binding, the G protein binds to the receptor and induces an intracellular
signal via a second messenger, e.g. phospholipase A or C, or adenylyl cyclase. G
proteins consist of an , and subunit.
Currently, 16 , 5 and 14 isoforms
are known, implicating a great variety in
G proteins4. In the inactive state, the G
subunit contains guanosine-5’-
diphosphate (GDP) in its binding site.
Upon activation of the receptor, GDP is
exchanged for guanosine-5’-triphosphate
(GTP), leading to activation or inhibition
of a second messenger effector protein.
The GPCR superfamily can be divided into different sub-classes, based on similar
structural features. Class A receptors or rhodopsin-like receptors form the largest
sub-family, and share a series of conserved amino acid residues. Amongst others,
adenosine receptors are members of this Class A receptors5.
Adenosine receptors and their subtypes
Adenosine receptors are named after their endogenous ligand, adenosine, which is
widespread in the body with a basal concentration in the nM-M range (Figure 1.2)6.
Besides being a neuromodulator, adenosine is also acting as a local hormone. It has
a very short half-life (seconds) and is produced instantaneously when and where it is
needed7. Extracellularly, adenosine is formed by the breakdown of the abundantly
present ATP by 5’-ectonucleotidase.
In 1929, Drury and Szent-Györgi were the first to describe the actions of adenosine
on the heartbeat and arterial pressure8. Almost 50 years later Burnstock proposed
two types of receptors, P1 and P2, which could be distinguished by their preference
Figure 1.1. Structure GPCR
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for either adenosine or adenine nucleotides, respectively9. The P1 receptor was
subsequently divided into A1 (or Ri) and A2 (or Rs) adenosine receptors according to
their ability to either inhibit or stimulate the cAMP production, respectively10,11. In
1983, it was found that the A2 receptor showed high and low affinity binding sites in
the brain12. Accordingly, the adenosine A2 receptor was subdivided into A2A receptors
with a high affinity binding site (striatum) and A2B receptors with a low affinity binding
site (throughout the brain)13. The adenosine A1, A2A, and A2B receptors were
discovered with help of ´classical´ ligand pharmacology. In contrast, the existence of
the adenosine A3 receptor subtype was discovered with help of molecular biology
studies, and later confirmed with pharmacological experiments14,15.
Cloning
As molecular biological techniques evolved in the 90’s, all
adenosine receptor subtypes were individually cloned and
identified for a number of species. The adenosine A1 receptor
has been cloned from tissues from rat16, cow17, rabbit18,
mouse19, guinea pig20 and human21,22. Interestingly, a slight
(5%) difference in sequence homology between bovine and
human adenosine A1 receptors accounts for considerable
interspecies differences in ligand binding23. The adenosine
A2A receptor has been cloned from rat24,25, mouse19, guinea
pig26, and human tissues27. The rat adenosine A2B receptor
was cloned in 1992, and appeared to share only 50% sequence homology with the
rat adenosine A1 and A2A receptor28 which explained its different pharmacological
profile like a low affinity for the reference A2A receptor antagonist CGS21680. In
addition, human29, mouse19 and chicken30 adenosine A2B receptors have been cloned
as well. Whereas the existence of adenosine A1, A2A and A2B receptors was based on
pharmacological experiments and later confirmed by cloning of the respective genes,
the opposite was true for the adenosine A3 receptor. After cloning of this receptor
from rat testis14, its pharmacology was determined15. Subsequently, the A3 receptor
was also cloned from sheep31, rabbit32 and human33. The sequence homology
among adenosine A3 receptors from different species is rather low e.g. the rat
adenosine A3 receptor shows only 74% sequence homology with the human
receptor, which is also reflected in its pharmacology. For instance xanthine-based
antagonists have a high affinity for human and sheep A3 receptors but a much lower
affinity for rat A3 receptors34.
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structure of adenosine
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Occurrence of adenosine receptors
The different adenosine receptors are distributed widely in varying levels throughout
the body, thus explaining the plethora of effects of adenosine 35,36. The adenosine A1
receptor is highly expressed in the central nervous system (CNS) and adipocytes.
The adenosine A2A receptor is found mostly in the striatum, spleen, thymus,
leukocytes and blood platelets. The adenosine A2B receptor is expressed in low
levels in the brain, but can be found in high levels in the colon and bladder. The
adenosine A3 receptor is hardly expressed in the CNS, however, and in the periphery
the highest levels have been found in the lung and liver.
Receptor Structure
The cloning of all four adenosine receptor subtypes and alignment of the amino acid
sequences, revealed that the adenosine receptors indeed belong to the GPCR
superfamily, sharing the characteristic 7 transmembrane (TM) domain structure37,38.
The human adenosine A1, A2A, A2B, and A3 receptors consist of 326, 412, 332 and
318 amino acids, respectively21,27,31,32,39. The TM domains consist of α helices
containing 21 to 28 amino acids and are connected by three extracellular and three
intracellular hydrophobic loops. The A2A receptor is the only subtype with an
extraordinary long C-terminus of 122 amino acids, explaining its larger size
compared to the other adenosine receptor subtypes40. The N-terminus of each
protein is on the extracellular side, and the C-terminus is located on the cytoplasmic
side of the membrane. The αhelices are arranged in such a way that they form a
core for ligand binding. Certain conserved amino acids contribute to ligand specificity
within the binding pocket, e.g. Glu16 in TM1, Asp55 in TM241 and Thr27742 and
His27817 in TM7 (numbering according to the human adenosine A1 receptor).
Fusion proteins
Activation of G protein-coupled receptors results in an interaction of these receptors
with their respective G proteins. Since it is known that upon activation the Gαsubunit
also interacts with intracellular domains including the C-terminus of receptors,
constructs in which Gαsubunits are physically linked to the C-termini of receptors
have been prepared. One of the first fusion proteins, the2-adrenergic receptor fused
to its Gs-subunit, was prepared by Bertin et al. in 1994. This2- Gsfusion protein
was shown to be functional in both ligand binding and in cAMP experiments43. Since
then, many fusion proteins have been engineered between various receptors and
their G proteins44, e.g. the2A-adrenergic with Gi1or G0subunits45-47, the serotonin
5-HT1A receptor with Gi1or G0 subunits48-50, the opioid receptor with a Gi1
subunit51 and the adenosine A1 receptor with Gi1or G052-54.
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Milligan and coworkers constructed nine different fusion proteins between the human
adenosine A1 receptor and different 351Cys-mutated Gi1 α-subunits. They used these
fusion proteins to investigate the ternary complex formation between agonist,
receptor and G protein, and also demonstrated that there is no selectivity for any
particular adenosine A1 receptor – Gi1/G0combination, using different agonists52,53.
Next to these G protein-receptor fusion proteins, fusion proteins between different
receptors and fluorescent tags have been prepared to visualize the receptor. In 1997,
Barak et al. were among the first to equip a GPCR with a fluorescent probe. They
tagged the β2-adrenergic receptor with a green fluorescent protein (β2R-GFP),
providing a tool to study intracellular trafficking and surface mobility of a functionally
intactβ2-adrenergic receptor55.
Concerning adenosine receptors, the human adenosine A2A receptor was recently C-
terminally tagged with the green fluorescent protein (GFP) by Niebauer et al. This
provided an easy and useful tool to investigate the expression levels over time of the
adenosine A2AR expressed in yeast56.
Desensitization and Internalization
Desensitization is generally defined as the phenomenon in which previous or
continued exposure of receptor to agonist results in a diminished functional response
of the receptor upon prolonged agonist treatment. Signal duration, intensity or quality
is attenuated upon receptor desensitization. This does not necessarily mean that the
receptor will disappear from the plasma membrane, it can remain their in the inactive
state. Desensitization of a signal can occur at different levels of the signal
transduction cascade, thereby terminating cellular responses. The process of
desensitization follows a series of sequential steps. For most receptors,
desensitization is initiated by the phosphorylation of serine and threonine residues in
the third intracellular loop and C-terminus of the receptor. Subsequently, the
phosphorylated receptors recruit the protein β-arrestin, which sterically inhibits G
protein coupling and is also able to target the receptor to clathrin coated pits for
internalization. During internalization, the receptor moves away from the plasma
membrane and is targeted to endosomes or lysosomes, depending on which β-
arrestin is attracted. Upon internalization, receptors can either be rapidly recycled to
the plasma membrane, targeted to larger endosomes and slowly recycled, or
degraded in lysosomes57,58.
The adenosine receptor subtypes display different rates of desensitization. For
example, adenosine A1 receptors are not (readily) phosphorylated and internalize
slowly which takes several hours. At the other extreme, adenosine A3 receptors
which are also Gi-coupled, require only a few minutes to internalize. The A2A and A2B
receptors, which are both Gs-coupled, show a fast downregulation with kinetics
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usually less than 1h for short-term desensitization. Apparently, receptor trafficking is
regulated via different pathways, which are specific for receptor type, cell type,
metabolic state of the cell, cell-specific factors etc59.
Agonists for the adenosine A1 receptor: traditional and non-ribose agonists.
As mentioned before, adenosine is the endogenous
ligand for all adenosine receptor subtypes. Adenosine is
composed of a purine group linked to a ribose moiety,
see Figure 1.2. Examples of potent and selective
adenosine A1 agonists are: N6-cyclopentyladenosine
(CPA), 2-chloro-N6-cyclopentyladenosine (CCPA), N6-
cyclohexyladenosine (CHA), (R)-N6-(2-
Phenylisopropyl)adenosine (R-PIA) and N6-cyclopentyl-
2-(3-phenylaminocarbonyltriazene-1-yl)adenosine
(TCPA). All these prototypic A1 receptor agonists are
based on the endogenous ligand adenosine, and the
ribose group of adenosine has long been considered
essential for agonistic activity on adenosine receptors. However, Rosentreter et al.,
(2003, 2004) recently described a new class of adenosine receptor ligands, the 2-
amino-4-(3,4 substituted phenyl)-6-(2-hydroxyethylsulfanyl)-pyridin-3,5-
dicarbonitriles, displaying significant affinity and efficacy towards different adenosine
receptor subtypes60-62. One of those new, non-adenosine compounds, LUF5834
(Figure 1.3), was characterized as a full agonist for the human adenosine A1 receptor
with a very high affinity comparable to the Ki, high-value of CPA (2.2 nM), and as a
partial agonist for the A2B receptor with high affinity63. Another non-adenosine
compound, LUF5831, appeared to be a partial agonist with an affinity of 18 1 nM
for the adenosine A1 receptor64. From this study it also appeared that allosteric
modulators such as PD81,723 and GTP seem to have no or much less effect on the
binding of LUF5831 than they have on the binding of the traditional adenosine
analogue CPA64. We have further investigated the properties of promising non-ribose
agonists which have revealed some remarkable novel features.
Allosteric Modulation
The ligand binding site of the endogenous receptor ligands is also referred to as the
orthosteric binding site. Next to such an orthosteric modulation more recently
allosteric modulation of receptors was discovered. The term ‘allosteric modulation’
with respect to receptor binding, was first mentioned in literature in the early
eighties65. The word ‘allosteric’ is derived from Greek and composed of two words:
‘allo’ and ‘stere’ which literally mean ‘other’ and ‘site’ or ‘shape’. Allosteric modulation
Figure 1.3. Structure of
LUF5834, one of the non-
adenosine compounds
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is thus achieved by adding compounds which act on a site of the receptor distinct
from the orthosteric binding site, thereby inducing a conformational change of the
receptor (Figure 1.4). Allosteric modulators for the adenosine receptors have been
described in literature. Amiloride analogues and sodium ions were demonstrated to
be common allosteric modulators for at least three subtypes of the adenosine
receptors, A1, A2A, and A366. Next to these non-selective allosteric modulators also
subtype selective modulators have been identified. The most well-known selective
allosteric modulator is probably PD81,723, a benzoylthiophene derivative. It was
demonstrated that several benzoylthiophene derivatives were selective enhancers of
agonist binding to the
adenosine A1 receptors,
with little or no effect on
other adenosine
receptor subtypes.
Allosteric enhancers at
the adenosine A1
receptor have received
attention as anti-
arrhythmic and anti-
lipolytic agents. In
addition, they may also
have therapeutic
potential as analgesics and neuroprotective agents67. Allosteric modulation of A2AR
has so far only been described for the already mentioned sodium ions and amiloride
analogues. In 2004, Van den Nieuwendijk et al, described a class of small organic
molecules, 2,3,5-substituted [1,2,4]thiadiazoles, that seemed to allosterically
modulate the A2AR68. However, investigation of the mechanism of action of these
compounds revealed that they acted as sulfhydryl modifiers rather than as allosteric
modulators of the receptor69. Recently, two classes of A3 AR allosteric modulators
were characterized: 3-(2-pyridinyl)isoquinolines (e.g. VUF5455) and 1H-imidazo-[4,5-
c]quinolin-4-amines (e.g. DU124183), which selectively decrease the agonist
dissociation rate at the human A3AR but not at A1- and A2AARs. Allosteric enhancers
for the adenosine A3 receptors may be useful against ischemic conditions70. At this
moment, allosteric modulators for adenosine receptors receive increasing interest
and as described above may have therapeutic advantages over orthosteric ligands71.
Therapeutic potential of adenosine A1 receptor regulation
As mentioned, the adenosine A1 receptor is abundantly expressed in the brain with
the highest levels in the hippocampus and the cerebral cortex. In addition, the
Figure 1.4. Schematic representation of the mechanism of allosteric
modulation. OL = orthostheric ligand, AM = allosteric modulator.
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adenosine A1 receptor is widely distributed and expressed at varying levels
throughout the body, e.g. vas deferens, testis, white adipose tissue, stomach, spleen,
adrenal gland, heart, aorta, liver, eye and bladder. Lower levels were found in the
lung, kidney and small intestine72-74. In view of this broad distribution pattern, many
therapeutic applications of adenosine A1 receptor compounds have been proposed.
For example, adenosine A1 agonists or the high release of adenosine during cerebral
ischaemia have been shown to reduce neuronal damage in cerebral ischaemia by
inhibiting glutamate release75. These findings provide hope for the treatment of
neurological disorders observed in Huntington’s disease and Alzheimer76. Next to the
neuroprotective effects of adenosine A1 receptor activation in the central nervous
system, also sedation, decreased locomotor activity and anticonvulsant effects have
been observed. Compounds that are able to block the receptor from receiving its
endogenous ligand in the CNS (antagonists) may be beneficial to counteract the
sedation and negative locomotor effects of adenosine. Antagonists have also been
found to enhance cognition, leading to an improvement in memory performance77-79.
They may therefore be potentially useful in the treatment of neurological disorders
such as Alzheimer’s disease. The depth and levels of sleep are also dependent on
the amount of adenosine present in the brain. Furthermore, adenosine plays an
important role via adenosine A1 receptors in analgesia in the periphery and at spinal
sites. The expression of the adenosine A1 receptor on atrial tissue suggests a role for
this receptor in cardiovascular diseases. Activation of adenosine A1 receptors was
demonstrated to play a protective role upon myocardial ischaemia and subsequent
reperfusion80. Patients with congestive heart failure often suffer from fluid retention
caused by elevated adenosine levels in the kidneys. Administration of A1 antagonists
prevents renal failure and increases the urine flow in these patients81.
The Scope and Content
In the previous paragraphs, an introduction into the history, occurrence, functioning,
trafficking and therapeutic potential of adenosine receptors and in particular the
adenosine A1 receptors was given. In earlier work we have demonstrated our ability
to design selective adenosine A1 receptor ligands with high affinity. Moreover, we
extended this ligand repertoire to include allosteric modulators and non-ribose
agonistic ligands. In this thesis we have expanded our knowledge space by
investigating the interaction of these compounds with the adenosine receptors in
more detail. To study in addition the role of these compounds in novel concepts such
as constitutive activity and trafficking we have applied recombinant DNA techniques,
among others to construct fusion proteins that can serve as tracers. In chapter 2, the
state of affairs is established with a review of the current literature concerning the
desensitization and internalization of adenosine receptors. Results from in vitro, ex
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vivo and in vivo studies are summarized, followed by the molecular mechanisms
involved in adenosine receptor desensitization and internalization. The role of
accessory proteins and the influence of receptor mutations are also taken into
account.
In chapters 3 and 4, the use of fusion proteins between the human adenosine A1
receptors and Giα-subunits or a yellow fluorescent protein as tools to investigate
inverse agonism or receptor trafficking is described, respectively. Furthermore, we
analysed if these constructs were still subject to allosteric modulation54,82. In Chapter
5, 6 and 7, the structure-activity relationships of differently substituted 2-amino-4-
(substituted)phenyl-6-(substituted)sulfanyl-pyridine-3,5-dicarbonitriles are reported.
These series of compounds display a wide variety of intrinsic efficacies, ranging from
inverse agonists, to partial agonists and very potent full agonists. I present the first
evidence that the properties of these non-adenosine agonists are very different from
the traditional agonists for the adenosine A1 receptor concerning allosteric
modulation and internalization.
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Chapter 2
Desensitization and Internalization of
Adenosine Receptors
Until now, more than 800 distinct GPCRs are identified in the human genome. The
four subtypes of the adenosine receptor (A1-, A2A-, A2B- and A3 receptor) belong to
this large family of GPCRs that represent the most widely targeted pharmacological
protein class. Since adenosine receptors are widespread throughout the body and
involved in a variety of physiological processes and diseases, there is great interest
in understanding how the different subtypes are regulated, as a basis for designing
therapeutic drugs that either avoid or make use of this regulation. The major GPCR
regulatory pathway involves phosphorylation of activated receptors by G protein-
coupled receptor kinases (GRKs), a process that is followed by binding of arrestin
proteins. This prevents receptors from activating downstream heterotrimeric G
protein pathways, but at the same time allows activation of arrestin-dependent
signaling pathways.
Upon agonist treatment, adenosine receptor subtypes are differently regulated. For
instance, the A1Rs are not (readily) phosphorylated and internalize slowly, showing a
typical half-life of several hours, whereas the A2AR and A2BR undergo much faster
downregulation, usually shorter than 1 hour. The A3R is subject to even faster
downregulation, often a matter of minutes. The fast desensitization of the A3R after
agonist exposure may be therapeutically equivalent to antagonist occupancy of the
receptor. This review describes the process of desensitization and internalization of
the different adenosine subtypes in cell systems, tissues and in vivo studies. In
addition, molecular mechanisms involved in adenosine receptor desensitization are
discussed.
Based upon Klaasse EC, IJzerman AP, de Grip WJ, Beukers MW., Purinergic
Signal., 2008, 4:21-37.
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Introduction
Adenosine is an important neuromodulator involved in a variety of brain activities and
it also serves many different functions in the periphery. This nucleoside, when
extracellular, exerts its action via specific G protein-coupled receptors (GPCRs) of
the P1 class, divided in four subtypes: A1R, A2AR, A2BR and A3R1. GPCRs consist of
a single polypeptide, containing 7 -helices which are oriented perpendicular to the
membrane. The N-terminus is located at the extracellular side of the cell and often
contains one or more glycosylation sites. The C-terminus is located intracellularly and
contains phosphorylation and palmitoylation sites, which are involved in regulation of
receptor desensitization and internalization2. All adenosine receptors, with the
exception of the A2AR, contain a palmitoylation site near the C-terminus. The A2AR is
the only subtype with an extraordinary long C-terminus, 122 amino acids versus 36
amino acids in e.g. the A1R3. All the adenosine receptors are glycosylated on the
second extracellular loop, although glycosylation does not appear to influence ligand
binding. The third intracellular loop and/or the C-terminus are involved in coupling the
adenosine receptors to G-proteins. Phosphorylation of in particular intracellular loop
3 is involved in desensitization and internalization of adenosine receptors4,5,6.
Adenosine and analogues
Adenosine, consisting of a purine ring connected to a ribose group, is the
endogenous ligand for the adenosine receptors (Figure 2.1). Under normal
conditions, adenosine is continuously formed extracellularly by dephosphorylation of
ATP, ADP and/or AMP to adenosine by NTPDases (ecto-nucleoside triphosphate
diphosphohydrolases). However, the A3R can also be activated by inosine, a
breakdown product from adenosine5. Most adenosine receptor agonists are
analogues of adenosine, modified by N6, C2 and C8 substitutions at the adenine
base, and C5’ modifications of the
ribose moiety5,6. Antagonists lack the
ribose group and usually possess a
mono-, bi- or tricyclic core-structure,
e.g. caffeïne, which contains a
xanthine as basic structure (Figure
2.1). For extended reviews on high
affinity agonists and antagonists for
adenosine receptors and their
structure-activity relationships, see
Palmer and Stiles1, Fredholm et al.5,
Jacobson and Gao7, Beukers et al.8,
Müller9 and Klotz10.
Figure 2.1. Chemical structures of the endogenous
ligand adenosine and the antagonist caffeine.
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Occurrence and Physiological functions of adenosine receptors
The adenosine receptors are widespread throughout the body, and exert many
different functions both in the CNS and in the periphery.
The A1R is particularly prevalent in the central nervous system, with high levels in the
cerebral cortex, hippocampus, cerebellum, thalamus, brain stem and spinal cord.
Numerous peripheral tissues also express the A1R, including vas deferens, testis,
white adipose tissue, stomach, spleen, pituitary, adrenal gland, heart, aorta, liver, eye
and bladder. Low levels are found in the lung, kidney and small intestine1,5,6. The A1R
is involved in cardiovascular effects (e.g. reducing heart rate), inhibition of lipolysis
and stimulation of glucose uptake in white adipocytes and the modulation of
neurotransmitter release in the CNS1. The A1R also plays a role in anxiety,
hyperalgesia, bronchoconstriction and the glomerular filtration rate and renin release
in the kidney5,6,11.
In the CNS, the A2AR is highly expressed in the striatum and olfactory tubercle1. In
the periphery, it is highly expressed in the spleen, thymus, leukocytes and blood
platelets, and intermediate levels are found in the heart, lung and blood vessels5,6.
The A2AR is involved in the onset of vasodilation, inhibition of platelet aggregation,
exploratory activity, aggressiveness and hypoalgesia1. In addition, A2AR play a role in
Parkinson’s disease, Huntington’s disease, Alzheimer’s disease, ischemia,
attenuation of inflammation, and neuroprotection, particularly in peripheral tissues5,6.
A2A receptor antagonists slow the neurodegeneration which occurs in Parkinson’s-
and Huntington’s disease, and also prevent toxicity induced by beta-amyloid in the
development of Alzheimer’s disease12-14.
The A2BR is widely expressed in the brain, but generally at very low levels. In the
periphery, high levels of A2BR were detected in the cecum, large intestine and urinary
bladder. Lower levels were observed in the lung, spinal cord, vas deferens, pituitary,
adipose tissue, adrenal gland, kidney, liver and ovaries5,6. Since there is a lack of
specific agonists for the A2BR, little is known about the functional significance of this
receptor. However, the A2BR plays a role in mediating vasodilation in a.o. the aorta,
the renal artery and the coronary artery of different species. It is also involved in
allergic and inflammatory disorders5,6.
The A3R is expressed in the CNS, but at relatively low levels, and only the
hypothalamus and the thalamus have been reported to contain A3R15. The highest
levels of adenosine A3R have been found in lung and liver, and somewhat lower
levels were found in the aorta1. In addition, the A3R was found in eosinophils, mast
cells, testis, kidney, placenta, heart, spleen, uterus, bladder, jejunum, aorta, proximal
colon and eye, although with pronounced differences in expression level between
species5,6,16. The A3R has been implicated in mediating allergic responses, airway
inflammation and apoptotic events, however, the latter is dependent on the cell type
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involved and/or the type of activation5,16. Furthermore, the A3R is involved in the
control of the cell cycle and inhibition of tumour growth both in vitro and in vivo6. In
fact, adenosine A3 receptors have been demonstrated to be more highly expressed in
tumours than in healthy cells, suggesting a role for A3R as a tumour marker17.
Signal transduction of adenosine receptors
G protein-coupling and second messengers
Heterotrimeric G proteins are guanine-nucleotide regulatory protein complexes
composed of andsubunits. They are responsible for transmitting signals from G
protein-coupled receptors to effectors, e.g. adenylyl cyclase. Until now, 16 , 5 and
14 isoforms have been reported18. G proteins are divided in several subclasses with
a specific activity profile: Gs proteins stimulate adenylyl cyclase, Gi proteins inhibit
adenylyl cyclase and stimulate GIRK channels, G0 proteins stimulate K+ ion
channels, Gq/11 proteins activate phospholipase C, G12 proteins activate Rho
guanine-nucleotide exchange factors (GEFs) and the olfactory G protein, Golf,
stimulates adenylyl cyclase. Upon receptor activation, both the subunit and the 
subunit can signal, but to different effectors19-21. For a recent review on G proteins,
see Milligan and Kostenis18.
The A1R is usually coupled to a pertussis toxin-sensitive Giprotein, which mediates
inhibition of adenylyl cyclase and regulates calcium and potassium channels1,3,5,6,11.
Both the third intracellular loop and the C-terminal tail of the A1R are involved in Gi
coupling5. In addition, it has been reported that under certain conditions the A1R
couples to Gs to stimulate adenylyl cyclase, or to Gq/11 to stimulate inositol phosphate
production. Apparently, the specific activity state of the receptor or the nature of the
agonist determine which G protein class is activated by the A1R22,23. The A2AR in the
periphery is coupled to cholera toxin-sensitive Gsproteins, which increase adenylyl
cyclase activity upon receptor activation. The A2AR in the striatum is presumably
coupled to Golf5,6. The third intracellular loop, but not the C-terminus of the A2AR, is
involved in Gscoupling5. The A2BR is coupled to Gsproteins leading to stimulation
of adenylyl cyclase upon receptor activation6. There is quite some evidence that A2BR
can activate phospholipase C as well, via Gq/11 proteins5. The A3R is coupled to
pertussis toxin-sensitive Giproteins, which mediate inhibition of adenylyl cyclase. In
addition, A3R can stimulate phospholipase C via Gq/11 proteins5,6. For an extensive
overview of adenosine receptor G protein-coupling, see Fredholm et al.24.
Chapter 2
28
Desensitization and internalization – general principles and players
Mechanisms to dampen GPCR signaling exist at every level in the cell. In this
paragraph attention will be paid to the underlying principles of desensitization and
internalization and the protein partners involved in these processes.
Receptor localisation
Depending on the localisation signal, GPCRs in the plasma membrane can be
targeted to lipid rafts11or caveolae2. Different regions of GPCRs can influence not
only the targeting to either lipid rafts or caveolae but may also enable an interaction
of the receptor with constituents of these rafts and caveoli. For instance the
extracellular part of the receptor might interact with GM1 gangliosides
(glycosphingolipids) present in lipid rafts/caveoli. In addition, the C-terminal fatty acid
acylation or palmitoylation may also affect targeting of GPCRs to either lipid rafts or
caveoli. Finally, transmembrane regions may interact with cholesterol in the lipid rafts
resulting in a change in conformation of the -helices. Since the conformation of -
helices depends on the activation state of GPCRs, it may well be that agonist binding
to the receptor may affect its localisation in lipid rafts by means of molecular
transitions leading to receptor activation25,26.
Desensitization
Desensitization reduces receptor activity and plays a role in signal duration, intensity
and quality. Desensitization is initiated by phosphorylation of serine and/or threonine
residues in the third intracellular loop and C-terminus of the receptor. Two types of
desensitization occur, heterologous and homologous desensitization, and both are
the result of receptor phosphorylation. Heterologous desensitization is induced by
phosphorylation of the receptor by protein kinase A or C – sometimes even without
agonist occupancy. On the other hand, homologous desensitization is specific for
agonist-occupied receptors, and consists in most cases of two steps. Firstly, the
receptor is phosphorylated by one of the G protein-coupled receptor kinases (GRKs
1-7); then it binds to -arrestin, of which two subtypes exist, that exhibit high affinity
for agonist-occupied, phosphorylated receptors.-Arrestin serves to sterically inhibit
1 Lipid rafts are planar domains of 25-100 nm in cell membranes enriched in specific lipids and
proteins. They are in particular characterised by a high cholesterol and glycosphingolipid content in
the outer leaflet of the lipid bilayer that gives them a gel-like liquid-ordered organisation in comparison
with the surrounding phospholipid-rich disordered membrane26.
2 Caveolae are flask-shaped invaginations located at or near the plasma membrane with a 50-100 nm
diameter. They are considered to be a non-planar subfamily of lipid rafts. The shape and structural
organisation of caveolae are due to the presence of caveolin-1, -2 and -3, that self-assemble in high-
mass oligomers to form a cytoplasmic coat on the membrane invaginations25,26.
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the receptor to clathrin-coated pits32for internalization (Figure 2.2)19,25,27,28.
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igure 2.2. a) Homologous and b) heterologous desensitization and subsequent internalization of
PCRs. = Gisubunit,= Gisubunit, L = ligand, GRK = G protein-coupled receptor kinase, P =
hosphorylated amino acids, -arr =-arrestin, AP-2 adaptin, E = effector, second messenger, PKA =
rotein kinase A, PKC = protein kinase C.
nternalization
eceptor desensitization, initiated by phosphorylation of the receptor by different
rotein kinases (A or C) or GRKs, can be subsequently followed by receptor
nternalization. Upon phosphorylation, -arrestin 1 or 2 is attracted to the receptor31.
-Arrestins not only interact with the phosphorylated receptor, but also bind to the
eavy chain of clathrin, to the2-adaptin subunit of the clathrin adaptor protein AP-2,
Clathrin-coated pit is a specialized region of the cell surface that mediates the internalization of
xtracellular macromolecules and GPCRs. Coated pits derive their name from the presence of a
istinctive polygonal lattice that decorates the inner surface of the membrane. This lattice is composed
f multiple triskelion-shaped subunits that contain three clathrin heavy chains (180 kD) and three
lathrin light chains (30-40 kD) plus a family of associated poteins with molecular sizes of 50 kD and
10 kD [29,30].
a)
b)
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and to phosphoinositides. These interactions direct the phosphorylated receptor to
punctate clathrin-coated pits in the cell membrane, which are internalized by action of
the GTPase dynamin. Upon internalization, receptors can either be rapidly recycled
to the plasma membrane, targeted to larger endosomes and slowly recycled, or
degraded in lysosomes. The final destination of the internalized receptors largely
depends on the -arrestin subtype (1 or 2) that is recruited by the receptor upon
phosphorylation and the duration of -arrestin binding. In this way, internalization
may regulate receptor resensitization and contributes to a positive regulation of
receptor signalling19,25,31.
Internalization pathways
From internalization studies with several receptors, it appears that the internalization
pathway is specific for receptor type, cell type, metabolic state of the cell, cell-specific
factors etc. Receptor trafficking can be regulated in different ways (Figure 2.3): a) the
receptor resides mainly in lipid rafts/caveolae and enters the cell via this pathway by
default; b) the receptor is in lipid rafts, but leaves these upon agonist binding to be
internalized via clathrin-coated pits; c) the receptor moves into lipid rafts upon agonist
binding and is internalized via this pathway; d) the receptor moves into lipid rafts after
agonist binding to activate certain signalling events, but is eventually moved out of
the lipid rafts to be internalized via clathrin-coated pits. Internalization can even be
achieved via uncoated vesicles or by a combination of two or more of the afore
mentioned pathways. For example, 1-AR is internalized via both lipid rafts and
clathrin-coated pits. PKA phosphorylation directs 1-AR to a clathrin-coated pit,
whereas GRK phosphorylation directs the receptor to lipid raft-mediated
internalization19,25,26.
Desensitization and Internalization of Adenosine Receptors
31
Figure 2.3. Different internalization pathways, adapted from Chini and Parenti, 200425. Internalization
via a) lipid rafts/caveolae b) upon agonist binding, the receptor moves to clathrin-coated pits to be
internalized c) the receptor moves into lipid rafts upon agonist binding and is internalized d) the
receptor moves into lipid rafts upon agonist binding to activate certain signalling events, but is
eventually moved out to be internalized via clathrin-coated pits. Ligand (L, green triangle), clathrin-
coated pits (dotted blue lines) and lipid rafts (solid pink lines) are indicated.
Function of lipid rafts/caveolae
The existence of lipid rafts/caveolae serves different functions. First of all, lipid rafts
act as ‘stations’ in which GPCRs accomplish specific signalling tasks by meeting a
selected set of signalling molecules, e.g. G proteins and adenylyl cyclases. Another
possible function of lipid rafts is the protection of receptors from rapid constitutive or
agonist-induced internalization, thus allowing their coupling to specific signalling
pathways. In addition, caveolin may regulate the constitutive activity of receptors32.
Finally, the endocytic pathways that GPCRs choose may depend on cell-specific
factors. Switching the internalization pathway from lipid rafts/caveolae to clathrin-
coated pits may alter the final receptor destination19,25,26. Research on adenosine
receptors probably provided the first account of receptor internalization via caveolae
and lipid rafts, as alternative to the well described β-arrestin pathway33.
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G protein-coupled receptor kinases (GRKs)
Upon agonist binding to GPCRs, not only G proteins are recruited to the activated
receptor conformation, but also two other protein families, namely the G protein-
coupled receptor kinases (GRKs) and the -arrestins31. The GRK family consists of
seven different genes. The GRKs have been divided into three protein subfamilies,
based on sequence similarity. GRK1 and -7 belong together. The second subfamily
consists of GRK2 and -3 since their membrane recruitment depends on interaction
with Gsubunits and phosphatidylinositol 4,5-bisphosphate. GRK2 and -3 are
primarily responsible for agonist-dependent receptor phosphorylation, -arrestin
recruitment and functional uncoupling of the receptor. GRK4, -5 and -6 form the third
subfamily and are constitutively associated with the membrane. GRK1 and -7 are
expressed mainly in the retinal rods and cones, whereas GRK4 expression is limited
to the cerebellum, testis and kidney. In contrast, GRK2, -3, -5 and -6 are widely
expressed in mammalian tissues31.
-arrestins
-arrestins belong to the arrestin family of which four members have been identified.
Arrestin-1 and arrestin-4 are expressed in the visual system in retinal photoreceptor
cells; arrestin-2 (also called -arrestin1) and arrestin-3 (also called -arrestin2) are
more widely expressed and are involved in the regulation of nonvisual GPCRs. The
-arrestins were originally discovered as molecules that bind to and desensitize the
activated and phosphorylated form of G protein-coupled receptors as described
before19,25,27,28,31. The -arrestin protein consists of an N and a C domain, which are
almost entirely composed of antiparallel sheets, connected by a linker of 12 amino
acids. A ‘polar core’ is embedded between those two domains, and its disruption by
the phosphorylated C-terminus of the activated receptor leads to conformational
changes in the -arrestin. The C tail of the -arrestin is then released, exposing both
the clathrin and the AP2-binding domains. Recently, it appeared that -arrestins not
only are involved in the desensitization of G protein-coupled receptors, but also act
as signal transducer on their own. As a consequence, they emerge as multifunctional
adaptor/scaffold proteins which mediate cellular processes such as chemotaxis,
apoptosis and metastasis besides receptor signalling and trafficking. For an
extensive and recent review on the interactions of -arrestins with other cellular
proteins, see Lefkowitz et al.34.
GRKs and -arrestins orchestrate GPCR activities at three different levels: 1)
silencing: the functional uncoupling of the receptor from its G protein by a mechanism
known as ‘homologous desensitization’, 2) trafficking, which involves receptor
internalization, resensitization and/or degradation, 3) cross-signalling: activation or
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inhibition of intracellular signalling pathways, independent of heterotrimeric G
proteins31.
Dampening adenosine receptor signals
In this section we will discuss the evidence for and mechanisms of desensitization
and internalization of the four adenosine receptor subtypes. For each receptor we will
first summarize results from in vitro, ex vivo and in vivo studies. This will be followed
by a more biochemical approach in which we will focus on the molecular mechanisms
of adenosine receptor desensitization and internalization by paying attention to the
role of accessory proteins, the influence of receptor mutations, etc. We will refer to
earlier seminal publications, but mostly focus on more recent evidence for adenosine
receptor desensitization and internalization.
A1 receptor
Cellular and physiological studies
The early evidence for adenosine A1 receptor desensitization was largely obtained
from primary cells, cell lines, tissues or tissue slices, and intact animals that were
exposed to varying concentrations of adenosine receptor agonists (either A1-selective
or not), often examined over several time periods.
Stiles and co-workers were among the first to study A1 receptor desensitization in
detail (1991). Ramkumar et al. pretreated DDT1 MF-2 cells, a smooth muscle cell line
expressing both A1 and A2A receptors, with (R)-N6-(2-Phenylisopropyl)adenosine (R-
PIA) for up to 24 h, after which the adenylyl cyclase activity was reduced by approx.
50%. This was associated with a significant decrease in cell membrane-bound A1
receptors, and a concomitant increase of receptor number in intracellular
compartments. The authors also showed an increase in receptor phosphorylation,
nicely paralleling the time course of adenylyl cyclase modulation35. In a later study,
Nie et al. reported similar findings in the same cell line, although desensitization
occurred at a somewhat faster pace (4 h)36. Interestingly, Palmer et al. were unable
to demonstrate desensitization in CHO cells expressing the human A1R37. Klaasse et
al., however, were able to show internalization of the human A1R tagged with a C-
terminal yellow fluorescent protein (hA1YFP-R), stably expressed in CHO cells.
Exposure of these cells for 16 h to 400 nM or 4 M CPA resulted in 25% and 40%
receptor-internalization, respectively. Addition of 10 M of the allosteric enhancer
PD81,723 did not accelerate the internalization process, but lowered the threshold-
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concentration at which internalization occurred. Under those conditions a small
degree of internalization was observed already at a concentration of 40 nM CPA, and
at 400 nM CPA, 59% of the receptors internalized38.
Exposure of cerebellar granule cells, endogenously expressing A1R, to 100 nM R-PIA
for 2 to 48 h led to a blunting of the inhibition of adenylyl cyclase. Along with this
observation, a decrease of [3H]cyclohexyladenosine ([3H]CHA) binding to intact
cerebellar granule cells, and an increase of [3H]CHA binding in microsomes was
detected. Simultaneously, a decrease in the steady-state level of Gi in plasma
membrane and microsomes was observed. These findings point not only to
homologous desensitization, but also to subsequent internalization of the A1R in the
microsomal fraction of cerebellar granule cells upon long-term agonist exposure.
However, no change in mRNA level was observed, suggesting that post-
transcriptional regulation underlies receptor desensitization39.
In hippocampal neurons, A1R are present on both presynaptic and postsynaptic
terminals, as well as on the cell body and dendrites where they exert different
actions. To address the question whether desensitization was influenced by
subcellular localization, neurons were exposed to the agonist 2-chloroadenosine
(CADO, 20 M) from 2 up to 96 h. It was found that upon agonist exposure in
cultured hippocampal neurons, the presynaptic A1Rs desensitize less quickly (>12 h)
than the postsynaptic A1Rs (2 h). In accordance, the recovery of desensitized
presynaptic A1Rs also requires more time (48 h vs. 8 h for postsynaptic A1R).
Desensitization of the postsynaptic A1Rs apparently occurs at the level of the
receptor, because the other elements of the signal transduction machinery appeared
to be fully functional upon receptor desensitization. All in all, these results suggest
that the extent and the kinetics of agonist-induced desensitization of A1Rs depend on
the subcellular localization of the receptors40.
Using a more intact preparation, Coelho et al. found that the density of A1R in rat
hippocampal slices was decreased with 30% upon 60 min of imposed hypoxia. This
desensitization could be mimicked by adding the A1R agonist CADO (10 M) for 60
min, and was prevented by adding the A1R antagonist DPCPX. These results
suggest that hypoxia leads to an increase in extracellular adenosine levels, and a
subsequent, quite rapid (<90 min) desensitization, possibly followed by subsequent
internalization of the A1R in nerve terminals41.
Rat in vivo studies also demonstrated A1R desensitization. In a study by Parsons and
Stiles rats were chronically (6 d) infused with R-PIA. Examination of adipocyte
membranes of both treated and control rats revealed a 40% lower inhibition of
adenylyl cyclase in the treated animals, coinciding with a reduced number of A1Rs
(68% agonist-occupied receptors remaining) as determined by radioligand binding42.
Upon further study it was noticed that the effects on adenylyl cyclase were not A1R
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specific but were controlled at the level of adipocyte G proteins. G i levels appeared
downregulated, whereas the amount of Gs in the preparation was increased,
although not at the level of their mRNA, suggesting a heterologous form of
desensitization43.
Chronic exposure of rats to R-PIA (6 d) also led to A1R desensitization in the brain,
and subsequent reduced inhibition of adenylyl cyclase. This loss of response was
accompanied by a significant decrease in both total numbers of A1R and G iproteins
in synaptic plasma membranes in the brain, paralleling the finding by Stiles and co-
workers in adipocytes44. As a consequence, a significant increase of A1R was
observed in microsomes and coated vesicles, which suggested a role for coated
vesicles in the internalization of A1R. Similarly, chronic agonist exposure of rats to
NECA (6 d) resulted in a significant decrease of A1R in the high-affinity state in the
rat brain, however without changes in adenylyl cyclase activity or inhibition of the Gi
proteins45.
Molecular mechanisms
As discussed in the general introduction to this review, receptor posttranslational
modifications, receptor phosphorylation, recruitment of arrestins, and the formation of
clathrin-coated pits are elements of the molecular machinery of desensitization and
internalization. In addition, other potential protein partners in the two processes have
been studied for the various adenosine receptor subtypes, which will also be
discussed.
Effect of receptor posttranslational modifications on desensitization and/or
internalization
Gao et al. studied the effects of preventing palmitoylation of the A1R. It appeared that
the Cys309Ala mutation, thus removing the palmitoylation site of the human A1R, had
no effect on internalization46. These findings were later confirmed by Ferguson et
al.47.
GRKs and arrestins
A1R phosphorylation by GRKs has been subject to debate. Palmer et al. and
Ferguson et al. failed to demonstrate GRK-2 phosphorylation of A1R; in the latter
study it was found that nonphosphorylated A1R redistributes arrestin-3 from the
cytoplasm into punctate clusters at the plasma membrane37,47. Nie et al., however,
reported that within 1 hr of exposure of DDT1MF-2 cells to R-PIA, rapid translocation
of GRKs was observed from the cytosol to the cytoplasm36. In a further biochemical
approach with both purified receptor and GRK-2, a phosphorylated receptor was
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obtained that showed enhanced affinity for arrestins over G proteins. The same
receptor kinase, upon overexpression in FRTL-5 cells, influenced A1R signaling,
however, not via G iα-mediated adenylyl cyclase but through Giβγ-mediated MAP
kinase activation48. It may be concluded that under physiological conditions A1R
phosphorylation does not (readily) take place, which would be a rationale for the long
time periods required for receptor internalization.
Other protein partners
The ecto-enzyme adenosine deaminase (ADA) regulates the extracellular adenosine
concentration by converting excess adenosine into inosine. However, ADA also plays
a role in the desensitization and internalization of A1R in smooth muscle DDT1MF-2
cells49,50 and LLC-PK1 epithelial cells51, acting as a receptor activity modifying protein
(RAMP). Upon agonist exposure (100 nM R-PIA, 2h), ADA and A1R formed
complexes on the cell surface, clustered and internalized together to intracellular
compartments. Such clustering of adenosine A1 receptors prior to internalization was
also reported by Ciruela et al. and Saura et al.49,52.The intracellular vesicles
contained the lipid raft marker protein caveolin. Filipin, an agent that disrupts rafts or
caveolae, inhibited A1R internalization. In contrast, acidic treatment disrupting
clathrin-coated vesicles, did not inhibit agonist-induced internalization of A1R. These
results indicate that ADA and A1R form a stable complex in the cell membrane of
LLC-PK1 cells, internalizing upon agonist exposure via lipid rafts, in a clathrin-
independent pathway. Furthermore, a direct interaction of the C-terminus of A1R with
caveolin was demonstrated50. These and other data suggest that the mode of
receptor compartmentalisation in response to agonist stimulation may be governed
by both receptor subtype and cell type51.
Another accessory protein, the heat shock cognate protein 73 (hsc73), a member of
the hsp70 family, was identified as a cytosolic component able to interact with the
third intracellular loop of the A1R. The interaction between hsc73 (30 nM) and A1R
led to a marked reduction in affinity of ligands for the A1R and also prevented
activation of the G proteins, even more so than the addition of GTP analogues or
GTP itself (100 M). These effects were completely prevented by the addition of 25
nM ADA. A high percentage of A1R was coupled to hsc73 in cell lysate, according to
immunoprecipitation experiments. A remarkable feature upon internalization of the
receptor in DDT1MF-2 cells was found; A1Rs internalized via two different vesicle
types, one in which A1R and hsc73 are colocalized and another in which hsc73 was
absent. These observations open the possibility that signalling via GPCRs is
regulated at least to some extent by heat shock proteins53.
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Receptor-receptor interactions
Dunwiddie et al. found that activation of A3R with a selective A3R agonist resulted in
subsequent heterologous desensitization of the A1R, as observed in
electrophysiological experiments in the CA1 region of rat hippocampus. Similar
results were obtained after A3R occupancy via a brief superfusion with a high
concentration of adenosine54.
Lopes et al. investigated how activated A2AR influenced A1R function and whether
this interaction was modified in aged rats. In hippocampal and cortical nerve
terminals, the A2AR agonist CGS 21680 (30 nM) was able to lower the binding affinity
of the A1R selective agonist CPA, and this was taken as proof for A1R
desensitization. The effect was counteracted by the addition of the A2AR antagonist
ZM 241385 (20 nM). This reduction in A1R function could only be detected in young
adult rats (6 weeks), but not in old rats (24 months). The addition of a PKC inhibitor,
chelerythine (6 M), also prevented the desensitization of A1R55. Similarly, Ciruela et
al. (2006) demonstrated that A1R-A2AR heteromers were able to modulate the
glutamatergic neurotransmission in the rat striatum. The main biochemical
characteristic of this heteromer is the ability of the agonist-occupied A2AR to reduce
the agonist affinity of the A1R56.
By binding to cannabinoid CB1 receptors in Purkinje fibers in the cerebellum, 9-
tetrahydrocannabinol inhibits adenylyl cyclase and consequently motor coordination.
Long-term 9-tetrahydrocannabinol treatment resulted in CB1R downregulation,
desensitization of the Giprotein and desensitization of adenylyl cyclase. G protein
activation by A1R, however, was unaffected. Surprisingly, heterologous attenuation of
A1R-mediated inhibition of adenylyl cyclase was observed. These results indicate that
long-term 9-tetrahydrocannabinol administration produces a disruption of inhibitory
receptor control of cerebellar adenylyl cyclase and suggest a potential mechanism of
cross-tolerance to the motor effects of cannabinoid and A1 agonists57.
D1R and A1R have been shown to form functionally interacting heteromeric
complexes in engineered cell lines and in cortical neurons in culture. Pretreatment
with an A1R agonist caused complex formation of both receptors. Combined
pretreatment with selective agonists for both receptors (but not one agonist alone)
substantially reduced cAMP accumulation induced via the D1R, indicative for this
receptor’s desensitization58.
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A2A receptor
Cellular and physiological studies
DDT1 MF-2 cells, expressing both A1R and A2AR, were exposed to an A2A-selective
agonist, which resulted in a rapid loss (t1/2=45 min) of agonist-stimulated cAMP
production in these cells. This receptor desensitization, however, did not involve a
reduction in cell membrane receptor number or a change in ligand affinity35.
Prolonged exposure of PC12 cells, expressing both A2AR and A2BR, to AR agonists
led to a fast (30 min) and significant inhibition of A2AR stimulation by the A2AR-
selective agonist CGS21680. This effect appeared to occur at the level of adenylyl
cyclase, since no change was observed in receptor number or in CGS21680’s affinity
for the receptor. This conclusion was corroborated by the finding of reduced
activation of adenylyl cyclase by forskolin. Longer agonist exposure (12-20h) led to a
reduction of Gsαlevels, whereas no changes occurred in the short-term protocol59.
NG108-15 neuroblastoma x glioma hybrid cells express both A2AR and A2BR60,61.
Treatment of the cells with the non-selective agonist NECA followed by its washout,
led to a rapid (t1/2=20 min) and pronounced reduction in cAMP production by the
A2AR-selective agonist CGS21680 when compared to vehicle-treated cells.
Palmer et al. (1994) generated CHO cells solely expressing the recombinant (canine)
A2AR and examined the desensitization process of this receptor. Cells exposed to
NECA showed a rapid desensitization of A2AR-stimulated adenylyl cyclase activity
with no obvious difference between pretreatment of 30 min or 24 h. This was
associated with a slightly reduced affinity of the receptor for the A2AR-selective
radiolabeled agonist [3H]CGS21680. Cell surface receptor numbers only diminished
significantly (up to 40%) upon longer-term pretreatment (t1/2 = 8 h)62.
Using a tissue preparation, Conti et al. investigated whether prolonged exposure of
A2AR to the non-selective agonist NECA, or to the selective A2AR agonists
CGS21680 and 2HE-NECA, influenced A2AR desensitization. The authors used the
porcine coronary artery as a sensitive vascular model, expressing among others
A2ARs. The arteries were first precontracted by adding 3 M PGF. NECA,
CGS21680 and 2HE-NECA showed high affinities for the A2AR (EC50’s of 72, 40 and
20 nM respectively) inducing vasorelaxation. Next, coronary arteries were pretreated
with 10 M NECA for 30 min or 2 h. After a two hour washout period, the functional
response was assessed. It appeared that preincubation with NECA did not hamper
the vasorelaxing effects of CGS21680 and 2HE-NECA. However, NECA response
curves were shifted to the right after NECA pretreatment63. These results seem
inconclusive, since NECA pretreatment might ‘hit’ other adenosine receptor
subtypes.
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A2ARs, next to A1R, are present on presynaptic baroreceptor afferent terminals within
the nucleus tractus solitarius (NTS) in the brain64. It was observed that these A2AR
modulate 5-HT release as a mechanism of baroreflex control mediated by the NTS.
Low concentrations of the non-selective agonist NECA (0.3-3 nM), briefly exposed (5
min) to NTS brain slices, induced the release of 5-HT caused by the activation of the
A2AR present at presynaptic nerves. This effect could be blocked by the addition of
the adenosine A2AR antagonist 8-(3-chlorostyryl)caffeine (CSC; 100 nM). Longer
exposure of NECA (20 min) to the NTS slices resulted in inhibition of the 5-HT
release, probably caused by quick desensitization of the A2AR (15 min) and
subsequent involvement of the A1R65. These findings were corroborated in a similar
study with CGS21680, an A2AR-selective agonist66.
The effects on AR fate upon chronic agonist exposure were studied in vivo in rat
brain45. After 6 days of NECA treatment, the adenylyl cyclase activity in synaptic
plasma membranes was decreased, suggesting a desensitization of A2Rs, although
the authors did not specify or study which A2R subtype was involved. Gs protein
levels were decreased indicating Gs down-regulation as the mechanism of
desensitization.
Interestingly, Rekik and Mustafa (2003) showed that chronic antagonist treatment (3
days) of porcine coronary arteries with ZM241,385 led to a decreased agonist
responsiveness. Although A2A receptor expression went up, it appeared that the
levels of Gs had decreased, altogether leading to a functional desensitization of the
relaxing response by e.g. CGS2168067. It should be kept in mind that ZM241,385 is
also a potent antagonist for the adenosine A2B receptor.
Molecular mechanisms
Effect of receptor C-terminus on desensitization and/or internalization
To investigate the importance of the (120 amino acid residues) long C-terminus of
the A2AR receptor in inducing desensitization and internalization, Palmer and Stiles
introduced several mutations and deletions into the receptor tail. It appeared that
deletion of the last 95 amino acids of the C-terminus, containing 10 possible
phosphorylation sites, did not have any effect on radioligand binding, adenylyl
cyclase activity or desensitization kinetics compared to the wild-type A2AR. However,
when two possible phosphorylation sites (Thr 298 and Ser 305) just upstream the 95
deleted amino acids were mutated to Ala, short term (30 min) agonist-induced
desensitization was attenuated, while the long-term (24h) desensitization was not
affected. Single mutations revealed that mutation of Thr 298 alone was sufficient to
reduce receptor phosphorylation and agonist-induced short-term desensitization.
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This study also shows that short-term and long-term desensitization have distinct
structural requirements and do not occur via the same mechanism4.
GRKs and arrestins
Which GRK isoforms are involved in the phosphorylation of the A2AR is not entirely
clear yet. However, a putative role for GRK2 and/or GRK5 has been suggested4. The
role of GRK2 in agonist-induced phosphorylation and subsequent desensitization of
A2AR and A2BR was thoroughly investigated by Kelly and coworkers. Wild-type GRK2
was stably expressed in NG108-15 cells, which endogenously express A2AR and
A2BR. The acute stimulation of adenylyl cyclase by activation of A2AR was markedly
reduced in NG108-15 cells overexpressing wild-type GRK2. This was probably
caused by GRK2-dependent pre-desensitization of the A2AR by extracellular
adenosine. This effect could be reversed by pretreating the cells 24h with 0.5 unit/mL
ADA68. The same research group investigated the effect of a dominant-negative
GRK2 mutant on the desensitization of the A2AR60. Stable transfection of a
GRK2Lys220Arg mutant in NG108-15 cells reduced desensitization of the A2AR by
50% following a 30 min treatment with the adenosine agonist NECA.
TNF-αtreatment of human monocytoid THP-1 cells expressing the A2AR prevented
desensitization of this receptor, occurring under control conditions upon pretreatment
with CGS21680 or NECA69. It was discovered that the TNF-αtreatment prevented
GRK2 translocation to and decreased GRK2 association with the plasma membranes
of these cells as a consequence of the activation of a sphingomyelinase-dependent
pathway.
In another study, Mundell and Kelly investigated the effect of inhibitors of receptor
internalization on desensitization and resensitization of ARs in NG108-15 cells70.
Before agonist exposure, cells were pretreated with hypertonic sucrose or
concanavalin A, both inhibitors of internalization. This pretreatment did not affect the
agonist-induced desensitization of the A2AR. However, the resensitization of the A2AR
upon agonist removal was abolished in the presence of con A or sucrose.
Arrestins-2 and -3 have been implicated in the downstream desensitization process.
CGS21680 stimulation of a tagged A2AR transiently transfected in HEK293 cells
induced the translocation of GFP-tagged arrestins-2 and -3 towards the plasma
membrane. A dominant-negative arrestin-2 mutant inhibited agonist-induced
internalization71.
Other protein partners
The long C terminus of the A2AR has been coined a ‘coincidence detector’ as it
recognizes quite a number of other proteins such as α-actinin and ARNO, the Arf
nucleotide site opener (for a review see Gsandtner and Freissmuth72). α-Actinin may
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play a role in receptor internalization, not unlikely for a protein involved in cytoskeletal
arrangements71, however ARNO does not73.
Receptor-receptor interactions
The A2AR colocalizes with D2 dopamine receptors in the basal ganglia, and their
interaction has been documented on several occasions74. For instance, the protein-
protein interaction between A2AR-D2R was confirmed in HEK293T cells. The most
likely mode of interaction is that helix 5 and/or helix 6 and the N-terminal portion of I3
in the D2R approach helix 4 and the C-terminus of the A2AR75. Within the scope of
this review fits the observation that activation of the D2 receptor actually sensitizes
A2AR-mediated increases in cAMP production, in CHO cells expressing both
receptors76 as well as in CAD and NS20Y neuroblastoma cells in which the D2
receptor was expressed77. In SH-SY5Y neuroblastoma cells co-stimulation of A2AR
and D2R accelerated D2R desensitization, probably by causing or enhancing D2R
internalization80. Recently it was found that in these SH-SY5Y neuroblastoma cells
the A2AR also formed heteromers with the endogenously expressed CB1R. The CB1R
is negatively coupled to adenylyl cyclase, and requires previous or simultaneous
activation of A2AR to signal in these cells79.
A2B receptor
Cellular and physiological studies
The adenosine A2B receptor (A2BR) is endogenously expressed on most artificial cell
lines, such as COS and HEK293 cells. The exception is formed by CHO cells that
lack this adenosine receptor subtype.
The A2BR, like the other three adenosine receptor subtypes, is subject to agonist-
induced desensitization. This was measured on the level of cAMP production by
Peters et al.80. Pretreatment of COS7 cells endogenously expressing A2B receptors
with the nonselective agonist NECA (1 M) for 1 up to17 h, led to a significant
reduction in cAMP production upon acute agonist challenge, already after 1 h of
pretreatment. Maximal reduction of cAMP production was reached after 4 h of
pretreatment. CHO cells stably expressing a 5’ FLAG epitope-tagged A2B receptor
showed the same result, albeit that maximal reduction of cAMP response was
already achieved after 1 h of pretreatment. Also mouse 3T3-L1 cells and human
HEK293 cells, endogenously expressing the A2BR, showed a decreased cAMP
response after 2 h and 5.5 h of pretreatment with 1 M NECA, respectively80. In
NG108-15 cells, expressing both A2AR and A2BR, the rate of desensitization for both
receptor subtypes appeared similar, with a half-life of 15-20 min. Pretreatment with
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NECA of these cells (0.1 mM, 30 min) reduced stimulation of adenylyl cyclase by
A2BR by approx. 50%60,61.
Rat pheochromocytoma PC12 cells also endogenously express both A2AR and A2BR.
Prolonged exposure (14 h) to 100 nM NECA or 1 M CGS21680 significantly
inhibited the cAMP response of the cells to subsequent stimulation with the A2A-
selective agonist CGS21680. Although a 100-fold higher NECA-concentration is
needed to stimulate the A2BR compared to A2AR, Chern et al. found that the A2B
receptor cAMP response was also desensitized upon desensitization of the A2A
receptor. This observation can be explained by the fact that the Gsprotein level and
the adenylyl cyclase activity were diminished upon long-term desensitization of the
A2AR by CGS2168059.
The domain in which the receptor resides is also important for desensitization events,
according to Sitaraman et al. NECA (10 M) added to either the apical or basolateral
side of T84 intestinal cells resulted in desensitization of the A2BR on the
corresponding side within 2-3 h. However, whereas applying NECA to the apical side
of the membrane had no effect on the basolateral A2BR, basolateral NECA induced a
complete desensitization of the apical receptor. Since receptor trafficking may play a
role in this cross-desensitization process, this effect may contribute to the
desensitization and subsequent downregulation of the A2BR81.
Trincavelli et al. observed a very rapid desensitization (t1/2=5 min) of A2BR in a human
astrocytoma cell line. Both G protein coupling efficiency and cAMP production were
diminished after pretreatment of the cells with NECA in the presence of an A2AR-
selective antagonist82.
Mundell et al. reported that acute exposure of human airway smooth muscle (ASM)
cells to adenosine receptor agonists resulted in a rapid accumulation of cAMP, most
probably via A2BR. Treatment with adenosine deaminase (ADA) suggested that ASM
cells produce adenosine which feeds back on the cells’ A2BRs thereby regulating
basal cAMP levels and inducing a small degree of A2BR desensitization. Chronic
treatment with adenosine agonists had a dual effect; both A2BR desensitization and
adenylyl cyclase sensitization (an increased responsiveness of adenylyl cyclase
upon stimulation) were observed83.
Haynes et al. (1999) studied A2BR desensitization in both pulmonary artery smooth
muscle cells and a more integrated preparation, the isolated perfused lung.
Pretreatment of the smooth muscle cells with NECA for 45 min abrogated the
increase in cAMP response otherwise observed for both NECA and isoproterenol,
suggesting heterologous desensitization. Indeed, experiments with cholera toxin
showed that the desensitization took place at the level of the Gs protein-adenylyl
cyclase complex. In the lung preparation NECA, when dosed acutely, caused a rapid
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vasodilation, which was not observed when the tissue was treated again with the
same compound 45 min after the first dose84.
Taken together, these results suggest that desensitization of the A2B receptor is a
robust phenomenon, rather independent from the cell type or tissue in which it is
expressed.
Molecular mechanisms
Effects of receptor mutations on desensitization and/or internalization
Matharu et al. studied the regions of the A2BR which are responsible for the
desensitization and internalization of the A2BR85. For this purpose they introduced
point mutations or deletions in the C-terminus of the A2BR. Deleting the final two
amino acids (Leu330-stop) did not affect the internalization properties of the A2BR. The
Phe328-stop and Gln325-stop mutants however, were resistant to agonist-induced
desensitization and internalization. GFP-tagged arrestin-2 did not translocate from
the cytosol to the plasma membrane upon agonist stimulation of these two truncated
receptors. From a single point mutation in the C-terminus, Ser329Gly, it became clear
that this serine residue is responsible for the rapid agonist-induced desensitization
and internalization. Surprisingly, a further deletion mutant Ser326-stop was able to
undergo rapid agonist-induced desensitization and internalization, however, arrestin-
2 was not attracted to the plasma membrane upon agonist stimulation. It appeared
that internalization of this truncated receptor occurred via an arrestin- and clathrin-
independent pathway, probably via caveolin-mediated internalization since the
internalization of Ser326-stop was dynamin-dependent. The destination of this
truncated receptor was also different; a compartment close to the plasma membrane,
instead of early endosomes. Whether the receptor will undergo rapid agonist-induced
desensitization and internalization, or influence the rate, extent and mechanism of
internalization depends on specific sites in the C-terminus of the A2BR and can be
influenced by their mutation or deletion.
GRKs and arrestins
The A2BR, endogenously expressed in NG108-15 cells, is desensitized through
phosphorylation by GRK2. This GRK2 effect was selective for A2AR and A2BR, since
the other endogenously expressed receptors (secretin R and IP-prostanoid R) were
not desensitized in this way68. In addition, stable transfection of a dominant negative
GRK2(Lys220Arg) mutant in the NG108-15 cells reduced the NECA-induced (30 min,
100 M) desensitization of the A2BR by 50%60. Peters et al. studied the role of
phosphorylation by PKA and PKC rather than GRK2 in agonist-induced
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desensitization in COS-7 cells transiently expressing the 5’-FLAG A2BR. They
concluded that these second messenger dependent kinases are not involved in A2BR
phosphorylation80. A similar conclusion for A2BR phosphorylation in NG108-15 cells
was reached by Mundell and Kelly61. Trincavelli et al. found that treatment of
astrocytoma cells with TNF- increased the A2BR functional response, without
changing receptor protein or mRNA levels. TNF-treatment appeared to markedly
reduce agonist-dependent receptor phosphorylation and also attenuated agonist-
mediated A2BR desensitization. These effects could be inhibited by the addition of the
A2BR antagonist MRS 170682. These findings resemble data obtained with the A2AR
(vide supra).
Mundell et al. found that within the arrestin family, both arrestin-2 and arrestin-3 are
involved in the internalization process of the A2B-receptor. Within 1 minute of agonist
exposure, both GFP-tagged arrestin isoforms were translocated to the plasma
membrane. Longer agonist exposure (>10 min) however, revealed that only arrestin-
2 colocalizes with the receptor in the early endosomes. One explanation for this may
be a higher affinity of the A2BR for arrestin-2 compared to arrestin-3. Interestingly,
arrestins are not only involved in the internalization of the A2B-receptor, but also in its
recycling. It appeared that the expression of stable arrestin anti-sense constructs,
reducing the levels of endogenous arrestins, not only resulted in less internalization
of the receptors, but also impaired the recycling process significantly. In contrast to
the internalization process, arrestin-3 induced a significantly faster rate of A2BR
recycling compared to arrestin-286.
Penn et al. also studied the behaviour of GFP-tagged arrestins, now in human airway
smooth muscle cells. Arrestin-2 and arrestin-3 were able to reduce the cAMP
production upon stimulation of endogenous A2BR by NECA and stimulation of 2-AR
by isoproterenol. In addition, a punctate clustering was observed in the membrane
upon exposure to either NECA (100 M) or isoproterenol (1 M), indicating that
arrestins play a role in receptor trafficking. On the contrary, signaling and trafficking
of the prostaglandin E2-R, another endogenously expressed receptor, was not
affected by arrestin-2 or arrestin-327.
A3 receptor
Adenosine A3 receptors (A3R) evoke considerable interest as novel drug targets to
address cerebral/cardiac ischemia, cancer, inflammation, asthma and chronic
obstructive pulmonary disease. So far, potent and selective antagonists for the hA3R
have been identified; the disadvantage however is that those antagonists show
extremely low binding affinity for the rodent A3R, typically 1000 times lower than in
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human. Since rodent models are essential for the pharmacological evaluation of new
therapeutic agents, this forms a serious drawback.
In addition, the adenosine A3 receptor (A3R) sequence holds a nuclear localization
signal in its C-terminal tail87. This typical stretch of 4 amino acids (KKFK) in helix 8
may direct the receptor to the cell nucleus, not necessarily as a consequence of
desensitization or internalization. This should be kept in mind when appreciating the
studies described below.
Cellular and physiological studies
Ramkumar et al. studied the characteristics of rat A3R, endogenously expressed on
RBL-2H3 mast cells. In one of their experiments the authors pretreated the cells with
NECA, and found a partial desensitization of the initial Ca2+ response to NECA88.
Trincavelli et al. studied the relationship between agonist-induced desensitization,
internalization and resensitization of hA3R in transfected CHO cells. Agonist-induced
endocytosis of hA3R was investigated by immunogold electron microscopy of plasma
membranes and intracellular vesicles and shown to occur with a half-life of 17 min.
Subsequent removal of the agonist led to recycling of 90% of the receptor population
to the cell surface, with a half-life of 35 min. Short-term exposure to agonist caused
rapid desensitization, as assessed in cAMP assays. Removal of the agonist led to
resensitization of the cAMP signal to 90% of the original signal within 120 min.
Internalization did not affect signal transduction, as was demonstrated after blockade
of internalization and recycling. Internalization occurred via clathrin-coated pits.
These results show that hA3R undergoes agonist-induced endocytosis, which is not
responsible for desensitization. Moreover, in the case of hA3R, receptor
sequestration rather than desensitization seems to be the first step in a cycle of
internalization, dephosphorylation and recycling to the plasma membrane89. A similar
cell line was used by Palmer et al. In stably transfected CHO cells prolonged
treatment with NECA (10 M, 20 h) induced uncoupling of recombinant hA3R from Gi
proteins and a functional desensitization. Upon this A3R desensitization, an
approximately 2-fold increase in adenylyl cyclase activity was found in the presence
or absence of forskolin. This sensitization of adenylyl cyclase activity was not caused
by an altered level of inhibitory or stimulatory G protein expression. The occurrence
of the sensitization was also not due to new protein synthesis, but probably to an
increased coupling efficiency between Gs and adenylyl cyclase. Compared to control
cells, long-term exposure of stably transfected CHO cells to NECA caused an
increase in phosphorylation of the cAMP-responsive element binding protein upon
addition of suboptimal concentrations of forskolin. The sensitization of adenylyl
cyclase activity upon long-term treatment might provide a molecular basis for the
observation that for several adenosine receptor-mediated events, acute agonist
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exposure produces opposite effects to those after chronic agonist treatment90.
Ferguson et al. studied the fate of the rat A3R expressed in CHO cells. The receptors
internalized rapidly after treatment with NECA or R-PIA over a time frame (t½=10 min)
that followed receptor phosphorylation (t½=1 min)91.
The desensitization, internalization and down-regulation of hA3R was also
investigated in human astrocytoma cells, natively expressing hA3R. Short-term (15
min) exposure of the cells to 100 nM Cl-IBMECA, an A3R-selective agonist, caused
rapid receptor desensitization, subsequently followed by receptor internalization
within 30 min. With help of immunogold electron microscopy, the localization of the
A3R was revealed. After 10 min of exposure, the A3R was found in smooth-surfaced
pits and in uncoated vesicles in the cytoplasm. After 30 min of exposure, the A3R was
found in vesicular endosomes. Upon removal of the agonist, resensitization of the
A3R occurred within 120 min through receptor recycling to the cell surface. Long-term
agonist exposure (1-24 h) resulted in a marked down-regulation of A3R to 22 3% of
control after 24 h. In conclusion, multiple, temporally distinct and sequential
processes are involved in the regulation of hA3R upon short- and long-term exposure
to agonists92.
A3Rs were found to be highly expressed on murine B16-F10 melanoma cells93. The
authors examined the association between A3R trafficking and receptor functionality
and tumour growth inhibition upon activation with the A3R-selective agonist IB-MECA.
Exposure to 10 nM IB-MECA (5 min) led to rapid internalization of A3R to the cytosol,
upon which receptors were directed to the endosomes for recycling or to lysosomes
for degradation. The addition of 100 nM MRS 1523 (5 min), an A3R antagonist, was
able to counteract the internalization process as well as the modulation of the Wnt
pathway leading to proliferation, thereby emphasizing the involvement of A3R in this
process. When the melanoma cells were injected into nude mice, tumours rapidly
developed. Tumour growth was significantly inhibited after administration of IB-MECA
to the animals, paralleled by a decrease in A3R expression in tumour lesions. In
hypoxic human A172 and U87MG glioblastoma cell lines it was found that adenosine
up-regulates the expression of hypoxia-inducible factor-1(HIF-1) and VEGF via
the A3 receptor. HIF-1 is a key regulator in the development of tumours. The
addition of the A3-antagonist MRE 3008F20 inhibited the adenosine-induced HIF-1
and VEGF accumulation in these hypoxic cells, thereby showing a putative role in
inhibiting tumour growth [94].
To circumvent the species differences mentioned in the introduction to the A3R
paragraph, Yamano et al. generated A3R humanized (A3ARh/h) mice in which the A3R
was replaced by its human counterpart. The expression level of hA3R in the
humanized (A3ARh/h) mice was equal to the expression levels of A3R in WT mice.
A3R agonists were able to elevate the intracellular Ca2+ concentration in bone
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marrow-derived mast cells from the humanized (A3ARh/h) mice. However, the rate of
hA3R internalization was markedly reduced compared with that of mA3R in these
mast cells95.
Molecular Mechanisms
Receptor phosphorylation, GRKs and arrestins
Palmer and Stiles, and Ferguson et al. investigated which amino acid residues in the
C-terminus are responsible and crucial for the rapid desensitization of the A3R96,91. A
triple mutant (Thr307, Thr318 and Thr319 to Ala) exhibited dramatically reduced
phosphorylation, desensitization and internalization of the rat A3AR. Individual
mutation of each Thr residue showed that Thr318 and Thr319 were the most important
sites for phosphorylation. In addition, phosphorylation of Thr318 was necessary to
observe phosphorylation of Thr319, but not vice versa. Moreover, changing Thr318 for
a negatively charged residue (Glu) was not sufficient to retain phosphorylation at
Thr319. Mutating two predicted palmitoylation-sites, Cys302,305 to Ala resulted in
agonist-independent basal phosphorylation of the rat A3AR. Such findings strongly
suggest that palmitoylation of these Cys residues is an important factor in controlling
accessibility of the C-terminus of the A3R in the process of recruiting GRKs. In fact,
the palmitoylation sites are highly conserved between different species, e.g. rat,
mouse, human, dog, sheep. Taking these results together, it appears that GRK-
mediated phosphorylation of the A3R C-terminus follows a sequential mechanism,
with the receptor palmitoyl moieties in an important regulatory role, and
phosphorylation of Thr318 being particularly crucial as an essential first step. In an
earlier study Palmer et al. replaced the carboxyl terminus of the A1R by that of the
A3R37. This chimaeric construct was able to undergo agonist-stimulated
phosphorylation and functional desensitization, similar to A3R. It was also found that
purified GRK2, GRK3 and GRK5 were all able to enhance agonist-dependent
phosphorylation of A3R as well as the A1-A3 chimaera.
Trincavelli et al. studied the involvement of extracellularly regulated kinases (ERK1
and 2), members of the mitogen-activated protein kinase (MAPK) family, in A3R
phosphorylation. It was found that within 5 minutes of exposure to 10M NECA, ERK
1 and 2 were already phosphorylated in CHO cells stably expressing hA3R. An
inhibitor of MAPK activation (PD98059) also caused inhibition of A3R
phosphorylation, desensitization and internalization, probably by preventing the
membrane translocation of GRK2. These results indicate that the MAPK cascade is
involved in A3R regulation by a feedback mechanism which controls GRK2 activity
and probably involves direct receptor phosphorylation97.
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The rat basophilic leukaemia cell 2H3 cell line (RBL-2H3 cells) endogenously
expresses equal levels of arrestin-2 and arrestin-3. Both arrestin isoforms also have
a high and comparable affinity for clathrin, thereby promoting agonist-induced
internalization. RBL-2H3 cells also endogenously express a high level of A3R, which,
however, did neither recruit arrestin-3 nor arrestin-2 upon stimulation with NECA.
Also no changes in A3R distribution were observed. One explanation is that A3R
follow an endocytic mechanism upon agonist stimulation that does not involve
arrestin-mediated clathrin-coated pit internalization. Another possible explanation is
that arrestin recruitment was below the limit of detection in the RBL-2H3 cells98.
Ferguson et al. observed that upon phosphorylation of A3R by GRK arrestin-3 is
redistributed into punctate vesicles both at the plasma membrane and within the
cytoplasm. Nevertheless, these authors also noticed that there was no colocalization
between A3R and arrestin-347.
Conclusions
The adenosine receptor subtypes are differentially regulated when exposed to
agonist treatment. A1Rs are not (readily) phosphorylated and slowly internalize with a
typical half-life of several hours. This feature may cause less than average
tachyphylaxis upon chronic agonist administration, for instance in type II diabetes.
A2AR and A2BR show much faster downregulation with similar kinetics, usually < 1h
for short-term desensitization. Agonists for the A2A receptor, currently profiled in
wound healing, may thus suffer from declining efficacy upon chronic administration,
in contrast to those for the A1 receptor. The A3R undergoes even faster
downregulation, often a matter of minutes. The latter receptor also holds a nuclear
localization signal in its carboxy terminal tail, possibly obscuring true agonist-induced
downregulation. The fast desensitization of the A3R after agonist exposure may be
therapeutically equivalent to antagonist occupancy of the receptor.
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Chapter 3
Allosteric modulation and constitutive activity of
fusion proteins between the adenosine A1 receptor
and different 351Cys-mutated Gi-subunits
We studied fusion proteins between the human adenosine A1 receptor and different
(351Cys) mutated Gi1subunits (A1-G i) with respect to two important concepts in
receptor pharmacology, i.e. allosteric modulation and constitutive activity/inverse
agonism. The aim of our study was twofold. We first analysed whether such fusion
products are still subject to allosteric modulation, and, secondly, we investigated the
potential utility of the fusion proteins to study constitutive receptor activity. We
determined the pharmacological profile of 9 different A1-G i fusion proteins in
radioligand binding studies. In addition, we performed [35S]GTPS binding
experiments to study receptor and G protein activation of selected A1-G ifusion
proteins. Compared to unfused adenosine A1 receptors, the affinity of N6-
cyclopentyladenosine (CPA) at wild-type A1-Gifusion proteins (351Cys) increased
more than eight-fold, while the affinity of 1,3-dipropyl-8-cyclopentylxanthine (DPCPX)
did not change significantly. Furthermore, we showed that the allosteric enhancer of
agonist binding, PD81,723 (2-amino-4,5-dimethyl-3-thienyl-[3-(trifluoromethyl)-
phenyl]methanone), elicited similar effects on ligand binding; i.e. CPA binding to the
A1-Gifusion proteins was enhanced, whereas the affinity of DPCPX was hardly
affected. Moreover, sodium ions were unable to decrease agonist binding to the
majority of the A1-G ifusion proteins, presumably because they exhibit their effect
through uncoupling of the R-G complex. From [35S]GTPS binding experiments we
learned that all the A1-Gifusion proteins tested had a higher basal receptor activity
than the unfused adenosine A1 receptor, thereby providing improved conditions to
observe inverse agonism. Moreover, the maximal CPA-induced stimulation of basal
[35S]GTPS binding was increased for the five A1-Gifusion proteins tested, whereas
the inhibition induced by 8-cyclopentyltheophylline (CPT) was more pronounced at
351Cys, 351Ile, and 351Val A1-G i fusion proteins. Thus, the maximal receptor
(de)activation depended on the amino acid at position 351 of the G i-subunit. In
conclusion, A1-G ifusion proteins, especially with 351Cys and 351Ile, can be used as
research tools to investigate inverse agonism, due to their increased readout window
in [35S]GTPS binding experiments.
Based upon Klaasse E, de Ligt RAF, Roerink SF, Lorenzen A, Milligan G, Leurs R,
IJzerman AP., Eur J Pharmacol. 2004, 499:91-98.
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Introduction
Adenosine A1 receptors belong to the superfamily of G protein-coupled receptors
(GPCRs). They preferentially interact with Gi and Go proteins1. Various strategies
have been employed to study the interaction between receptor and G protein. One
method is the construction of so-called fusion proteins, in which both signalling
partners, GPCR and G -subunit, are physically linked to each other. In 1994, the
first fusion protein (between 2-adrenoceptor and Gs-subunit) was described and
found to be functional in both ligand binding experiments and cAMP determinations2.
The same strategy has been applied to adenosine A1 receptors. Waldhoer et al.
analysed the kinetic behaviour of the adenosine A1 receptor linked to both Gi- and
Go-subunits3. The authors also introduced a fusion protein in which the Gi-subunit (of
rat G i1) was mutated at position 351Cys. This cysteine residue is known to be ADP-
ribosylated by pertussis toxin (PTX); changing it for another amino acid (glycine or
isoleucine in this case) renders the fusion protein insensitive to the toxin4.
Endogenous G proteins present in the cell which the fusion protein is expressed in,
remain sensitive to PTX and can be ‘knocked out’. Similar constructs were used in
studies to analyse the action of both receptor ligands such as adenosine analogues
and G protein inhibitors such as suramin and derivatives5,6. Curiously, Bevan et al.
introduced a “trivalent” fusion protein between adenosine A1 receptor, green
fluorescent protein, and Gi-subunit, which behaved very much as the wild-type
receptor in terms of ligand binding and G protein activation7.
In the present study we performed a further analysis of such fusion proteins with two
aims that have not yet been subject of investigation. Firstly, we wondered whether
the constructs can still be influenced by allosteric modulators. In our laboratory, we
have been investigating allosteric modulation of adenosine receptors by, e.g., sodium
ions and PD81,7238-10.
Secondly, we wanted to learn whether the fusion proteins might be useful tools in the
analysis of constitutive activity and its inhibition by inverse agonists. This inhibition of
constitutive activity is commonly observed at GPCRs (for review see de De Ligt et
al.)11. Inverse agonism is not always easily detected, since basal receptor activity is,
in general, not pronounced. We reasoned that fusion proteins, due to the proximity of
both signalling partners, might have a higher spontaneous receptor activity and,
consequently, might offer an enlarged “window” to study inverse agonism.
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Materials and Methods
Chemicals
CPA, DPCPX, CPT, and PD81,723 were purchased from Research Biochemicals
Inc. (Natick, USA). Adenosine deaminase (ADA), diethylaminoethyl (DEAE) dextran,
chloroquine, and dithiothreitol were purchased from Sigma, while EDTA, MgCl2,
GDP,
3-[(3-cholamidopropyl)dimethylammonio]propanesulfonate (CHAPS), and GTPS
were obtained from Boehringer (Mannheim, Germany). [3H]DPCPX (120 Ci/mmol),
[3H]CCPA (2-chloro-N6-cyclopentyladenosine, 55 Ci/mmol), and [3H]cAMP (25
Ci/mmol) were purchased from NEN (DuPont Nemours, ‘s-Hertogenbosch, NL).
[35S]GTPS (1250 Ci/mmol) was obtained from NEN (Cologne, Germany). BSA and
BCA protein assay reagent were purchased from Pierce Chemical Company
(Rockford, IL, U.S.A.). All other chemicals were obtained from standard sources. A
fraction containing protein kinase A was isolated from bovine adrenal glands
according to Leurs et al.12. Except for foetal calf serum (FCS, Greiner, Netherlands),
all cell culture materials were taken from laboratory stocks. All other chemicals were
obtained from standard sources, and were of the highest purity commercially
available. The cDNAs encoding either the unfused adenosine A1 receptor or a fusion
protein between the human adenosine A1 receptor and rat Gi1 -subunit were
produced by one of us (G.M.). Full fusion constructs were excised from pCR-Script
with EcoRI and XhoI and ligated into the mammalian expression vector pcDNA3
according to the instructions supplied by the vendor (Invitrogen, San Diego, USA).
Cell culture and transfection
African green monkey kidney (COS-7) cells were maintained at 37 C in a humidified
atmosphere with 7% CO2 in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 5% FCS, penicillin (50 IU/ml), and streptomycin (50g/ml). COS-
7 cells were transiently transfected with either the unfused adenosine A1 receptor, or
a fusion protein (A1-Gi) using a slightly modified protocol of the ‘in suspension’
DEAE dextran method previously described by Brakenhoff et al.13. In short, COS-7
cells were subcultured one day prior to transfection. The next day cells were
trypsinised, counted, and resuspended in RPMI 1640 amino acids solution
supplemented with 2% FCS and 100 M chloroquine (RSC), at a density of 2 x 106
cells/ml. DNA (4-10 g/106 cells) and DEAE dextran (400 g/ml) were mixed in a
total volume of 4 ml RSC, and incubated at room temperature for two minutes. Then
0.5 ml (106 cells) of the cell suspension was added, and the total mixture was
incubated for 60 min at 37 C and 7% CO2. Cells were subsequently spun down at
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1000 x g for 5 min, resuspended in normal growth medium, and seeded in the
appropriate plates.
Membrane preparation
After 48 hrs, transiently transfected COS-7 cells were harvested with a cell scraper,
and recovered by a 5-min centrifugation at 1000 x g. Cells were then homogenised in
ice-cold 50 mM Tris HCl buffer (pH 7.4) with a polytron homogeniser (5 sec, speed
8), and used for radioligand binding studies. To measure [35S]GTPS binding, the cell
homogenates were purified with two additional centrifugation steps at 4 C: a 10-min
centrifugation at 1000 x g and the obtained supernatant for 30 min at 60,000 x g
(Beckman L8-50 M/E Ultracentrifuge). The final pellet was resuspended in 3 ml ice-
cold 50 mM Tris HCl buffer (pH 7.4), supplemented with ADA (2 U/ml). Protein
concentrations were measured with the bicinchoninic acid method with BSA as a
standard14.
Radioligand binding studies
For displacement studies, membranes (10-30 g) were incubated for 1 hour at 25 C
in 50 mM Tris HCl (pH 7.4) in the presence of ADA (1 U/ml), approximately 1.6 nM
[3H]DPCPX, and increasing concentrations of CPA, or DPCPX in a total volume of
400 l. To study the modulatory effects of 1 M NaCl and 10 M PD81,723, the
indicated concentrations were added when appropriate. For displacement
experiments in the presence of 1 M NaCl, approximately 0.5 nM [3H]DPCPX was
used.
Incubations were stopped by rapid dilution with 2 ml of ice-cold 50 mM Tris HCl buffer
(pH 7.4) and bound radioactivity was subsequently recovered by filtration through
Whatman GF/C filters using a Brandel harvester. Filters were then washed twice with
2 ml of the buffer described above. The retained radioactivity was measured by liquid
scintillation counting (LKB Wallac, 1219 Rackbeta). Non-specific binding of
[3H]DPCPX was measured in the presence of 10 M CPA.
Saturation experiments were carried out under similar conditions with increasing
concentrations of [3H]DPCPX (0-5 nM) or [3H]CCPA (0-4 nM). Filters were washed
five times with 2 ml of 50 mM Tris HCl buffer (pH 7.4) to remove all unbound
radioligand. Non-specific binding of [3H]CCPA was measured in the presence of 10
M DPCPX.
[35S]GTPS binding
[35S]GTPS binding was measured in 100 l containing 50 mM Tris HCl (pH 7.4), 1
mM EDTA, 5 mM MgCl2, 10 M GDP, 1 mM dithiothreitol, 100 mM NaCl, 5 U/ml
ADA, 0.3 nM [35S]GTPS (~50,000 cpm), 0.004% CHAPS, and 0.5% BSA.
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Incubations were started by addition of the membrane suspension (1-3 g
protein/tube) to the test tubes, and carried out in duplicate for 90 min at 25 C. They
were stopped by rapid filtration through Whatman GF/B filters, pre-soaked in 50 mM
Tris HCl, 5 mM MgCl2 (pH 7.4) containing 0.02% CHAPS. The filters were washed
twice with 4 ml of the buffer mentioned before, and retained radioactivity was
measured using liquid scintillation counting. Non-specific binding of [35S]GTPS was
measured in the presence of 10 M unlabelled GTPS, and subtracted from total
bound radioactivity.
Data and statistical analysis
All receptor binding data were analysed by using a non-linear regression computer
program (Prism 3.0, GraphPad Software, Inc., San Diego, CA, USA). Statistical
significance was evaluated with the Student’s t test. Saturation experimental data (Kd
and Bmax values) were obtained by computer analysis of saturation curves. From
displacement experiments IC50 values were calculated. All values obtained are
means of at least three independent experiments performed in duplicate.
EC50/IC50 values for stimulation or inhibition of [35S]GTPS binding were calculated
from fitting experimental results to sigmoid dose-response curves with SigmaPlot
(SPSS Science, Inc., Chicago, IL, USA), and are given as geometric means with
95% confidence limits from at least three experiments.
Results
First, we established Bmax and Kd values in saturation experiments with [3H]DPCPX
on COS-7 membranes expressing either the adenosine A1 receptor alone or fusion
proteins (A1-G i) between the adenosine A1 receptor and three (mutated) Gi
proteins (351Cys
(= wild-type), 351Gly, and 351Ile). Saturation experiments were performed both in the
absence and presence of 1 M NaCl (Table 3.1). The affinity of [3H]DPCPX for these
A1-Gi fusion proteins was similar to its affinity for the unfused adenosine A1
receptor. Moreover, the A1-Gifusion proteins were expressed at similar receptor
densities, which were lower than those for the adenosine A1 receptor alone. The
other A1-G ifusion proteins (351Phe, 351His, 351Pro, 351Arg, 351Ser, and 351Val) were
tested in a single saturation experiment with [3H]DPCPX in the absence of sodium
ions. They showed Kd values in a similar range as observed for the adenosine A1
receptor alone (1.2 - 2.1 nM), while receptor expression varied to some extent (0.4 -
1.0 pmol/mg of protein).
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Table 3.1. Kd and Bmax values from saturation experiments with [
3H]DPCPX on COS-7 cell
homogenates transfected with the human adenosine A1 receptor or various (mutated) A1-Gifusion
proteins (351Cys (= wild-type Gi), 351Gly, and 351Ile). The experiments were carried out in the presence
or absence of 1 M NaCl. Data are expressed as means S.E.M. from three independent experiments
performed in duplicate.
Construct
control 1 M NaCl
Kd (nM)
Bmax
(pmol/mg
protein)
Kd (nM)
Bmax
(pmol/mg
protein)
unfused A1 1.80.31 2.180.13 0.83/0.83a 2.71/2.81a
A1G i 351Cys 1.50.04 1.290.38 0.500.06b 1.590.41
A1G i 351Gly 1.90.38 1.220.21 0.410.05c 1.390.27
A1G i
351Ile 1.50.03 1.530.48 0.500.02b 1.580.38
a n=2; b p <0.005, c p <0.001, significant difference versus control
Next, we determined the IC50 values of CPA and DPCPX for the nine A1-G i
constructs and compared the values obtained with their IC50 for the unfused
adenosine A1 receptor. We also studied the modulatory effects of 1 M NaCl and 10
M PD81,723 on ligand binding to these A1-G ifusion proteins. We could not convert
the IC50 values into Ki values, since we did not determine radioligand Kd values for all
fusion products under all three conditions, i.e. without or in the presence of 1 M NaCl
or PD81,723.
The results from radioligand binding experiments with the adenosine A1 receptor
agonist, CPA, are listed in Table 3.2. CPA had significantly higher affinities for five of
the A1-G i fusion proteins (351Cys, 351Gly, 351Ile, 351Ser, and 351Val) than for the
unfused adenosine A1 receptor. In the presence of 1 M NaCl, CPA’s affinity for the
unfused adenosine A1 receptor decreased three-fold. Contrarily, the A1-Gifusion
proteins did not seem to be affected very much by sodium ions, exhibiting no
significant shifts in the presence of 1 M NaCl, except for 351Arg and 351Pro. In these
two cases, the affinity of CPA decreased five- and eight-fold, respectively, and
resembled the affinity of CPA for the unfused adenosine A1 receptor in the presence
of sodium ions (Table 3.2). Furthermore, in the presence of 10 M PD81,723 all A1-
G ifusion proteins exhibited an increased affinity for CPA. This PD81,723-induced
enhancement of CPA binding was also observed at unfused adenosine A1 receptors,
which had a four-fold higher affinity for CPA in the presence of 10M PD81,723. Yet,
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under these conditions all nine A1-G ifusion proteins had a higher affinity for CPA
(13-76 nM) than the unfused adenosine A1 receptor (111 nM, Table 3.2).
Table 3.2. IC50 values (nM) for CPA binding to COS-7 cell homogenates transfected with the human
adenosine A1 receptor or different
351Cys-mutated A1-Gi fusion proteins. The experiments were
carried out in the presence or absence of 1 M NaCl or 10 M PD81,723. Shifts were calculated by
dividing the IC50 (in the presence of modulator) by IC50 (control). Data are expressed as means 
S.E.M. from at least three independent experiments performed in duplicate (n = 3-5).
Construct
control 1 M NaCl 10 M PD81,723
IC50 (nM) IC50 (nM) shift IC50 (nM) shift
unfused A1 436118 1355 173 3.11a 111 18 0.25b
A1-Gi 351Cys 51 9 78 18 1.53 25 9 0.49b
A1-Gi 351Gly 167 17 171 46 1.02 32 8 0.19c
A1-Gi
351Ile 95 17 65 10 0.68 13 2 0.14a
A1-Gi
351Phe 328 74 601179 1.83 49 13 0.15a
A1-Gi 351His 279 72 456 67 1.63 76 15 0.27b
A1-Gi 351Pro 270 59 2194 609 8.13b 54 7 0.20b
A1-Gi 351Arg 222 17 1135 281 5.11b 42 7 0.19c
A1-G i 351Ser 135 23 121 33 0.90 22 7 0.19a
A1-Gi 351Val 87 21 84 5 0.97 16 4 0.18a
Significant shift compared to unity, aP<0.005, bP<0.05, cP<0.001
The results from radioligand displacement studies with the adenosine A1 receptor
antagonist/inverse agonist DPCPX are presented in Table 3.3. The A1-Gifusion
proteins 351Ile, 351Ser, and 351Val had slightly, but significantly lower affinities for
DPCPX than the unfused adenosine A1 receptor, while the other constructs showed
statistically similar affinities for DPCPX. Moreover, sodium ions increased the affinity
of DPCPX for the unfused adenosine A1 receptor approximately two-fold. The binding
of DPCPX to the A1-Gifusion proteins 351Phe, 351Pro, 351Arg, 351Ser, and 351Val also
increased two- to threefold, while DPCPX binding to the other A1-Gifusion proteins
(351Cys, 351Gly, 351Ile, and 351His) was unaffected. In the presence of 10 M
PD81,723 the IC50 value of DPCPX at A1-Gifusion protein 351Arg increased almost
two-fold (p <0.05). However, the affinity of DPCPX for the other A1-G i fusion
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proteins, as well as for the unfused adenosine A1 receptor, was not significantly
changed in the presence of 10 M PD81,723. Since we used 8-
cyclopentyltheophylline (CPT) in our GTPS binding studies (see below), we also 
determined its affinity for one of the fusion proteins. CPT displayed an IC50 value of
30 12 nM on the A1-Gi351Ile product in the absence of any modulator, being
sevenfold less active than DPCPX.
Table 3.3. IC50 values (nM) for DPCPX binding to COS-7 cell homogenates transfected with the
human adenosine A1 receptor or different
351Cys-mutated A1-Gi fusion proteins. The experiments
were carried out in the presence or absence of 1 M NaCl or 10 M PD81,723. Shifts were calculated
by dividing the IC50 (in the presence of modulator) by IC50 (control). Data are expressed as means 
S.E.M. from at least three independent experiments performed in duplicate (n = 3-5).
Construct
control 1 M NaCl 10 M PD81,723
IC50 (nM) IC50 (nM) shift IC50 (nM) shift
unfused A1 3.00.34 1.60.12 0.55a 4.20.79 1.40
A1-Gi 351Cys 4.50.92 5.10.44 1.13 8.82.40 1.96
A1-Gi 351Gly 4.60.94 3.30.37 0.72 5.40.64 1.17
A1-Gi
351Ile 4.50.66 4.61.12 1.02 3.31.10 0.73
A1-Gi
351Phe 3.70.80 1.70.34 0.46a 5.10.53 1.38
A1-Gi 351His 2.30.58 1.40.14 0.61 4.10.72 1.78
A1-Gi 351Pro 4.30.95 1.40.17 0.33a 4.40.45 1.02
A1-Gi 351Arg 3.60.31 1.30.21 0.36b 6.10.99 1.69a
A1-G i 351Ser 6.40.69 1.80.07 0.28b 6.00.29 0.94
A1-Gi 351Val 4.70.74 1.50.21 0.32b 7.91.80 1.68
Significant shift compared to unity, aP<0.05, bP<0.005
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To study the functionality of the A1-G ifusion proteins, we determined [35S]GTPS
binding on membranes prepared from transfected COS-7 cells, expressing the A1-
G ifusion proteins of interest. In these studies, CPT, a more water-soluble analogue
of DPCPX, was used as reference adenosine A1 receptor inverse agonist in
[35S]GTPS binding experiments. Figure 3.1 shows the results of [35S]GTPS binding
to COS-7 membranes, expressing the wild-type A1-Gifusion protein (351Cys). The
agonist CPA increased basal [35S]GTPS binding more than seven-fold, while CPT
decreased [35S]GTPγS binding to 52% of the basal level. To obtain a reasonable
window to observe inhibition of basal [35S]GTPS binding by the adenosine A1
receptor inverse agonist CPT, we used more protein (3 g) than in experiments with
the agonist CPA (1 g of membrane protein).
Figure 3.1. Stimulation by CPA (panel A) and inhibition by CPT (panel B) of basal [35S]GTPS binding
in membranes prepared from COS-7 cells transfected with the A1-Gifusion protein 351Cys. Data are
from a representative experiment performed in duplicate.
We performed similar experiments with COS-7 membranes expressing the unfused
adenosine A1 receptor (10 g of protein) and the A1-G i fusion proteins 351Cys,
351Gly, 351Ile, 351Pro and 351Val (1-3 g of protein). For the latter two A1-Gifusion
proteins, we tested only a single concentration of 1 M CPT. It should be noted that
less protein was needed in experiments with the A1-Gifusion proteins to give similar
basal [35S]GTPS binding. The results from these [35S]GTPS binding experiments
are summarised in Table 3.4.
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Table 3.4. Modulation by CPA or CPT of basal [35S]GTPS binding to the unfused adenosine A1
receptor and various A1-Gifusion proteins (351Cys, 351Gly, 351Ile, 351Pro, and 351Val). EC50/IC50 values
are expressed with 95% confidence limits (n = 3). Effects of CPA and CPT are expressed as
percentage of basal [35S]GTPS binding. Basal [35S]GTPS binding on membranes with the A1-Gi
fusion proteins was ~600 cpm and ~1600 cpm in experiments with CPA and CPT, respectively. Basal
[35S]GTPS binding on membranes expressing the unfused adenosine A1 receptor was ~800 cpm for
both CPA and CPT.
CPA CPT
construct
EC50 (nM)
effect
(% of basal)
IC50 (nM)
effect
(% of basal)
unfused 0.25 (0.15-0.43) 165 14 (7-27) 75
A1-G i 351Cys 3.74 (2.55-5.50) 744 91 (71-117) 52
A1-G i 351Gly 49.2 (36.8-
65.9)
580 148 (89-244) 84
A1-G i 351Ile 5.94 (4.40-8.01) 1014 89 (41-192) 51
A1-G i 351Ile+PTX 6.03 (5.71-6.36) 996 n.d. 49
A1-G i 351Pro 1.70 (1.56-1.86) 437 n.d. 76
A1-G i 351Val 9.03 (8.23-9.90) 967 n.d. 55
n.d. not determined
First, the extent of the CPA-induced stimulation of basal [35S]GTPS binding differed
for the various membrane preparations. Membranes expressing the unfused
adenosine A1 receptor showed only a modest effect of CPA, i.e. 165% stimulation
over basal [35S]GTPS binding, whereas the membrane preparations with the
selected A1-G i fusion proteins all had larger CPA-induced increases in basal
[35S]GTPS binding (Table 3.4). Similar observations were made when the inverse
agonist, CPT, was present. In all cases, CPT decreased basal [35S]GTPS binding,
and to a different extent depending on the A1-Gimembrane preparation used. The
CPT-induced decrease of basal [35S]GTPS binding was most prominent in
experiments with COS-7 cell membranes expressing A1-Gifusion protein 351Cys or
351Ile, i.e. a reduction to 52 and 51% (49% in the presence of PTX) of the basal
levels, respectively. On membranes with the A1-G i fusion protein 351Val, CPT
lowered basal [35S]GTPS binding to 55% of control values. Finally, the inhibitory
effect of CPT on basal [35S]GTPS binding measured at the A1-G ifusion proteins,
351Gly and 351Pro, or at unfused adenosine A1 receptors, was less pronounced (Table
3.4).
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Discussion
In 1994, the first fusion protein between the 2-adrenoceptor and its cognate Gs
-subunit was described2. The authors showed that this fusion protein (2-Gs), when
expressed in S49 cyc- cells, was functional in both ligand binding experiments and
cAMP determinations. Since then, fusion proteins have been engineered between
various receptors (e.g. 2A-adrenoceptor, adenosine A1, serotonin 5-HT1A receptor)
and G proteins (e.g. Gi1, Go) (for review see Milligan)15. Because of the physical
connection between receptor and G -subunit, fusion proteins may resemble the
precoupled receptor-G protein complex (RG and/or R*G) (Lefkowitz et al., and
references therein)16,17. These R-Gfusion proteins may also enable the examination
of receptor interactions in a system with a fixed R:G (1:1) ratio.
As outlined in the introduction the adenosine A1 receptor has also been linked to G
protein α-subunits. Interestingly, this receptor subtype has been shown to be a target
for allosteric modulation, a relatively new concept in receptor theory. Agonist binding
can be enhanced (PD81,723) or inhibited (e.g., by sodium ions) in an allosteric
manner (Van der Klein et al., Kourounakis et al. and references therein)8,10.
Constitutive activity, another recent receptor concept, has also been demonstrated at
adenosine A1 receptors, but only at high levels of receptor expression and with a
relatively poor “window”18. Therefore, we decided to use this new instrument of fusion
proteins to study allosteric modulation and constitutive activity/inverse agonism
further.
In the present and other studies, mutated G -subunits were used. As demonstrated
by Molinari et al. R-G fusion proteins might also couple to and activate
endogenously expressed G proteins19. Treatment with pertussis toxin (PTX) assures
that receptor activation arises solely through a mutated G i-subunit of the fused R-G
construct, since the -subunits of endogenously expressed G proteins are ADP-
ribosylated by the toxin, and hence inactivated. Interestingly, we did not find
significant differences in modulation of [35S]GTPS binding between PTX-treated and
untreated membranes of COS-7 cells transfected with A1-G i(351Ile) fusion proteins
(Table 3.4). In our hands, it thus seemed that the fusion proteins hardly activated
endogenously expressed G -subunits, if at all. Therefore, we did not use PTX-
treated membranes in our further experiments.
Saturation experiments with the radiolabelled antagonist/inverse agonist [3H]DPCPX
taught us that its affinity was similar for the fusion proteins and the adenosine A1
receptor itself (see Table 3.1 and text in Results section). Consequently, we found no
signif icant differences in the IC50 values of DPCPX determined in radioligand binding
displacement studies with COS-7 membranes expressing the various A1-Gifusion
proteins (control column in Table 3.3). On the other hand, the affinity of CPA was
higher for most A1-Gi fusion proteins compared to the unfused adenosine A1
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receptor (436 nM, Table 3.2). These findings are in line with the idea that fusion
proteins of this nature resemble a precoupled state of the natural complex between
receptor and G protein, for which agonists have an increased affinity, whereas
antagonists/inverse agonist binding is virtually undisturbed. The relatively low affinity
of CPA for the unfused receptor may be due to the low abundance of endogenous G
proteins in COS-7 cell membranes, such that a precoupled complex hardly occurs.
After this characterization of the fusion proteins under control conditions we next
examined allosteric modulation of ligand binding to the mutated A1-Gi fusion
proteins by sodium ions and PD81,723, as our first objective of this study.
In the presence of 1 M NaCl, CPA’s affinity for the unfused adenosine A1 receptor
decreased three-fold (Table 3.2). Sodium ions act through an aspartate residue in
transmembrane helix II, which is highly conserved in GPCRs20. Their interaction with
this aspartate residue, Asp55 in the human adenosine A1 receptor, presumably
induces a change in receptor conformation towards the inactive R state. Moreover,
mutation of this residue into an asparagine (Asp55Asn) diminished the sodium-
induced decrease in agonist affinity21. In the latter study it was also shown that
concentrations of NaCl lower than 1 M also affect agonist binding, although less
outspoken. Remarkably, the affinity of CPA for most of the A1-G ifusion proteins was
unaffected by sodium ions. Although the adenosine A1 receptor was not mutated in
the A1-Gifusion proteins, sodium ions appeared unable to elicit their effect. It may
be that the physical connection between receptor and Gi-subunit causes a
conformational change, which, in turn, prevents the sodium ions from binding to the
adenosine A1 receptor. Alternatively, sodium ions may promote the formation of an
inactive state (R) of the receptor, which cannot or only partly be achieved in
receptors already fused with a G protein17. The latter explanation may make more
sense, since the same concentration of NaCl did affect DPCPX binding at the wild-
type receptor and at many of the fusion proteins (Table 3.1 and Table 3.3).
Apparently, the binding of the antagonist/inverse agonist DPCPX remains sensitive to
sodium ions. Surprisingly, sodium ions were able to decrease CPA binding at 351Pro
and 351Arg A1-Gi fusion proteins (Table 3.2). Although speculative, the distinct
characteristics of proline (ring structure) and arginine (positive charge) residues may
have more profound effects on the conformation of the Gi-subunit, and of the fusion
protein as a whole.
The effects of 10 M PD81,723 on ligand binding were rather similar for both the
unfused adenosine A1 receptor and the different A1-Gi fusion proteins. In the
presence of PD81,723, CPA’s affinity for the unfused receptor increased four-fold.
The allosteric modulator increased the affinity of CPA for the various A1-Gifusion
proteins to a varying extent, namely two- to six-fold (Table 3.2). It should be noted
here that in the presence of 10 M PD81,723, the affinity of CPA for the unfused
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receptor was lower compared to its affinity for the different A1-Gifusion proteins
under similar conditions. Thus, PD81,723 is still able to enhance CPA’s binding to the
adenosine A1 receptor when the Gi-subunit is physically linked to it. The molecular
mechanism of action for PD81,723 has not been resolved yet, but these findings
suggest that PD81,723 has a direct effect on the receptor itself and, subsequently,
shifts the receptor equilibrium towards a more activated form (R*) of the receptor17.
The binding of DPCPX (Table 3.3) was not very much affected by PD81,723,
suggesting that the antagonist/inverse agonist binding is relatively insensitive to the
presence of an allosteric enhancer of agonist binding.
The second objective of this research was to investigate whether these A1-Gifusion
proteins may be used to detect inverse agonism at adenosine A1 receptors more
easily. To observe inverse agonistic activity of e.g., DPCPX, a sufficient basal
receptor activity is required11. Possibilities to increase basal receptor activation
include receptor overexpression18, or the design of constitutively active mutant
receptors22. Assuming that these A1-G ifusion proteins resemble a ‘precoupled’ and,
therefore, an active receptor conformation, we reasoned that basal receptor activity
of A1-Gi fusion proteins should be higher than the basal activity of unfused
adenosine receptors. We indeed found far higher basal [35S]GTPS binding for all A1-
G ifusion proteins tested in [35S]GTPS binding experiments. Despite lower receptor
densities (see Table 3.1 and text in Results section), membranes expressing A1-G i
fusion proteins showed more than seven-fold higher basal [35S]GTPS binding than
that found in membranes with the unfused receptor, approx. 600 and 80 cpm/g of
protein, respectively. Moreover, for all A1-G ifusion proteins tested, the maximal
stimulation of basal [35S]GTPS binding was significantly larger than the maximal
CPA-induced effect with unfused adenosine A1 receptors (Table 3.4). For instance
CPA caused a 14-fold increase [(1014%-100%)/(165%-100%)] in stimulation on the
351Ile fusion protein compared to the unfused receptor. The same was observed for
inhibition of basal [35S]GTPS binding by the adenosine A1 receptor inverse agonist
CPT. This compound decreased basal [35S]GTPγS binding to the 351Ile and 351Cys
fusion proteins very effectively (-49 and -48% vs. –25% for the unfused receptor
expressed in COS-7 cells). Differences in absolute numbers are also substantial. We
used up to 10-fold less protein when studying the fusion constructs, implicitly
showing the enormous increase in “window”.
The maximal stimulation and inhibition of basal [35S]GTPS binding appeared to
depend on the nature of the amino acid at position 351 of the G i-subunit (Ile > Val >
Cys > Gly > Pro > unfused receptor, for agonist activation). These observations are
in line with the report by Bahia et al.23. They found a good correlation between the
hydrophobicity of the amino acid at this position and the maximal activation of the
porcine 2A adrenoceptor. Note that the authors co-expressed the mutated Gi
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proteins and the 2A adrenoceptor, while we used A1-Gifusion proteins. Here, we
show that their conclusions regarding the correlation mentioned above were also
applicable to our mutated A1-Gifusion proteins.
Conclusions
In the present study we analysed fusion proteins between the adenosine A1 receptor
and (mutated) G protein αi-subunits with respect to two novel concepts in receptor
pharmacology, i.e. allosteric modulation and constitutive activity.
Allosteric modulation of ligand binding was not always similar for A1-G i fusion
proteins compared to the unfused adenosine A1 receptor. In most cases, sodium ions
were unable to decrease CPA binding to membranes expressing A1-G i fusion
proteins. Their lack of effect may result from a change in receptor conformation
induced by the coupling of the Gi-subunit. In contrast, allosteric modulation by
PD81,723 was comparable for the unfused adenosine A1 receptor and the A1-G i
fusion proteins. Thus, PD81,723 is able to shift the ‘fusion’ receptor equilibrium
further towards R*G.
We also demonstrated that fusion proteins between the human adenosine A1
receptor and various 351Cys-mutated rat G isubunits can be used as a research tool
to investigate inverse agonism at adenosine A1 receptors. Despite lower receptor
densities, basal [35S]GTPS binding to COS-7 membranes expressing A1-Gifusion
proteins was higher than in membranes with the unfused adenosine A1 receptor. In
addition, proper substitution of 351Cys, for instance into an isoleucine residue,
increased the readout window of CPA-stimulated [35S]GTPS binding substantially.
The same fusion protein (351Ile A1-Gi) also showed increased inhibition of basal
[35S]GTPS binding induced by CPT.
In conclusion, fusion proteins between GPCRs and their G proteins may be subject
to allosteric modulation. They emerge as very useful research tools in the study of
constitutive activity and inverse agonism.
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Chapter 4
Allosteric modulators affect the internalization of
human adenosine A1 receptors
.
To study the effect of allosteric modulators on the internalization of human adenosine
A1 receptors, the receptor was equipped with a C-terminal yellow fluorescent protein
tag. The introduction of this tag did not affect the radioligand binding properties of the
receptor. CHO cells stably expressing this receptor were subjected during 16 h to
varying concentrations of the agonist N6-cyclopentyladenosine (CPA) in the absence
or presence of 10 μM of the allosteric enhancer PD81,723 ((2-amino-4,5-dimethyl-3-
thienyl)-[3-(trifluoromethyl)phenyl]methanone) or SCH-202676 (N-(2,3-diphenyl-1,2,4-
thiadiazol-5(2H)-ylidene)methanamine). CPA itself was able to internalize 25% and
40% of the receptors at a concentration of 400 nM or 4 μM, respectively. Addition of
either PD81,723 or SCH-202676 alone had no effect on internalization. However,
with PD81,723 a slight amount of internalization was obtained already at 40 nM of
CPA, and at 400 nM CPA 59% of the receptors internalized. SCH-202676 on the
other hand effectively prevented CPA-induced internalization of the receptor.
Based upon Klaasse EC, van den Hout G, Roerink SF, de Grip WJ, IJzerman AP,
Beukers MW., Eur J Pharmacol. 2005, 522:1-8.
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Introduction
Adenosine receptors are members of the superfamily of G protein-coupled receptors
(GPCRs) and are pharmacologically classified into four distinct types, namely the
adenosine A1, A2A, A2B and A3 receptor. Adenosine A1 and A3 receptors are coupled
to a Gi protein, thereby inhibiting the production of cAMP via adenylyl cyclase. In
contrast, adenosine A2A and A2B receptors are coupled to a Gs protein, thereby
stimulating the production of cAMP (for review on adenosine receptors, see
Fredholm et al.)1.
Like other members of the GPCR family, adenosine receptors are subject to allosteric
modulation (for reviews on allosteric modulation, see Soudijn et al.; Christopoulos
and Kenakin)2,3. PD81,723 ((2-amino-4,5-dimethyl-3-thienyl)-[3-
(trifluoromethyl)phenyl]-methanone) is an allosteric enhancer selectively exerting its
action on the adenosine A1 receptor. It potentiates the agonist binding, thereby
enhancing the functional effects of adenosine or its analogues4. It has also been
reported that PD81,723 potentiates constitutive activity of the adenosine A1 receptor5.
SCH-202676 (N-(2,3-diphenyl-1,2,4-thiadiazol-5(2H)-ylidene)methanamine) on the
other hand inhibits both agonist and antagonist binding to a number of GPCRs such
as human μ-, -, and -opioid, - and -adrenergic, muscarinic M1 and M2, and
dopaminergic D1 and D2 receptors6, including adenosine receptors7,8. Recent studies
revealed that SCH-202676 and analogues are not strict allosteric modulators as
originally thought, but rather sulfhydryl modifying agents that reversibly modify
cysteine residues in proteins9,10.
Adenosine receptors, like other GPCRs, undergo internalization upon agonist
stimulation. Internalization or sequestration is described as the loss of cell surface
receptor number, determined by the combined effects of endocytosis and recycling11.
In the present study, we focus on the internalization of the human adenosine A1
receptor. The process of internalization has been shown to be initiated by the
functional desensitization of the adenosine A1 receptor. After a short period of agonist
exposure (5-15 min), the adenosine A1 receptors uncouple from the Gi proteins due
to phosphorylation, catalyzed by specific receptor kinases12-15. Especially serine and
threonine residues close to the C-terminus of the receptor are susceptible to
phosphorylation12,16. Upon phosphorylation of the adenosine A1 receptor, -arrestins
are attracted, which couple to the phosphorylated receptor. -arrestins do not only
desensitize the receptor, but also function as clathrin adaptors thereby inducing the
process of sequestration and internalization. Although phosphorylation of the
adenosine A1 receptor returned to its basal state within minutes, the desensitization
continued for hours. Unlike the uncoupling, t1/2 for the internalization process of the
adenosine A1 receptor is quite slow, 10 1 h14. In contrast, t1/2 for internalization of
the other G i coupled adenosine receptor (A3 receptor) is short, only 10 min16.
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In the present study, we have examined whether allosteric modulators are able to
influence the internalization of the human adenosine A1 receptor. To visualize this
process, we engineered a yellow fluorescent protein (YFP) C-terminal of the human
adenosine A1 receptor. Our findings indicate that the presence of the allosteric
enhancer PD81,723 lowers the threshold of agonist concentration at which receptor
internalization occurs. In contrast, the presence of SCH-202676 almost completely
prevented internalization of the human adenosine A1 receptor.
Materials and methods
Materials
N6-cyclopentyladenosine (CPA) was obtained from Research Biochemicals Inc.
(Natick, MA, U.S.A.). 8-cyclopentyl-1,3-cylcopentyladenosine ([3H]DPCPX -specific
activity 124 Ci/mmol) was purchased from NEN (Du Pont Nemours, ‘s
Hertogenbosch, The Netherlands). G418 (neomycin) was obtained from Stratagene
(Cedar Creek, U.S.A.). (2-amino-4,5-dimethyl-3-thienyl)-[3-
(trifluoromethyl)phenyl]methanone (PD81,723) and (N-(2,3-diphenyl-1,2,4-thiadiazol-
5(2H)-ylidene)methanamine (SCH-202676) were synthesized in our own laboratory
as described by Van der Klein et al.18 and Van den Nieuwendijk et al.7 respectively.
All other chemicals were of analytical grade and obtained from standard commercial
sources.
Construction of human adenosine A1YFP receptor
The human adenosine A1 receptor cDNA (1.3 kb) was isolated from pcDNA3
(Invitrogen BV, Breda, The Netherlands) and inserted into the pBluescript II SK (-)
vector (Stratagene, Cedar Creek, USA) using HindIII/XbaI sites. A reverse primer
was designed to mutate the stop codon, introduce an extra base and an ApaI site at
the 3’ end: 3’ gggtcttctctccggactactgccccgggcgc 5’ (ApaI restriction site is
underlined). The human adenosine A1 receptor cDNA was amplified by a polymerase
chain reaction (PCR) using a universal forward primer (un-4) for pBlueScript II SK(-)
and the designed reverse primer. The PCR product was purified on gel and
subcloned into the peYFP-N1 vector digested with HindIII/ApaI (kindly provided by C.
Backendorf, Leiden University), resulting in a human adenosine A1YFP receptor
construct.
Cell culture
CHO cells were cultured in a humidified atmosphere at 37 C and 5% CO2 in a 1:1
mixture of Dulbecco's Modified Eagle Medium (DMEM) and Ham’s F12 medium,
containing 10% newborn calf serum, 50 IU/ml penicillin, 50 μg/ml streptomycin and
Internalization of the human adenosine A1 receptor
77
0.8 μg/ml G418 for selection. CHO cells were stably transfected with the human
adenosine A1YFP receptor construct, using 1mg/ml N-(2,3-dioleoyloxy-1-
propyl)trimethylammonium methyl sulfate (DOTAP) as described by Beukers et al.19.
In short, 5 x 104 cells per well (24 wells plate) were seeded the day before
transfection. For each well, 2.3 μL DOTAP (1 mg/ml) plus 0.7 μg human adenosine
A1YFP receptor cDNA was added to 50 μL DMEM without serum. Liposomes were
formed during 20 min at room temperature. Cells were washed twice with DMEM
without serum, next 50 μL DMEM without serum was added followed by the
transfection mix. Cells were left for 2 h at 37 °C, 5% CO2. Subsequently, the cells
were washed with phosphate buffered saline (PBS) and treated with 5% Dimethyl
Sulfoxide (DMSO) in PBS for 3 min. The DMSO mixture was removed and 500 μL of
a 1: 1 mixture of DMEM/F12 medium, containing 10% newborn calf serum, 2 mM
glutamax, 50 IU/ml penicillin and 50 mg/ml streptomycin was added per well. G418
(0.8 mg/ml) was added to the medium to select for cells that had taken up the
plasmid. The medium was replaced every other day. After 10 days, individual
colonies were selected and transferred to separate wells in a 24 wells plate.
Radioligand binding experiments were performed to select a clone with a sufficiently
high expression level of the human adenosine A1YFP receptor. This clone was used
for internalization experiments. Cells were subcultured twice a week (1:40).
Preparation of cell membranes
CHO cells stably expressing the wt human adenosine A1 receptor were obtained from
A. Townsend-Nicholson20. Confluent CHO cells expressing either the wt human
adenosine A1 receptor or the human adenosine A1YFP receptor were scraped in PBS
and centrifuged for 10 min at 250 g. The cell pellets were resuspended in ice-cold
Tris-HCl buffer, 50 mM, pH 7.4, and homogenized on ice for 5 s at position 8 using
an Ystral homogenizer. The homogenates were centrifuged for 45 min at 17000 g at
4 C. The resulting pellets were resuspended in Tris-HCl buffer, 50 mM, pH 7.4, and
2 IU/ml adenosine deaminase was added. Aliquots were stored at –80 C. The
protein concentration of the membranes was measured using the BCA method21.
Receptor binding assays
Radioligand displacement experiments were performed with minor modifications as
described previously for the wt human adenosine A1 receptor in CHO cells22. In brief,
membranes (10 μg protein) were incubated in 400μL Tris-HCl buffer, 50 mM, pH 7.4,
in the presence or absence of 10 μM PD81,723 or 10 μM SCH-202676 and in the
presence of 1.6 nM [3H]DPCPX and increasing concentrations of CPA. Non-specific
binding was determined in the presence of 1 10-4 M CPA. For saturation
experiments, concentrations of [3H]DPCPX ranged from 0.1 to 10 nM. Samples were
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incubated at 25 C for 1 h in a shaking water bath and the incubation was terminated
by adding 1 ml of ice-cold Tris-HCl, 50 mM, pH 7.4 followed by rapid filtration over
Whatman GF/B glass-fiber filters. Filters were washed three times with 2 ml of ice
cold Tris-HCl buffer and placed in scintillation vials. For saturation experiments, filters
were washed six times with 2 ml of ice cold Tris-HCl buffer. Scintillation fluid
(Emulsifier Safe, Packard BioScience), 3.5 ml, was added and after 2 h extraction,
radioactivity was counted in an LKB Wallac 1219 rackbeta scintillation counter.
Experiments were performed in triplicate.
Internalization experiments
CHO cells stably expressing the human adenosine A1YFP receptor were plated on
coverslips in 24 wells plates at a density of 3 x 104 cells/well in a volume of 0.5 ml.
The cells were allowed to attach for 24 h, after which the medium was aspirated and
the cells were exposed for 16 h to 0 nM, 40 nM, 400 nM, 4 μM CPA in the presence
or absence of 10 μM PD81,723 or 10μM SCH-202676. Cells were washed once with
0.5 ml PBS, and fixed with 0.5 ml 4.0% formaldehyde (pH 7.0-7.2) for 10 min at room
temperature. Coverslips containing the cells were washed another 3 times with 0.5
ml PBS and subsequently mounted on object glasses using Aqua Polymount
(Polysciences). Coverslips were allowed to dry on air in darkness, and stored at 4 C
for short term storage or –20 C for long term storage. Images of the incubated cells
were obtained using confocal microscopy (Nikon Eclipse TE 2000-U), excitation at
520 nm, emission at 532 nm, 60x oil enlargement.
Quantification of internalization
The computer program Image Pro Plus (MediaCybernetics, Germany) was used to
quantify the amount of fluorescence in representative transsections of cells. The
amount of fluorescence in the cell membrane was determined and expressed as
percentage of the total fluorescence and was corrected for the differences in surface
area of the transsection. Transsections of at least three different cells were analyzed.
Quantification of internalization through radioligand binding
In addition, the amount of internalization was quantified with help of radioligand
binding experiments. Therefore, confluent 10 cm plates of CHO cells stably
expressing the human adenosine A1YFP receptor were incubated with or without 4
µM CPA for 16 hrs. Both were washed once with 5 ml PBS and subsequently
scraped in 5 ml PBS. The preparation of the membranes was performed as
described in section 2.4. The only modification was that the homogenates were
centrifuged for 2 x 20 min at 17000 g at 4 C. Radioligand binding studies were
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performed on membranes of the control cells as well as the exposed cells as
described in section 2.5.
Data analysis
Data of radioligand binding- and saturation experiments were analysed using the
non-linear regression curve fitting program Prism v. 3.0 (GraphPad, San Diego, CA,
USA). Apparent inhibitory binding constants (Ki values) were derived from the IC50
values according to the Cheng and Prusoff equation Ki = IC50/(1 + [L*]/KD) where [L*]
is the concentration of the radioligand and KD its dissociation constant23.
Results
Binding profile of wt human adenosine A1 receptors and human adenosine A1YFP
receptors, stably expressed in CHO cells.
First, we assessed the affinity and binding capacity of the radioligand [3H]DPCPX for
the human adenosine A1YFP receptor. In Table 4.1, the Kd and Bmax values of
[3H]DPCPX for the human adenosine A1YFP receptor in the presence or absence of
PD81,723 and SCH-202676 are shown. The Kd value of [3H]DPCPX for the human
adenosine A1YFP receptor was hardly affected by the addition of PD81,723 and
SCH-202676. The Bmax value was slightly but not significantly lowered in the
presence of PD81,723. Subsequently, radioligand binding studies were performed on
membranes of human adenosine A1YFP-CHO cells to characterize the binding
properties of the newly constructed human adenosine A1YFP receptor. In Figure 4.1,
displacement curves for the human adenosine A1YFP receptor are shown.
Displacement experiments were performed using the reference agonist CPA alone,
and CPA in the presence of 10μM PD81,723 or 10 μM SCH-202676.
Table 4.1. Saturation parameters of [3H]DPCPX on CHO-hA1YFP cell membranes
Compound Kd (nM) Bmax (fmol/mg)
Control 1.450.05 862 50
+ PD81,723 (10 μM) 1.510.15 669 55
+ SCH-202676 (10 μM) 1.210.09 805 127
Bmax and Kd-values of [3H]DPCPX in the absence or presence of PD81,723 (10 μM) or SCH-202676
(10 μM) on CHO-hA1YFP cell membranes were determined. Values are the means (S.E.M.) of three
independent experiments, performed in duplicate. None of the determined values is significantly
different compared to the control values, P > 0.05.
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[3H]DPCPX was used as radioligand. The binding properties of the human
adenosine A1YFP receptors were compared with the binding profile of the wt human
adenosine A1 receptors. Like the wt human adenosine A1 receptor, the human
adenosine A1YFP shows a biphasic behaviour towards CPA binding, and is also
susceptible to allosteric modulation. PD81,723, the allosteric enhancer, shifts the
CPA-curve to the left (gain of affinity) whereas in the presence of SCH-202676 the
CPA-curve is shifted to the right (loss of affinity). In addition, the high affinity state of
the human adenosine A1YFP receptor was shifted to the low affinity state in the
presence of SCH-202676. Ki-values of CPA for the human adenosine A1YFP
receptor in the presence or absence of PD81,723 and SCH-202676 are shown in
Table 4.2. The shifts in the Ki-values of CPA were 0.24 and 4.0 for the human
adenosine A1YFP receptor in the presence of PD81,723 or SCH-202676,
respectively.
Figure 4.1. Displacement of
[3H]DPCPX with CPA (■) only,
or in the presence of 10 μM
PD81,723 (○) or 10 μM SCH-
202676 (●). Membranes (10 
μg) were incubated for 60 min
at 25C as described in section
2.5. The graph is the mean of
three displacement curves of
the specific binding of
[3H]DPCPX to CHO-hA1YFP
membranes, each performed in
duplicate.
Table 4.2. Ki values of CPA in the presence or absence of 10μM PD81,723 or 10 μM SCH-202676 for
hA1YFP receptors expressed in CHO cells.
CHO-A1YFP
Ki low (nM)
Ki low
(nM)
Ki high
(nM)
Fraction
high (%) K i (nM) Shift
CPA 154 ± 9.5 0.610.20 37 2.0 42.57.2
CPA + PD81,723 47 ± 7.8 0.400.12 40 5.4 10.43.3 0.24
CPA + SCH-202676 172 28 4.0
The affinity of CPA for the hA1YFP-receptors in the presence or absence of different modulators was
determined by its displacement of [3H]DPCPX binding. Membranes (10 μg) were incubated for 60 min
at 25 C with CPA (in the presence or absence of PD81,723 and SCH-202676 as described in section
2.5. K i values S.E.M. were calculated from three independent experiments. Shifts were calculated by
dividing the K i value in the presence of allosteric modulator by the K i-value of CPA alone. To calculate
the K i values, the respective Kd values (Table 4.1) were used.
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Internalization of the human adenosine A1YFP receptors
The internalization of human adenosine A1YFP receptors induced by CPA, and the
influence of PD81,723 and SCH-202676 on this process, was investigated. First, we
determined the time-course needed to observe proper internalization. We incubated
CHO cells stably expressing the human adenosine A1YFP receptor at increasing
CPA concentrations for the following time points; 0, 2, 4, 6, 8, 16, 24 hours, and
observed them with help of fluorescence microscopy. From these experiments it
appeared that clear internalization was only observed after at least 16 hours of
incubation (results not shown), which is in agreement with the fact that the t1/2 for the
internalization process of the adenosine A1 receptor is 10 ± 1 h14. Additionally, we
observed that the presence of the allosteric modulator PD81,723 (10 µM) did not
accelerate the occurrence of internalization, but only increased the amount of
internalized receptors (data not shown).
Subsequently, human adenosine A1YFP-CHO cells were plated on coverslips and
incubated for 16 hours with CPA in a concentration range of 0 nM, 40 nM, 400 nM
and 4 μM, in the presence or absence of 10 μM PD81,723 or 10 μM SCH-202676.
Several confocal images were made from each incubation, and representative
transsections are shown in Figure 4.2. Control human adenosine A1YFP-CHO cells
show a clear, equally distributed membrane staining. The lowest CPA concentration
(40 nM, approximate K i-value) did not induce internalization of the human adenosine
A1YFP receptor. At 400 nM CPA (approx. 10 Ki), internalization of the human
adenosine A1YFP receptor was apparent as green fluorescent dots in the cytoplasm.
This effect was more distinct at the highest concentration CPA (4 μM, approx. 100 
Ki). In the presence of the allosteric enhancer PD81,723 (10 μM) at the lowest CPA
concentration (40 nM), membrane staining was not as equally distributed as in the
control cells. The internalization of the human adenosine A1YFP receptor at CPA
concentrations of 400 nM and 4 μM in the presence of PD81,723 was more
substantial than internalization with CPA alone. Incubation of human adenosine
A1YFP-CHO cells in the presence of SCH-202676 (10 μM) almost completely
prevented the internalization of the human adenosine A1YFP receptors. No
internalization was observed, except for the highest concentration of CPA (4 μM)
where SCH-202676 was not able to completely prevent the internalization of the
human adenosine A1YFP receptors. PD81,723 or SCH-202676 alone did not induce
internalization.
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Figure 4.2. Confocal fluorescent pictures of internalized hA1YFP receptors in CHO cells. hA1YFP CHO
cells were incubated for 16 hours with increasing concentrations of CPA in the presence or absence of
PD81,723 (10 μM) and SCH-202676 (10 μM). Pictures were taken from a representative transsection
of the cell.
Quantitative analysis of internalization
The amount of receptor internalization was quantified with help of the computer
program Image Pro Plus. In Figure 4.3, the remaining fluorescence in the cell
membrane is represented as a bar graph. At least three transsections of independent
cells were quantified. Control human adenosine A1YFP-CHO cells as well as cells
exposed to either one of the compounds showed between 84% and 88% fluorescent
membrane staining. The 40 nM CPA incubation showed only 11% internalization in
the presence of 10 μM PD81,723, the membrane staining was reduced from 88% to
77%. However, this reduction was not significant. CPA alone (40 nM) and in the
presence of SCH-202676 (10 μM) showed values comparable to control cells for
membrane staining (resp. 87% and 84%). Exposure to 400 nM CPA reduced the
membrane staining from 88% to 63% (25% internalization), whereas the addition of
10 μM PD81,723 reduced the membrane staining even further to 29% (59% receptor
internalization). SCH-202676 counteracted the effect of 400 nM CPA, such that no
internalization was observed (90% fluorescence in the membrane). Exposure to 4 μM
CPA reduced membrane staining from 88% to 48%, whereas the addition of 10 μM
PD81,723 reduced this percentage to 27% (61% internalized human adenosine
A1YFP receptors), yielding approximately the same amount of internalized receptors
Control 40 nM CPA 400 nM CPA 4M CPA
Control
PD81,723
SCH-202676
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as obtained after incubation with 400 nM CPA plus PD81,723. Incubation with 4 μM
CPA in the presence of 10 μM SCH-202676 led to a marginal, non-significant,
reduction of membrane staining from 84% to 74%.
Figure 4.3. Quantitative analysis of the internalization of human adenosine A1YFP-receptors in CHO
cells. This bar graph corresponds with the confocal pictures shown in figure 2. The bars represent the
percentage fluorescence in the cell membrane. Transsections of at least three different cells were
analyzed. Values are means S.E.M. ** P ≤ 0.005, *** P ≤ 0.0005, percentage fluorescence
compared to the percentages fluorescence of corresponding incubations in the absence of CPA. ## P≤
0.005 compared to the percentage fluorescence of the respective internal control (equal CPA
concentration).
Confirmation of these results was obtained by performing radioligand binding studies
on plasma membranes of human adenosine A1YFP-CHO cells, exposed to 4 µM
CPA for 16 hours. The percentage of internalization measured as decrease of
radioligand binding compared to control (i.e. cells treated identically but without CPA
present) was 32±1%, corresponding very well to the 40% internalization measured by
confocal microscopy.
Discussion
The introduction of a yellow fluorescent protein at the C-terminus of the human
adenosine A1 receptor and stable transfection of this human adenosine A1YFP
receptor into CHO cells, provided us with a tool to study internalization of the human
adenosine A1 receptor. By making the human adenosine A1 receptor visible, there is
no need to add fluorescent antibodies or gold particles as has been described before
to visualize the internalization of the adenosine A1 receptors12,14,24-26.
Saturation experiments revealed that the addition of YFP to the C-terminus of the
adenosine A1 receptor did not affect the Kd value of [3H]DPCPX for the human
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adenosine A1YFP receptor (1.45 0.05 vs 1.60.1 nM for the wt human adenosine
A1 receptor22. The addition of the allosteric modulator PD81,723 or SCH-202676 also
hardly affected the Kd-value (1.510.15 and 1.210.09 nM, respectively, see Table
4.1). However, in the presence of PD81,723, the Bmax value was slightly lower, 669 
55 fmol/mg vs 862 50 fmol/mg for control, although these values did not differ
significantly. Similar effects of PD81,723 on Bmax and Kd values for the wt human
adenosine A1 receptor had been found by Battacharya and Linden27 and Kollias-
Baker et al.5.
As is shown in Figure 4.1 and Table 4.2, the addition of the C-terminal YFP did not
markedly influence the binding properties of the adenosine A1 receptor. The human
adenosine A1YFP receptor showed a two state binding curve, similar as described for
the wild-type human adenosine A1 receptor28. The fraction of high affinity receptors
was 37– 40% for the human adenosine A1YFP receptors, stably expressed in CHO
cells. Slightly higher percentages of wild-type human adenosine A1 receptors in the
high affinity state were found by Musser et al.4 and Dalpiaz et al.28, 52% and 74%
respectively. The addition of PD81,723 did not increase the number of human
adenosine A1YFP receptors receptors in the high affinity state, in accordance with
experiments by Musser et al.4.
The affinity of CPA for the human adenosine A1YFP receptor is in the same order of
magnitude as reported in the literature for the wt human adenosine A1 receptor. The
Ki value for the low affinity state was 154 ± 9.5 nM vs 76 ± 6 nM for the wt human
adenosine A1 receptor and the Ki value for the high affinity state was 0.61 ± 0.2 nM
vs 2.8 ± 0.2 nM for the wt human adenosine A1 receptor, respectively28. We observed
a shift in affinity caused by the addition of PD81,723 of 0.30 for the low affinity state,
and of 0.66 for the high affinity state, respectively. This corresponds well with the
values found by Musser et al.4, reporting shifts for the wt human adenosine A1
receptor of 0.29 and 0.57, respectively. The addition of SCH-202676 caused a shift
towards the low affinity state, resulting in a one-site binding curve with a Ki value of
172 ± 28 nM. This is in the same order of magnitude as the Ki value found by
Heitman (personal communication) for binding of CPA in the presence of SCH-
202676 to the wt human adenosine A1 receptor, 225 ± 8 nM. SCH-202676 inhibited
the binding of the agonist CPA to the human adenosine A1YFP receptor with a shift
of 4. This is in accordance with the results found by van den Nieuwendijk et al., who
observed that the binding of the agonist radioligand [3H] 2-Cl-N6-
cyclopentyladenosine ([3H]CCPA) to human adenosine A1 receptors was reduced to
only 10% in the presence of 10 μM SCH-2026767. Gao et al. found that the
dissociation of the antagonist [3H]DPCPX was decreased almost 4 times by the
presence of SCH-2026768.
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These binding experiments showed us that the human adenosine A1YFP receptor
retains its pharmacological profile and that the allosteric modulator PD81,723 and
SCH-202676 have the same effect on the wt and the YFP-tagged adenosine A1
receptor.
As reviewed in Chapter 2, desensitization and presumed internalization of adenosine
A1 receptors after long term exposure to (R)-N6-(2-Phenylisopropyl)adenosine (R-
PIA) was observed earlier in other tissues such as rat brain13, DDT1 MF-2 cells12,15
and rat adipocytes29. Human adenosine A1 receptors, stably expressed in HEK293
cells and pretreated with 10 μM CPA for 24 h showed a downregulation of 48%16. In
these experiments, the desensitization was quantified using radioligand binding
experiments on plasma membranes. Here, we describe the internalization of the
human adenosine A1YFP receptor in CHO cells induced by different concentrations
of CPA and monitored by confocal microscopy, and confirm the results with
radioligand binding experiments. After 16 hours of incubation with 400 nM CPA,
which is approximately 10 Ki of CPA, 25% of the receptors were internalized. It is
striking that CPA is not able to induce receptor internalization at a concentration of 40
nM, close to CPA’s K i value (42.5 nM) at which half of the receptor population is
assumed to be occupied. This is in contrast to DDT1MF-2 cells exposed to 50 nM R-
PIA for 12-24 h, which showed clear internalization12. The Ki value of R-PIA for the
adenosine A1 receptor in DDT1MF-2 cells is 76 nM15. This difference may be
explained to a different regulation of receptor internalization for each cell type
adenosine A1 receptors are expressed in. Apparently, over 50% of the human
adenosine A1YFP receptors have to be occupied by CPA before the receptors start to
cluster, subsequently followed by internalization. Internalization became more
apparent (40%) at a concentration of 4 μM CPA (approx. 100 Ki). Radioligand
binding experiments performed on membranes of this incubation confirmed this
percentage (32 ± 1%). In the presence of the allosteric enhancer PD81,723 (10 μM),
however, some internalization (11%) was already observed at a concentration of 40
nM CPA. The internalization at 400 nM and 4 μM became more distinct in the
presence of 10 μM PD81,723 (59% and 61% respectively). Allosteric enhancers,
such as PD81,723, have the property that they bind to a site distinct from the
orthosteric ligand binding site. By doing so, they change the 3D-conformation of the
receptor and facilitate ligand binding. In other words, they enhance the affinity of
agonists for the receptor. Our data show that this change in receptor conformation,
induced by PD81,723, also enhances clustering and internalization of de human
adenosine A1YFP receptor upon agonist binding, thereby increasing the amount of
internalized receptors. This results in a higher percentage of internalized receptors in
the presence of PD81,723 at the same CPA concentration. The action of PD81,723
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is synergistic. PD81,723 (10 μM) alone has no effect on receptor distribution. This is
in accordance with Bhattacharya and Linden27 who did not observe a decrease in
membrane binding sites after 24 h of pretreatment with 20 μM PD81,723.
Pretreatment of CHO cells stably expressing recombinant human adenosine A1
receptors with either 10 μM CPA or 10 μM CPA plus 20 μM PD81,723 resulted in a
loss of membrane binding sites of over 40%.
Recently, it has been shown that the enzyme adenosine deaminase (ADA) acted as
a receptor activity modifying protein (RAMP) on the adenosine A1 receptor, and
stimulated R-PIA induced A1 receptor internalization24. Thus, ADA also appears to
regulate A1 receptor function allosterically. However, the role of ADA was different
compared to that of PD81,723. ADA accelerated the internalization of adenosine A1
receptors, t1/2 decreased from 10 h to 2.9 h14, whereas PD81,723 lowers the treshold
of agonist concentration at which internalization occurs. ADA did not increase the
number of receptors which are internalized25, whereas PD81,723 increases the
percentage of internalized receptors from 40% to 61% at the highest concentration of
CPA tested (4 μM).
Next to the allosteric enhancer PD81,723 we also studied SCH-202676. In contrast
to PD81,723, SCH-202676 (10 μM) completely prevented the internalization of the
human adenosine A1YFP receptors at all CPA concentrations, except for 4μM CPA.
At the highest CPA concentration, some clustering of human adenosine A1YFP
receptors was observed (10%). Even at a concentration of 4 μM CPA, the
percentage of occupied receptors is not high enough to induce substantial
internalization due to the presence of 10 μM SCH-202676. To the best of our
knowledge the effects of this modulator on receptor processing have not been
addressed before.
In conclusion, in this study we present the effect of the allosteric modulator PD81,723
and SCH-202676 on the internalization of the human adenosine A1 receptor.
PD81,723, an allosteric enhancer, is able to lower the threshold of agonist
concentration for inducing internalization. Already at a concentration of 40 nM CPA,
some internalization is observed. On the contrary, SCH-202676 is a strong inhibitor
of agonist binding, thereby preventing internalization of the human adenosine A1YFP
receptors.
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Structure-activity relationships of 2-amino-4-
(substituted)phenyl-6-(substituted)sulfanyl-
pyridine-3,5-dicarbonitriles
reveal full agonists with picomolar affinity
for the human adenosine A1 receptor
Recently, we reported on selective agonists for human adenosine A1 receptors with
an unusual structure lacking the ribose moiety of traditional adenosine-like agonists.
The synthesis, affinity and activity of twelve such non-ribose ligands, all 2-amino-4-(3
and/or 4-disubstituted phenyl)-6-(substituted)sulfanyl-pyridine-3,5-dicarbonitriles, are
described in this study. The substitution pattern of the phenyl ring determined the
affinity of the compounds for the adenosine A1 receptor, whereas efficacy was
determined by the substituents on both the phenyl ring and the sulfanyl chain.
The di-methoxyphenyl substituted compounds had very little affinity. The
monosubstituted compounds recognized one binding state/site with higher
nanomolar affinity. cAMP second-messenger studies revealed an activity profile
ranging from partial agonism to partial inverse agonism.
3,4-Methylenedioxyphenyl substituted compounds recognized two binding
states/sites with a picomolar affinity for the high affinity site. These compounds were
full agonists that largely superseded the prototypic agonist N6-cyclopentyladenosine
(CPA) in affinity and potency.
Based upon Klaasse EC, Roerink SF, van Veldhoven JPD, von Frijtag Drabbe
Künzel JK, de Grip WJ, Brussee J, IJzerman AP, Beukers MW. Manuscript in
preparation.
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Introduction
Traditionally agonists for adenosine receptors are structurally related to the
endogenous ligand adenosine, consisting of an adenine base coupled to a ribose
moiety. In the search for selective, high affinity agonists for the human adenosine A1
receptor, adenosine has been substituted at different positions. Especially the
introduction of a hydrophobic substituent such as cyclopentyl at the N6-position
resulted in potent adenosine A1 agonists1.
We recently learned from patent literature about a new class of adenosine ligands,
the 2-amino-4-(3,4-disubstituted-phenyl)-6-(2-hydroxyethylsulfanyl)-pyridine-3,5-
dicarbonitriles, structurally unrelated to adenosine itself2,3. We synthesized a number
of such compounds ourselves and observed that several compounds displayed a
significant affinity and efficacy towards different adenosine receptor subtypes.4,5. In
our hands it turned out that the substitution pattern at the phenyl ring R1 greatly
affected the efficacy of the compounds (for structures see Table 5.1). But what would
happen to the affinity and efficacy of the compounds for the human adenosine A1
receptor if the ethanol substituent R2 would be modified? To address this issue,
ethanol was replaced with methylethanol or ethylpropionate for four classes of
phenyl-substituted compounds.
This synthetic program yielded a number of compounds with unprecedented high
affinity and potency, some of which were significantly more potent (10 to 100-fold)
than the decades-long reference agonist, N6-cyclopentyladenosine (CPA).
Experimental section
Materials and Methods
N6-cyclopentyladenosine (CPA) and N6-cyclopentyl-9-methyladenine (N0840) were
obtained from Research Biochemicals Inc. (Natick, MA, U.S.A.). Bovine serum
albumin (BSA), 1,3-dipropyl-8-cyclopentylxanthine (DPCPX), forskolin, DEAE dextran
and chloroquine were from Sigma (St. Louis MO, U.S.A.). Adenosine deaminase
(ADA) was purchased from Roche Biochemicals (Mannheim, Germany) and
Bicinchonic acid (BCA) protein assay reagent was obtained from Pierce Chemical
Company (Rockford, IL, U.S.A.). [3H] 1,3-dipropyl-8-cyclopentylxanthine ([3H]DPCPX
with a specific activity of 124 Ci/mmol) was purchased from NEN (Du Pont Nemours,
‘s Hertogenbosch, The Netherlands). [3H] cyclic adenosine monophosphate ([3H]
cAMP with a specific activity of 32.1 Ci/mmol) was obtained from Perkin Elmer Life
Sciences Inc. (Boston, MA, U.S.A.). G418 (neomycin) was obtained from Stratagene
(Cedar Creek, U.S.A.). Protein kinase A (PKA) was isolated from bovine adrenal
glands according to Leurs et al.6. Chinese hamster ovary (CHO) cells stably
expressing the human adenosine A1 receptor were obtained from A. Townsend –
Nicholson7. HEK293 cells expressing the human adenosine A2A or the A3 receptor
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were kindly provided by Dr. J. Wang, Biogen, USA and Dr. K.-N. Klotz, University of
Würzburg, Germany, respectively.
All other reagents were obtained from commercial sources and all solvents were of
analytical grade. 1H and 13C NMR spectra were recorded on a Bruker AC 200 (1H
NMR, 200 MHz; 13C NMR, 50.29 MHz) spectrometer with tetramethylsilane as an
internal standard. Chemical shifts are reported in δ(ppm) and the following
abbreviations are used: s = singlet, d = doublet, t = triplet, m = multiplet, br = broad.
Melting points were determined on a Büchi melting point apparatus and are
uncorrected. Elemental analyses on all end products (13-24) were performed by the
Leiden Institute of Chemistry and are within 0.4% of the theoretical values unless
otherwise stated. Reactions were routinely monitored by TLC using Merck silica gel
F254 plates.
Synthesis
General Procedure for functionalized malononitriles (1-4)
To malononitrile (1.32 mL, 20.8 mmol) dissolved in EtOH (14 mL) was added an aldehyde (20 mmol)
followed by 3 drops of piperidine. This reaction mixture was then refluxed for 1 hour, and then allowed
to cool to room temperature, upon which a precipitate was formed. The crude product was collected
by filtration and used without any further purification.
2-(3,4-Dimethoxy-benzylidene)-malononitrile (1)
Off white solid, 53% yield. 1H-NMR δ(DMSO): 8.39 (s, 1H, CH), 7.66-7.60 (m, 2H, phenyl-H), 7.27-
7.22 (m, 1H, phenyl-H), 3.91 (s, 3H, CH3), 3.83 (s, 3H, CH3).
2-Benzo[1,3]dioxol-5-ylmethylene-malononitrile (2)
Off white solid, 46% yield. 1H-NMR δ(DMSO): 8.39 (s, 1H, CH), 7.57-7.54 (m, 2H, phenyl-H), 7.24-
7.19 (m, 1H, phenyl-H), 6.25 (s, 2H, -OCH2O-).
2-(4-Dimethylamino-benzylidene)-malononitrile (3)
Off white solid, 45% yield. 1H-NMR δ(DMSO): 8.08 (s, 1H, CH), 7.87 (d, 2H, J = 9.5 Hz phenyl-H),
6.89 (m, 2H, J = 9.5 Hz, phenyl-H), 3.13 (s, 6H, 2 CH3).
2-(3-Fluoro-benzylidene)-malononitrile (4)
Off white solid, 56% yield. 1H NMR δ(DMSO): 8.59 (s, 1H, CH), 7.84-7.60 (m, 4H, phenyl-H).
General Procedure for 2-Amino-4-(substituted)-phenyl-6-phenylsulfanyl-pyridine-3,5-
dicarbonitriles (5-8)
To a solution of the functionalized malononitrile (1-4) (10 mmol) in EtOH (10 mL), was added
malononitrile (0.64 mL, 10 mmol), thiophenol (1.02 mL, 10 mmol) and triethylamine (50 µL), and the
mixture heated at reflux for approximately 4 h. The reaction mixture was then allowed to cool to room
temperature. The crude product precipitated upon cooling and was collected by filtration.
2-Amino-4-(3,4-dimethoxy-phenyl)-6-phenylsulfanyl-pyridine-3,5-dicarbonitrile (5)
Yellow solid, 28% yield. 1H-NMR δ(DMSO): 7.77 (br s, 2H, NH2), 7.65-7.50 (m, 7H, phenyl-H), 7.15 (d,
2H, J = 8.8 Hz, phenyl-H), 3.67 (s, 3H, CH3), 3.63 (s, 3H, CH3).
2-Amino-4-benzo[1,3]dioxol-5-yl-6-phenylsulfanyl-pyridine-3,5-dicarbonitrile (6)
Yellow solid, 34% yield. 1H-NMR δ(DMSO): 7.80 (br s, 2H, NH2), 7.64-7.60 (m, 2H, S-phenyl-H), 7.53-
7.50 (m, 3H, S-phenyl-H), 7.20-7.04 (m, 3H, phenyl-H), 6.18 (s, 2H, -OCH2O-).
2-Amino-4-(4-dimethylamino-phenyl)-6-phenylsulfanyl-pyridine-3,5-dicarbonitrile (7)
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Yellow solid, 32% yield. 1H-NMR δ(DMSO): 7.68 (br s, 2H, NH2), 7.64-7.60 (m, 2H, phenyl-H), 7.54-
7.48 (m, 2H, phenyl-H), 7.44 (d, 2H, J = 8.8 Hz, 4-NMe2-phenyl-H), 6.86 (d, 2H, J = 8.8 Hz, 4-NMe2-
phenyl-H), 3.03 (s, 6H, 2 CH3).
2-Amino-4-(3-fluoro-phenyl)-6-phenylsulfanyl-pyridine-3,5-dicarbonitrile (8)
Yellow solid, 24% yield. 1H-NMRδ(DMSO): 7.90 (br s, 2H, NH2), 7.71-7.40 (m, 9H, phenyl-H).
General Procedure for 2-Amino-4-(substituted)-phenyl-6-mercapto-pyridine-3,5-dicarbonitriles (9-12)
The pyridine (5-8) (3 mmol) was dissolved in DMF (10 mL) and to this was added sodium sulfide (0.78
g, 10 mmol) and the mixture stirred at 80 °C for 2 h. Upon cooling to room temperature, 1 M HCl (20
mL) was added, resulting in the formation of a yellow precipitate. The crude product was collected by
filtration.
2-Amino-4-(3,4-dimethoxy-phenyl)-6-mercapto-pyridine-3,5-dicarbonitrile (9)
Yellow solid, quantitative yield. 1H-NMR δ(DMSO): 7.17-7.13 (m, 3H, phenyl-H), 3.85 (s, 3H, OCH3),
3.81 (s, 3H, OCH3).
2-Amino-4-benzo[1,3]dioxol-5-yl-6-mercapto-pyridine-3,5-dicarbonitrile (10)
Yellow solid, quantitative yield. 1H-NMR δ(DMSO): 7.13-7.00 (m, 3H, phenyl-H), 6.17 (s, 2H, -OCH2O-
).
2-Amino-4-(4-dimethylamino-phenyl)-6-mercapto-pyridine-3,5-dicarbonitrile (11)
Yellow solid, quantitative yield. 1H-NMR δ(DMSO): 7.41 (d, 2H, J = 8.8 Hz, phenyl-H), 6.83 (d, 2H, J =
8.8 Hz, phenyl-H), 3.03 (s, 6H, 2CH3).
2-Amino-4-(3-fluoro-phenyl)-6-mercapto-pyridine-3,5-dicarbonitrile (12)
Yellow solid, quantitative yield. 1H-NMR δ(DMSO): 7.65-7.59 (m, 1H, phenyl-H), 7.48-7.35 (m, 3H,
phenyl-H).
General Procedure for 2-Amino-4-[(substituted)phenyl]-6-[(substituted)sulfanyl)]-pyridine-3,5-
dicarbonitriles (13-24)
The free thiol (9-12) (1 mmol) was stirred with the bromo compounds (1 mmol), NaHCO3 (0.34 g, 1
mmol) in DMF (2 mL) at room temperature for 2 h. Water (10 mL) was added to precipitate the crude
product, which was collected by filtration. Purification by column chromatography on SiO2, eluting with
dichloromethane-methanol mixtures or ethylacetate-petroleum ether mixtures and/or ethylacetate,
followed by recrystallisation gave the desired products (13-24) in approximately 40% yield.
2-Amino-4-(3,4-dimethoxy-phenyl)-6-(2-hydroxy-ethylsulfanyl)-pyridine-3,5-dicarbonitrile (13)
White Solid. mp: 209 ºC. 1H-NMR δ(DMSO): 7.96 (br s, 2H, NH2) 7.19-7.13 (m, 3H, phenyl-H), 5.02
(m, 1H, OH), 3.86 (s, 3H, OCH3), 3.81 (s, 3H, OCH3), 3.69-3.66 (m, 2H, OCH2), 3.32-3.19 (m, 2H,
CH2S).
13C-NMR δ(DMSO): 167.0, 159.7, 158.0, 150.4, 148.3, 126.0, 121.5, 115.7, 115.6, 112.3,
111.5, 92.7, 85.9, 59.5, 55.7, 55.6, 32.8. MS (ESI): 356.9. Anal. (C17H16N4O3S) C, H, N, S.
2-Amino-4-(3,4-dimethoxy-phenyl)-6-(2-hydroxy-propylsulfanyl)-pyridine-3,5-dicarbonitrile (14)
White Solid. mp: 198 ºC. 1H-NMR δ(DMSO): 7.97 (br s, 2H, NH2) 7.19-7.13 (m, 3H, phenyl-H), 4.99 (d,
1H, J = 5.1 Hz, OH), 3.86 (s, 3H, OCH3), 3.81 (s, 3H, OCH3), 3.88-3.80 (m, 1H, CH), 3.42-3.17 (m, 2H,
CH2), 1.20 (d, 3H, J = 6.6 Hz, CH3).
13C-NMR δ(DMSO): 167.3, 159.7, 158.0, 150.4, 148.3, 125.9,
121.6, 118.6, 112.3, 111.5, 93.6, 88.6, 68.1, 55.7, 55.6, 22.6. MS (ESI): 370.8. Anal. (C18H18N4O3S) C,
H, N, S.
3-[2-amino-3,5-dicyano-4-(3,4-dimethoxy-phenyl)-pyridin-6-ylsulfanyl]-propionic acid ethyl ester
(15)
White Solid. mp: 172 ºC. 1H-NMR δ(DMSO): 8.04 (br s, 2H, NH2), 7.19-7.13 (m, 3H, phenyl-H), 4.12
(q, 2H, J = 7.3 Hz, OCH2), 3.86 (s, 3H, OCH2), 3.81 (s, 3H, OCH3), 3.46-3.39 (m, 2H, CH2CO), 2.82 (t,
2H, J = 6.9 Hz, CH2S), 1.22 (t, 3H, J = 6.9 Hz, CH3).
13C-NMR δ(DMSO): 171.4, 166.6, 159.8, 158.1,
150.4, 148.3, 125.8, 121.5, 115.6, 112.3, 111.5, 91.9, 88.8, 60.2, 55.7, 55.6, 33.4, 24.9, 14.1. MS
(ESI): 412.7. Anal. (C20H20N4O4S) C, H, N, S.
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2-Amino-4-benzo[1,3]dioxol-5-yl-6-(2-hydroxy-ethylsulfanyl)-pyridine-3,5-dicarbonitrile (16)
White Solid. mp: 192 ºC. 1H-NMR δ(DMSO): 7.99 (br s, 2H, NH2), 7.16-7.01 (m, 3H, phenyl-H), 6.17
(s, 2H, -OCH2O-), 5.02 (t, 1H, J = 5.5 Hz, OH), 3.67 (m, 2H, OCH2), 3.38-3.32 (m, 2H, CH2S).
13C-
NMR δ(DMSO): 197.7, 167.0, 159.7, 157.9, 148.9, 147.4, 127.4, 123.0, 115.6, 115.4, 108.9, 108.5,
101.8, 93.8, 59.5, 32.6. MS (ESI): 341.1. Anal. (C16H12N4O3S) C, H, N, S.
2-Amino-4-benzo[1,3]dioxol-5-yl-6-(2-hydroxy-propylsulfanyl)-pyridine-3,5-dicarbonitrile (17)
White Solid. 1H-NMR δ(DMSO): 7.98 (br s, 2H, NH2), 7.12-7.00 (m, 3H, phenyl-H), 6.17 (s, 2H, -
OCH2O-), 4.99 (d, 1H, J = 4.7 Hz, OH), 3.94-3.83 (m, 1H, CH), 3.41-3.16 (m, 2H, CH2), 1.20 (d, 3H, J
= 6.2 Hz, CH3).
13C-NMR δ(DMSO): 167.3, 159.6, 157.9, 148.9, 147.4, 127.5, 123.0, 115.6, 115.4,
108.9, 108.6, 101.9, 93.8, 85.8, 65.1, 38.3, 22.7. Anal. (C17H14N4O3S) C, H, N.
3-(2-Amino-4-benzo[1,3]dioxol-5-yl-3,5-dicyano-pyridin-6-ylsulfanyl)-propionic acid ethyl ester
(18)
White Solid. mp: 162 ºC. 1H-NMR δ(DMSO): 8.05 (br s, 2H, NH2), 7.16-7.01 (m, 3H, phenyl-H), 6.17
(s, 2H, -OCH2O-), 4.12 (q, 2H, J = 6.6 Hz, OCH2), 3.44-3.35 (m, 2H, CH2CO), 2.85-2.78 (m, 2H,
CH2S), 1.22 (t, 3H, J = 7.3 Hz, CH3).
13C-NMR δ(DMSO): 171.4, 166.5, 159.8, 157.9, 148.9, 147.4,
127.4, 123.0, 115.3, 108.9, 108.6, 101.8, 93.7, 86.0, 60.2, 33.3, 24.9, 14.1. MS (ESI): 396.7. Anal.
(C19H16N4O4S) C, H, N, S.
2-Amino-4-(4-dimethylamino-phenyl)-6-(2-hydroxy-ethylsulfanyl)-pyridine-3,5-dicarbonitrile (19)
White Solid. mp: 268 ºC dec. 1H-NMR δ(DMSO): 7.87 (br s, 2H, NH2) 7.39 (d, 2H, J = 8.8 Hz, phenyl-
H), 6.82 (d, 2H, J = 8.8 Hz, phenyl-H), 4.99 (t, 1H, J = 5.5 Hz, OH), 3.69-3.60 (m, 2H, OCH2), 3.38-
3.32 (m, 2H, CH2S), 3.00 (s, 6H, 2 CH3). 13C-NMR δ(DMSO): 167.1, 160.0, 158.3, 151.5, 129.9,
120.0, 116.1, 116.0, 111.3, 93.2, 85.0, 59.6, 39.5, 32.6. MS (ESI): 339.8. Anal.
(C17H17N5OS∙0.2CH2Cl2) C, H, N, S.
2-Amino-4-(4-dimethylamino-phenyl)-6-(2-hydroxy-propylsulfanyl)-pyridine-3,5-dicarbonitrile
(20)
White Solid. mp: 245 ºC. 1H-NMR δ(DMSO): 7.86 (br s, 2H, NH2) 7.39 (d, 2H, J = 8.8 Hz, phenyl-H),
6.83 (d, 2H, J = 8.8 Hz, phenyl-H), 4.98 (d, 1H, J = 5.1 Hz, OH), 3.94-3.83 (m, 1H, CH), 3.40-3.10 (m,
2H, CH2S), 3.02 (s, 6H, 2 CH3), 1.20 (d, 3H, J = 5.8 Hz, CH3). 13C-NMR δ(DMSO): 167.4, 160.0,
158.3, 151.6, 129.9, 120.1, 116.1, 111.4, 93.2, 84.9, 65.2, 39.6, 38.3, 22.7. MS (ESI): 353.9. Anal.
(C18H19N5OS∙0.2 MeOH) C, H, N, S.
3-[2-Amino-3,5-dicyano-4-(4-dimethylamino-phenyl)-pyridin-6-ylsulfanyl]-propionic acid ethyl
ester (21)
White Solid. mp: 186 ºC. 1H-NMR δ(CDCl3): 7.47 (d, 2H, J = 8.8 Hz, phenyl-H), 6.76 (d, 2H, J = 8.8
Hz, phenyl-H), 5.71 (br s, 2H, NH2), 4.18 (q, 2H, J = 7.3 Hz, OCH2), 3.43 (t, 2H, J = 6.6 Hz, CH2CO),
3.03 (s, 6H, 2 CH3), 2.76 (t, 2H, J = 6.6 Hz, CH2S), 1.27 (t, 3H, J = 7.3 Hz, CH3). 13C-NMR δ(CDCl3):
171.6, 168.2, 159.6, 158.2, 151.9, 130.0, 119.5, 116.3, 115.7, 111.4, 85.8, 60.9, 39.9, 34.0, 25.4, 14.1.
MS (ESI): 396.0. Anal. (C20H21N5O2S) C, H, N, S.
2-Amino-4-(3-fluoro-phenyl)-6-(2-hydroxy-ethylsulfanyl)-pyridine-3,5-dicarbonitrile (22)
White Solid. mp: 189 ºC. 1H-NMR δ(DMSO): 8.09 (br s, 2H, NH2), 7.70-7.59 (m, 1H, phenyl-H), 7.52-
7.37 (m, 3H, phenyl-H), 5.05 (t, 1H, J= 5.5 Hz, OH), 3.72-3.64 (m, 2H, OCH2), 3.40-3.33 (m, 2H,
CH2S).
13C-NMR δ(DMSO): 167.8, 159.5, 130.3, 130.2, 123.7, 117.1, 116.7, 115.2, 114.8, 114.3,
105.6, 83.3, 59.8, 31.5. MS (ESI): 314.8 Anal. (C15H11FN4OS∙0.3MeOH) C, H, N, S.
2-Amino-4-(3-fluoro-phenyl)-6-(2-hydroxy-propylsulfanyl)-pyridine-3,5-dicarbonitrile (23)
White Solid. mp: 185 ºC. 1H-NMR δ(DMSO): 8.09 (br s, 2H, NH2), 7.61-7.57 (m, 1H, phenyl-H), 7.52-
7.36 (m, 3H, phenyl-H), 5.00 (d, 1H, J= 5.1 Hz, OH), 3.91-3.82 (m, 1H, CH), 3.21 (d, 2H, J = 6.6 Hz,
CH2S), 1.18 (d, 3H, J = 5.8 Hz, CH3).
13C-NMR δ(DMSO): 167.3, 164.2, 159.5, 156.9, 136.3, 136.1,
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131.2, 131.0, 124.8, 117.5, 117.1, 115.9, 115.5, 115.3, 115.1, 93.6, 85.7, 65.1, 22.7. MS (ESI): 328.7
Anal. (C16H13FN4OS∙0.1CH2Cl2) C, H, N, S.
3-[2-Amino-3,5-dicyano-4-(3-fluoro-phenyl)-pyridin-6-ylsulfanyl]-propionic acid ethyl ester (24)
White Solid. mp: 131 ºC. 1H-NMR δ(MeOD): 6.86-6.75 (m, 1H, phenyl-H), 6.57-6.50 (m, 3H, phenyl-
H), 3.39 (q, 2H, J = 7.3 Hz, OCH2), 2.71 (t, 2H, J = 6.6 Hz, CH2CO), 2.03 (t, 2H, J = 6.6 Hz, CH2S),
0.49 (t, 3H, J = 7.3 Hz, CH3).
13C-NMR δ(MeOD): 173.3, 168.9, 166.4, 161.3, 158.5, 137.6, 132.1,
131.9, 125.7, 118.5, 118.1, 117.0, 116.5, 115.9, 95.5, 89.8, 61.9, 35.0, 26.4, 14.5. MS (ESI): 370.9.
Anal. (C18H15FN4O2S) C, H, N, S.
Cell culture
CHO cells stably expressing the human adenosine A1 receptor were cultured in a 1:1
mixture of Dulbecco’s modified Eagle’s medium (DMEM) and Ham’s F12 medium
containing 10% newborn calf serum, streptomycin (50 µg/mL), penicillin (50 IU/mL)
and 0.2 or 0.8 mg/mL neomycin (G418), respectively. The cells were maintained in a
humidified atmosphere at 37 ºC and 5% CO2, and subcultured twice weekly.
Preparation of cell membranes
Membranes of CHO cells stably expressing the human adenosine A1 receptor and of
HEK293 cells stably expressing the human adenosine A2A receptor or human
adenosine A3 receptor were prepared as previously described8,9. The protein
concentration in the membrane preparation was determined using the BCA method
with BSA as a standard10.
Radioligand displacement assay
Radioligand binding studies were carried out as previously described11. In short,
membrane aliquots containing 10 µg of protein were incubated in 400 µL of 50 mM
Tris-HCl buffer, pH 7.4 at 25 ºC for 60 min in the presence of ADA (1 U/mL) and
approximately 1.6 nM [3H]DPCPX. Increasing concentrations of cold ligand were
added to determine the affinity of the ligands. Non-specific binding was measured in
the presence of 10 µM CPA. Incubations were stopped by rapid dilution with 1 mL
ice-cold 50 mM Tris-HCl, pH 7.4 and bound radioligand was separated from free
radioligand by rapid filtration through Whatman GF/B filters using a Brandel
harvester. Filters were subsequently washed three times with 2 mL ice-cold buffer.
Filter-bound radioactivity was measured by liquid scintillation counting (Tri-Carb
2900TR, Perkin Elmer) after the addition of 3.5 mL of Packard Emulsifier Safe.
Experiments were performed in triplicate. Radioligand binding to membranes of
HEK293 cells expressing the adenosine A2A and A3 receptors was performed in
duplicate with [3H]ZM241385 (KD = 1.0 nM) and [125I]I-ABMECA (KD = 5.0 nM) as
radioligands, respectively. Details of these experiments have been previously
described8.
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cAMP assay
cAMP assays were performed according to Kourounakis et al. (2001)12. In short, cells
stably expressing the human adenosine A1 receptor were harvested using a trypsin
solution (0.25% in PBS/EDTA), resuspended in medium and plated in 24-well plates
at 500 µl or 2 × 105 cells/well. After 24 hr, the cells were washed two times with 500
µl DMEM containing 50 mM HEPES, pH 7.4. Subsequently, cells were incubated at
37 ºC in 250 µL DMEM + HEPES supplemented with ADA (2 IU/mL), rolipram (50
µM) and cilostamide (50 µM). After 30 min of preincubation, ligands (50 µL) were
added, giving a final concentration between 1 to 20 M based on the Ki value of the
ligand. For the same reason, the reference compounds CPA, DPCPX and N0840
were tested at 1, 1 and 100 M, respectively. The concentration was at least 100 ×
Ki, to achieve maximal receptor activation as reported e.g. by Beukers et al. (2004)4.
In addition, concentration-effect curves were generated for CPA, LUF5853 and
LUF6037 with concentrations ranging from 1 pM to 1 µM. After 10 min of incubation
(37 ºC), 100 µL forskolin was added (final concentration 10 µM) and cells were
incubated for an additional 15 min at 37 ºC. The assay was terminated by quick
aspiration of the medium and cells were lysed by adding 200 µL of 0.1 M ice-cold
HCl. Plates were stored at -20 ºC until further use. To determine the amount of cAMP
produced, 100 µL PKA in buffer (150 mM K2HPO4; 10 mM EDTA; 0.2% BSA, pH
7.5), 50 µL [3H]cAMP (20,000 dpm) in K2HPO4/EDTA buffer (150 mM K2HPO4; 10
mM EDTA, pH 7.7) and 50 µL of the cell lysate or cAMP solution for generation of a
standard curve (0-16 pmol/200 µL 0.1 M HCl) were incubated on ice for 2.5 hr.
Separation of bound and free radioligand was performed by rapid filtration through
Whatman GF/C filters that were subsequently washed once with ice-cold buffer.
Scintillation fluid (Emulsifier Safe, Packard Bioscience), 3.5 mL, was added and after
2 hr extraction, radioactivity was counted using a Tri-Carb 2900TR, Perkin Elmer
scintillation counter.
Data analysis
Data of radioligand binding and cAMP experiments were analyzed using the non-
linear regression curve fitting program Prism v. 4.0.2 (GraphPad, San Diego, CA,
USA). Radioligand displacement curves were fitted to one and two site binding
curves. For LUF5853 (16), LUF6037 (17), LUF5854 (18) and CPA the data were best
fitted to a two site binding model. K i values were derived from the IC50 values
according to the Cheng & Prusoff equation Ki = IC50/(1+[L*]/Kd), where [L*] is the
radioligand concentration, and Kd its dissociation constant13.
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Results
Chemical synthesis
Compounds 13-24 were synthesized according to Scheme 5.1 essentially as
previously described2,3,5. Intermediates (1-4) were obtained in moderate to good
yields (46-56%) via a straightforward Knoevenagel condensation of the respective
aldehyde with malononitrile in the presence of a few drops of piperidine. The
formation of the pyridine occurred according to the preparation previously described
by Kambe et al. (1981) resulting in the phenyl protected sulfide at the 6-position of
the ring14. The functionalized malononitrile was refluxed with another equivalent of
malononitrile and an equivalent of thiophenol in ethanol and triethylamine, resulting in
compounds 5-8 (24-34% yields). The free thiol in the 6-position of the pyridine ring
was obtained by adding 3.3 equivalents of sodium sulfide in DMF at 80 °C for 2-3
hours and resulted in quantitative yields of compounds 9-12. The yields stated
correspond to the crude material, and it was this crude substance that was used in
subsequent reactions. Purification of the crude product was not performed
throughout the synthesis, nor were the reactions optimized. The final step was the
reaction of the free thiol with the bromo compounds in the presence of NaHCO3 in
DMF at room temperature. The final compounds 13-24 were obtained in 35-43%
yields. They were purified by chromatography and subsequent recrystallisation gave
clean, fully characterized compounds.
Scheme 5.1. Synthetic route to 2-Amino-4-(substituted)phenyl-6-(substituted)sulfanyl-pyridine-3,5-
dicarbonitriles 13-24.a
R1 CHO CNNC R
1
NC CN
N
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CN
SNH2
NC
N
R1
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SHNH
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N
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SNH2
NC
R2
+
1-4
9-1213-24
a
b
cd
5-8
(a) piperidine, EtOH, 1 h reflux; (b) malononitrile, thiophenol, triethylamine, EtOH, 4 h reflux; (c) (i)
Na2S, DMF, (ii) 1M HCl; (d) bromo compound, NaHCO3, DMF.
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Affinities of the novel, non-ribose ligands for the human adenosine A1 receptor
The affinity of the newly synthesized non-ribose ligands was assessed with help of
radioligand binding studies on membranes of CHO cells stably expressing the human
adenosine A1 receptor. First of all, single point measurements at a concentration of 1
µM were performed for each ligand to determine the percentage inhibition of
radioligand binding. For those compounds that gave more than 50% displacement at
a concentration of 1 µM, whole displacement curves were generated, to determine
the Ki value of the ligand. In Table 5.1, the percentages displacement at 1 µM or the
Ki values in nM for each non-ribose ligand are presented. From this table it appears
that within the different subsets – based on the R1 group - a change in R2 group from
ethanol, to methylethanol or ethylpropionate did not affect the affinity of the ligand for
the human adenosine A1 receptor to a great extent.
On the other hand, modification of the R1 substituent had striking effects on the
affinity. LUF5850 – 5852 (13-15), containing a 3,4-dimethoxyphenyl-group as R1
group, showed a displacement between 22% and 37% at a concentration of 1 µM,
whereas introduction of a (4)-N,N-dimethylphenyl group as in LUF5874 (19),
LUF5875 (20) and LUF5876 (21) resulted in affinities of 245, 340 and 231 nM,
respectively. A 3-fluoro-phenyl group at the R1 position resulted in ligands (22-24)
with a rather high affinity for the human adenosine A1 receptor (Ki of 40 – 69 nM).
Non-ribose ligands for the human adenosine A1 receptor
99
Table 5.1. Reported KI values or % displacement of compounds 13-24 for human adenosine A1
receptors. The double figures for compounds 16-18 represent the Ki, high and Ki, low values.
N
R1
CN
SNH2
NC
R2
R1 R2 Compound Ki [nM]
[b] or
Displacement at 1 M [%]
O
O
OH LUF5850 (13) [a] 25 ± 1%
OH
LUF5851 (14) 22 ± 6%
O
O
LUF5852 (15) 37 ± 9%
O
O
OH LUF5853 (16) 0.026 ± 0.020 12 ± 3.9
OH
LUF6037 (17) 0.021 ± 0.008 7.9 ± 2.8
O
O
LUF5854 (18) 0.28 ± 0.18 45 ± 6.6
N
OH
LUF5874 (19)[a] 245 ± 103
OH
LUF5875 (20) 340 ± 111
O
O
LUF5876 (21) 231 ± 93
F
OH LUF5877 (22) [a] 40 ± 10
OH
LUF5878 (23) 43 ± 24
O
O
LUF5879 (24) 69 ± 17
[a] Data from Chang et al. (2005) J Med Chem 48:2045-20535.
[b] Mean of three experiments SEM
Much higher affinities were obtained with LUF5853 (16), LUF6037 (17) and LUF5854
(18), containing a 3,4-methylenedioxyphenyl as R1 group. Interestingly, the three
compounds recognized two binding states/sites on the receptor, whereas all other
non-ribose compounds recognized just one binding site (see Figure 5.1). Moreover,
the affinity of LUF5854 (18) for the high affinity site was 10 fold higher than CPA,
0.28 ± 0.18 nM and 2.2 ± 0.9 nM, respectively15. The affinities of LUF5853 (16) and
LUF6037 (17) for the high affinity site were even higher, 100-fold, compared with
CPA, 26 pM and 21 pM, respectively.
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Figure 5.1. Displacement of
3H]DPCPX from the human
adenosine A1 receptor expressed
on CHO membranes by LUF5853
(16) (○), LUF6037 (17) (●) or CPA 
(■). A representative curve from
one experiment performed in
duplicate is shown.
Selectivity of the novel, non-ribose ligands for the human adenosine A1 receptor
To determine the selectivity of the non-ribose ligands for the adenosine A1 receptor
the interaction of the compounds with the adenosine A2A and adenosine A3 receptors
expressed on HEK293 cells was investigated. None of the compounds (13-24) was
able to displace to a considerable extent either [3H]ZM241385 or [125I]I-ABMECA
from the adenosine A2A or adenosine A3 receptors, respectively (Table 5.2).
Efficacies of the novel, non-ribose ligands on the human adenosine A1 receptor
Subsequently, the functional activity of the novel, non-ribose ligands was tested in a
cAMP assay. The final concentration varied between 1-20 μM, to obtain a
concentration of at least 100 × K i to ensure full receptor occupancy. LUF5850 –
LUF5852 (13-15) were not considered in the activity assay, because of their low
affinity. The basal cAMP concentration in the CHO cells was set at 0%, and the
cAMP concentration in forskolin-stimulated cells was set at 100%. For comparison,
three reference ligands, CPA (1 μM), DPCPX (1,3-dipropyl-8-cyclopentylxanthine, 1
μM) and N0840 (N6-cyclopentyl-9-methyladenine, 100 μM) were also included. The
agonist CPA inhibited the forskolin-stimulated cAMP production from 100% to 41 ±
9%. DPCPX, an inverse agonist, increased the cAMP production from 100% to 297 ±
37%. A somewhat smaller increase was observed for N0840 (210 ± 41%). The set of
non-ribose ligands represented the whole range of full agonists to inverse agonists
(Figure 5.2). LUF6037 (17) (29 ± 7%), LUF5853 (16) (31 ± 20%), LUF5854 (18) (50 ±
14%), and LUF5877 (22) (40 ± 14%) performed better than or equally well as CPA
(41 ± 9%) in inhibiting the cAMP production, and are thus considered full agonists.
LUF5874 (19) (68 ± 19%) and LUF5878 (23) (56 ± 13%) rather behaved as partial
agonists in this test system. LUF5875 (20) and LUF5879 (24) can be regarded as
neutral antagonists, given their slight influence on forskolin-stimulated cAMP
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production, 107 ± 19% and 118 ± 9%, respectively. Finally, LUF5876 (21) appeared
to be a (partial) inverse agonist, given its increase in cAMP production to 187 ± 31%.
Table 5.2. Reported% displacement of compounds 13-24 for human adenosine A2A and A3
receptors.
Compound
hA2A
Displacement at 1 M
hA3
Displacement at 1M
LUF5850 (13)[a] 25% 0%
LUF5851 (14) 19% 1%
LUF5852 (15) 26% 4%
LUF5853 (16)[a] 33% 13%
LUF6037 (17) 22% 1%
LUF5854 (18) 28% 2%
LUF5874 (19)[a] 0% 7%
LUF5875 (20) 3% 9%
LUF5876 (21) 5% 11%
LUF5877 (22)[a] 19% 8%
LUF5878 (23) 19% 1%
LUF5879 (24) 24% 16%
[a] Data from Chang et al. (2005) J Med Chem 48:2045-20535.
Figure 5.2. Modulation of
forskolin-induced cAMP
production in CHO cells stably
expressing the human adenosine
A1 receptor, after exposure to
reference ligands (CPA, DPCPX,
N0840) and non-ribose ligands
(LUF5853-5879, 16-24) at a
concentration between 1 to 100
μM to obtain full receptor
occupancy (n = 3). Each subset
of non-ribose ligands with
identical R1 group but different
R2 groups is labeled with the
same bar pattern.
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Full cAMP concentration-effect curves were generated for the high, picomolar, affinity
non-ribose agonists LUF6037 (17) and LUF5853 (16). Representative curves for
CPA, LUF6037 (17) and LUF5853 (16) are shown in Figure 5.3. The EC50 values
were 2.1 0.7 nM, 0.060.05 nM and 0.10.03 nM, respectively.
Figure 5.3. Representative curves
of the inhibition of forskolin-
stimulated cAMP production by
CPA (■), LUF5853 (16) (○) and 
LUF6037 (17) (●) in CHO cells
stably expressing the human
adenosine A1 receptor (n = 5,
except for LUF5853 (16), n = 4).
Discussion
Structural analogues of adenosine, especially when substituted at the N6 position are
known to, often selectively, activate the human adenosine A1 receptor1. Moreover the
presence of a ribose moiety has always been considered essential for receptor
activation16,17. The publication of several patents2,3 describing a series of compounds
as agonists for the adenosine receptors lacking a ribose moiety firmly challenged that
hypothesis. These findings prompted us to synthesize a number of such ligands, all
substituted 3,5-dicyanopyridine derivatives, that indeed showed a high affinity,
activity and selectivity for the human adenosine A1 receptor5. In the present study, we
extended our research program by synthesizing and evaluating compounds 13-24.
Affinity and selectivity of the novel, non-ribose ligands for the human adenosine A1
receptor
The compounds with an ethanol substituent at the R2 position were part of a larger
series of non-ribose ligands, with more variation in the 3,4-substituents at the phenyl
ring at the R1 position5. It was found that increasing the electronegativity by
introducing e.g. a fluorine atom or a hydroxyl group at especially the 3-position is
important to increase the affinity of the ligands5. These findings were confirmed and
extended in our current experiments, demonstrating that the R2 group itself is
important for affinity, but does not affect the rank order of potency that is dictated by
the R1 group. Moreover, three highly potent ligands, LUF5853 (16) and LUF6037 (17)
and LUF5854 (18), were identified, all with unprecedented picomolar affinity. In fact
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we had missed the very high affinity of LUF5853 (16) in our previous publication5. but
due to our experimental observations with 17 and 18 we were prompted to
reexamine these earlier findings. These compounds share a 3,4-methylenedioxy
group at R1 with an alcohol or ester function at R2. Whereas these agonists
recognized two binding states of the receptor, all other non-ribose compounds
recognized just one binding state/site. This is in line with previous data on a similar
compound, LUF5831, a partial adenosine A1 receptor agonist that recognized a
single binding state/site only15. Strikingly, the rigidity and somewhat smaller size
provided by the closed ring structure of these three compounds is strongly preferred
over the low affinity compounds 13-15. The latter have a minor change in substitution
pattern, namely two adjacent methoxy groups, which may cause too much steric
hindrance in the receptor binding site.
To determine the selectivity of these compounds for the adenosine A1 receptor the
interaction with the adenosine A2A and A3 receptors was determined. In agreement
with the previously reported data for a series of related analogues, none of the
compounds (13-24) was able to interact with these receptors to a considerable
extent5.
Efficacy of the novel, non-ribose ligands for the human adenosine A1 receptor
Whereas the affinity was mainly determined by the substitution pattern on the phenyl
ring, different results were obtained with respect to efficacy. In this series of
compounds (13-24) the efficacy was affected both by the substitution pattern on the
phenyl ring, and by the substitution pattern on the sulfanyl chain. The effects of the
substitution pattern on the phenyl ring were in line with previously reported data5.
Interestingly, however, the substitution pattern on the sulfanyl side-chain was also
important. The efficacy to activate the receptor decreased with increasing chain
length. Thus a change from ethanol to methylethanol and ethylpropionate resulted in
a decrease in efficacy from an agonist such as LUF5874 (19), a neutral antagonist
such as LUF5875 (20), to an inverse agonist such as LUF5876 (21). In our hands
and in this cAMP assay N0840, which is generally claimed to be a neutral antagonist
and behaved as such in [35S]GTPS binding studies18,19, was an inverse agonist (210
± 41%), quite similar to LUF5876 (21).
In conclusion, structure-activity relationship studies documented very potent full
agonists for the adenosine A1 receptor in a series of 3,5-dicyanopyridines substituted
at both the phenyl and sulfanyl position. These compounds lack any obvious
similarity with the traditional ribose, adenosine-like compounds. Substitution at the
phenyl ring mostly dictated affinity, whereas the substitution pattern at the sulfanyl
position appeared to rather govern intrinsic activity. Compounds such as LUF5853
(16) and LUF6037 (17) largely superseded CPA in its affinity and potency.
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LUF6037, a non-adenosine agonist with picomolar
potency for the adenosine A1 receptor is unable to
internalize the receptor
We and others have recently shown that a novel class of non-adenosine compounds
interacts with adenosine A1 receptors. Here we report on a new derivative, LUF6037,
a very potent non-adenosine A1 receptor agonist. The striking structural differences
between traditional adenosine-like agonists and LUF6037 prompted us to investigate
its interaction with the receptor and its ability to induce internalization. Radioligand
binding and cAMP studies were carried out with CHO cells expressing the human
adenosine A1 receptor. The ability of LUF6037 to internalize the receptor was
determined with an adenosine A1 receptor equipped with a yellow fluorescent protein
(YFP) tag. LUF6037 recognized two binding states/sites on the human adenosine A1
receptor with affinities of 44 ± 30 pM and 8.7 ± 3.7 nM, both much higher than the
reference agonist cyclopentyladenosine (CPA) with affinities of 2.2 ± 0.9 nM and 338
± 24 nM. The interaction of LUF6037 with the receptor did not change in the
presence of the allosteric enhancer PD81,723, whereas PD81,723 increased CPA’s
affinity. LUF6037 behaved as a full agonist in thermodynamic radioligand binding
experiments as well as in a second messenger assay, where it completely inhibited
forskolin-stimulated cAMP production with an EC50 value of 60 5 pM. Finally,
whereas CPA dose-dependently induced receptor internalization, LUF6037 had no
effect. LUF6037 fully activates the human adenosine A1 receptor just like traditional
agonists such as CPA. However, unlike CPA the activation by LUF6037 is insensitive
to the allosteric modulator PD81,723. Moreover, LUF6037 does not induce receptor
internalization. Apparently full agonism does not necessarily lead to receptor
internalization. This behaviour may be therapeutically advantageous as drug
resistance, as a result of receptor internalization, may less readily occur.
Based upon Klaasse EC, Roerink SF, van Veldhoven JPD, von Frijtag Drabbe
Künzel JK, de Grip WJ, IJzerman AP, Beukers MW. Manuscript in preparation.
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Introduction
During the past decades, several agonists with high affinity for the human adenosine
A1 receptor have been developed. These ligands are structurally related to the
endogenous agonist adenosine, consisting of the adenine base coupled to a ribose
moiety. To increase the affinity and the selectivity of the agonists for the human
adenosine A1 receptor, adenosine has been substituted at different positions.
Especially substitutions at the N6-position often lead to potent and selective
adenosine A1 receptor agonists1.
Recently, a new class of adenosine ligands has been described in the patent
literature, the 2-amino-4-(3,4 substituted phenyl)-6-(2-hydroxyethylsulfanyl)-pyridin-
3,5-dicarbonitriles2,3. Although this class of ligands shows very little structural
similarity to adenosine, it was observed that several compounds displayed a
significant affinity and efficacy towards different adenosine receptor subtypes2,3,4,5. A
more detailed pharmacological characterization of one of these compounds,
LUF5831, revealed that this compound was a partial agonist with an affinity of 18 nM
for the adenosine A1 receptor6.
In this report we characterized a new non-adenosine agonist, LUF6037 (Figure 6.1),
and demonstrated it is a full agonist with very high picomolar affinity, largely
surpassing the potency of the reference agonist, N6-
cyclopentyladenosine (CPA). However, unlike CPA,
we found that this full agonist is insensitive to the
allosteric enhancer PD81,723. LUF6037 was also
tested for its ability to induce internalization of the
human adenosine A1 receptor. Again unlike CPA,
LUF6037 did not cause any translocation of a YFP-
tagged A1 receptor from the cell membrane to the
cytoplasm. This observation is first-time evidence
that full activation of this receptor does not
necessarily lead to internalization.
Methods
Materials
N6-cyclopentyladenosine (CPA) was obtained from Research Biochemicals Inc.
(Natick, MA, U.S.A.). 1,3-dipropyl-8-cyclopentylxanthine (DPCPX), bovine serum
albumin (BSA), forskolin, DEAE dextran and chloroquine were from Sigma (St. Louis
MO, U.S.A.). Adenosine deaminase (ADA) was purchased from Roche Biochemicals
(Mannheim, Germany) and Bicinchonic acid (BCA) protein assay reagent was
obtained from Pierce Chemical Company (Rockford, IL, U.S.A.). [3H] 1,3-dipropyl-8-
cyclopentylxanthine ([3H]DPCPX -specific activity 124 Ci/mmol) was purchased from
N
CNNC
NH2S
O
O
OH
Figure 6.1. Structure of LUF6037
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NEN (Du Pont Nemours, ‘s Hertogenbosch, The Netherlands). [3H] cyclic adenosine
monophosphate ([3H] cAMP – specific activity 32.1 Ci/mmol) was obtained from
Perkin Elmer Life Sciences Inc. (Boston, MA, U.S.A.). G418 (neomycin) was obtained
from Stratagene (Cedar Creek, U.S.A.). (2-Amino-4,5-dimethyl-3-thienyl)-[3-
(trifluoromethyl)phenyl]-methanone (PD81,723) was synthesized in our laboratory as
described by Van der Klein et al.7. Protein kinase A (PKA) was isolated from bovine
adrenal glands according to Leurs et al.8. LUF6037 was synthesized in our
laboratory, as described for the 2-amino-4-(3,4 substituted phenyl)-6-(2-
hydroxyethylsulfanyl)-pyridin-3,5-dicarbonitrile compounds5. Chinese hamster ovary
(CHO) cells stably expressing the human adenosine A1 receptor were obtained from
A. Townsend – Nicholson9. CHO cells stably expressing the human adenosine
A1YFP receptor were made in our laboratory10. All other chemicals were of analytical
grade and obtained from standard commercial sources.
Cell culture
CHO cells stably expressing the human adenosine A1 receptor or the human
adenosine A1YFP receptor were cultured in a 1:1 mixture of Dulbecco’s modified
Eagle’s medium (DMEM) and Ham’s F12 medium containing 10% newborn calf
serum, streptomycin (50 µg/mL), penicillin (50 IU/mL) and 0.2 or 0.8 mg/mL
neomycin (G418), respectively. The cells were maintained in a humidified
atmosphere at 37 ºC and 5% CO2, and subcultured twice weekly.
Preparation of cell membranes
Membranes of CHO cells stably expressing the human adenosine A1 receptor were
prepared as previously described10. The protein concentration in the membrane
preparation was determined using the BCA method11 with BSA as a standard.
Radioligand displacement assay
Radioligand binding studies were carried out as previously described12. In short,
membrane aliquots containing 10 µg of protein were incubated in 400 µL of 50 mM
Tris-HCl buffer, pH 7.4 at 25 ºC for 60 min or at 0 ºC for 120 min in the presence of
ADA (1 U/mL) and approximately 1.6 nM [3H]DPCPX. Increasing concentrations of
cold ligand were added in the presence or absence of 10 µM PD81,723. This
concentration of PD81,723 was chosen based on its EC50 value of 9.8 M13. Non-
specific binding was measured in the presence of 10 µM CPA. Incubations were
stopped by rapid dilution with 1 mL ice-cold 50 mM Tris-HCl, pH 7.4 and bound
radioligand was separated from free radioligand by rapid filtration through Whatman
GF/B filters using a Brandel harvester. Filters were subsequently washed three times
with 2 mL ice-cold buffer. Filter-bound radioactivity was measured by liquid
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scintillation counting (Tri-Carb 2900TR, Perkin Elmer) after the addition of 3.5 mL of
Packard Emulsifier Safe. Experiments were performed at least in triplicate.
Thermodynamic data determination
The values of the thermodynamic parameters were obtained by measuring Ki values
at 0 ºC and at 25 ºC, followed by van ‘t Hoff analysis14. The standard free energy,
ΔG0, was calculated according to ΔG0 = -RT ln KA with KA = 1/Ki. The van ‘t Hoff
equation yields a graph of ln KA versus 1/T. The standard enthalpy, ΔH0, can be
calculated from the slope (ΔH0/R), whereas the standard entropy, ΔS0, can be
calculated either from the intercept (ΔS0/R) or from ΔS0 = (ΔH0- ΔG0)/T, with R =
8.314 JK-1 mol-1 and T = 298.15 K
cAMP assay
cAMP assays were performed according to Kourounakis et al.15. In short, cells stably
expressing the human adenosine A1 receptor were harvested using a trypsin solution
(0.25% in PBS/EDTA), resuspended in medium and plated in 24-well plates at 500 µl
or 2 × 105 cells/well. After 24 hr, the cells were washed two times with 500 µl DMEM
containing 50 mM HEPES, pH 7.4. Subsequently, cells were incubated at 37 ºC in
250 µL DMEM + HEPES supplemented with ADA (2 IU/mL), rolipram (50 µM) and
cilostamide (50 µM). After 30 min of preincubation, ligands were added, to obtain the
concentrations as indicated. After 10 min of incubation (37 ºC), 100 µL forskolin was
added (final concentration 10 µM) and cells were incubated for an additional 15 min
at 37 ºC. The assay was terminated by quick aspiration of the medium and cells were
lysed by adding 200 µL of 0.1 M ice-cold HCl. Plates were stored at -20 ºC until
further use. To determine the amount of cAMP produced, 100 µL PKA in buffer (150
mM K2HPO4; 10 mM EDTA; 0.2% BSA, pH 7.5), 50 µL [3H]cAMP (20,000 dpm) in
K2HPO4/EDTA buffer (150 mM K2HPO4; 10 mM EDTA, pH 7.7) and 50 µL of the cell
lysate or cAMP solution for generation of a standard curve (0-16 pmol/200 µL 0.1 M
HCl) were incubated on ice for 2.5 hr. Separation of bound and free radioligand was
performed by rapid filtration through Whatman GF/C filters, that were subsequently
washed once with ice-cold buffer. Scintillation fluid (Emulsifier Safe, Packard
Bioscience), 3.5 mL, was added and after 2 hr extraction, radioactivity was counted
using a Tri-Carb 2900TR, Perkin Elmer scintillation counter. Experiments were
performed at least in triplicate.
Internalization experiments and quantification
CHO cells stably expressing the human adenosine A1YFP receptor were exposed to
the reference agonist CPA, to LUF6037 and to the inverse agonist DPCPX at a
concentration of 4 M to observe if internalization occurred. Internalization
experiments were performed as described before10. Briefly, 3 × 104 cells were plated
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on coverslips in a 24 wells plate (500 µL), and allowed to attach for 24 hr.
Subsequently, cells were exposed for 16 hr to the ligands, washed, fixed with 4.0%
formaldehyde (pH 7.0 - 7.2) and mounted on object glasses using Aqua Polymount®
(Polysciences). Images of representative transsections of the cells were obtained
using confocal microscopy (Nikon Eclipse TE 2000-U) with excitation at 520 nm and
emission at 532 nm under 60 × oil enlargement. In representative transsections of
cells, total cell fluorescence and fluorescence in the cytosol were measured using the
computer program Image Pro Plus (MediaCybernetics, Germany). Transsections of
at least three different cells were analyzed. The percentage plasma membrane
staining relative to total was subsequently calculated according to the method
described in Klaasse et al.10.
Data analysis
Data of radioligand binding and cAMP experiments were analyzed using the non-
linear regression curve fitting program Prism v. 4.0.2 (GraphPad, San Diego, CA,
USA). Radioligand displacement curves were fitted to one and two state/site binding
curves. For LUF6037 and CPA the data were best fitted to a two state/site binding
model. Ki values were derived from the IC50 values according to the Cheng & Prusoff
equation Ki = IC50/(1+[L*]/Kd), where [L*] is the radioligand concentration, and Kd its
dissociation constant16. The Kd values of [3H]DPCPX were 0.69 nM at 0 ºC, and 1.6
nM and 8.8 nM at 25 ºC in the absence and presence of PD81,723, respectively6.
Results
Affinity of LUF6037 for the human adenosine A1 receptor
To determine the affinity of LUF6037, radioligand binding studies were performed on
membranes of CHO cells stably expressing the human adenosine A1 receptor with
[3H]DPCPX as the radioligand (see Figure 6.2). LUF6037 recognized two binding
states/sites with affinities of 44 ± 30 pM and 8.7 ± 3.7 nM for the high and low affinity
sites, respectively (see Table 6.1). Both affinities are substantially higher than the
previously determined affinities of the reference agonist CPA, which were 2.2 ± 0.9
nM and 338 ± 24 nM, for the high and low affinity sites, respectively6.
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Figure 6.2. Displacement of
[3H]DPCPX from the human
adenosine A1 receptor expressed
on CHO membranes by LUF6037
(○) or CPA (■). A representative
curve from one experiment
performed in duplicate is shown.
Effect of the allosteric modulator PD81,723 on the affinity of LUF6037
Radioligand binding experiments were performed in the presence and absence of 10
M of the allosteric modulator PD81,723 (see Figure 6.3 and Table 6.1). In contrast
to CPA (Heitman et al.6, Table 6.1), LUF6037 was virtually insensitive to this
compound. The Ki,H and Ki,L values were 73 ± 32 pM and 9.9 ± 4.3 nM, respectively,
almost identical to the values reported in the absence of PD81,723 (Table 6.1).
Figure 6.3. Displacement of
[3H]DPCPX from the human
adenosine A1 receptor expressed
on CHO membranes by LUF6037
in the presence (closed symbols)
or absence (open symbols) of 10
M PD81,723.
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Table 6.1. Effect of PD81,723 (10 M) and temperature (25 ºC versus 0 ºC) on the high (K i,H) and low
(Ki,L) affinity binding of LUF6037 to the human adenosine A1 receptor. Data for CPA are shown for
comparison.
Condition LUF6037 CPAa
Ki,H in pM Ki,L in nM Ki,H in nM Ki,L in nM
25 ºC 44 ± 30 8.7 ± 3.7 2.2 ± 0.9 338 ± 24
25 ºC + PD81,723 73 ± 32 9.9 ± 4.3 2.3 ± 0.4 93 ± 22
0 ºC 55 ± 30 3.9 ± 0.3 7.0 ± 3.0 128 ± 64
a: data are from Heitman et al. 20066.
Effect of temperature on the affinity of LUF6037
To study the effect of temperature on the displacement of [3H]DPCPX with LUF6037,
radioligand binding studies were performed at 25 ºC and 0 ºC (see Table 6.1).
Neither the affinity for the high affinity site nor the affinity for the low affinity site was
strongly affected.
From these affinities the equilibrium binding association constants, KA (=1/Ki), were
calculated. The thermodynamic parameters ΔG0 (Gibbs energy), ΔH0 (standard
enthalpy) and ΔS0 (standard entropy) were determined with a van ‘t Hoff plot (Figure
6.4 and Table 6.2). The interaction of both CPA6 and LUF6037 with the high affinity
site is entropy driven and endothermic. The interaction with the low affinity state/site
was also similar for the two compounds, being exothermic and partially entropy and
partially enthalpy driven.
Figure 6.4. Van ‘t Hoff plots
showing the effect of
temperature on the equilibrium
binding constants, KA, for the
high and low affinity binding
sites of LUF6037 (open and
closed circles, respectively) and
CPA (open and closed squares,
respectively). The
thermodynamic parameters are
presented in Table 6.2.3.2 3.3 3.4 3.5 3.6 3.7 3.8
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Table 6.2. Thermodynamic parameters, ΔG0, ΔH0 and ΔS0, for the high and low affinity binding of
LUF6037 to the human adenosine A1 receptors. Data for CPA are shown for comparison.
Compound
ΔG0
kJ mol-1
ΔH0
kJ mol-1
ΔS0
J mol-1 K-1
LUF6037 (high) -59 ± 2 7.0 ± 12 223 ± 40
LUF6037 (low) -46 ± 9 -19.7 ± 5.7 89 ± 20
CPA (high) a -50 ± 1 45 ± 17 318 ± 60
CPA (low) a -37 ± 1 -16 ± 9 71 ± 31
a: data are from Heitman et al. 20066.
Efficacy of LUF6037
LUF6037 was further tested in cAMP experiments on CHO cells expressing the
human adenosine A1 receptor. For comparison the reference agonist CPA and the
reference inverse agonist DPCPX were also tested. The compounds were tested at
the concentrations indicated (see Figure 6.5). The basal cAMP production in the cells
was set at 0%, whereas the amount of cAMP produced in the presence of 10 M
forskolin was set at 100%. The reference agonist CPA (30 nM) inhibited the cAMP
production to 27 ± 7%, whereas the reference inverse agonist DPCPX (100 nM)
increased the cAMP production to 143 ± 15%. LUF6037 (30 nM) was equipotent to
CPA resulting in an inhibition of the cAMP production to 34 ± 5%. DPCPX at a
concentration of 100 nM was able to antagonize the effect of both CPA and LUF6037
to a similar extent resulting in values of 102 ± 9% and 109 ± 9%, respectively.
Figure 6.5. Modulation
of forskolin-induced
cAMP production in
CHO cells stably
expressing the human
adenosine A1 receptor,
after exposure to
reference ligands (CPA,
DPCPX) or LUF6037.
DPCPX was tested at a
concentration of 100 nM,
whereas CPA and
LUF6037 were tested at
a concentration of 30
nM.
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Figure 6.6. Representative
curves of the inhibition of cAMP
production by CPA (■) and
LUF6037 (○) in CHO cells stably
expressing the human adenosine
A1 receptor (n = 5).
In addition, full dose response curves for both CPA and LUF6037 were made (Figure
6.6). Analysis of these data revealed EC50 values for CPA and LUF6037 of 2.1 0.7
nM and 60 50 pM, respectively. These EC50 values are similar to the affinities of
CPA and LUF6037 for the high affinity state/site of the receptor, as obtained in the
radioligand binding studies.
Internalization of the human adenosine A1 receptor by LUF6037
CHO cells stably expressing the human adenosine A1YFP receptor were incubated
for 16 h with CPA and LUF6037 at a concentration of 4 M. Transsections of the
cells were studied with confocal microscopy, and the amount of plasma membrane
fluorescence was assessed. In Figure 6.7 the percentage fluorescence retained in
the plasma membrane is shown for the ligand-free situation as well as upon
incubation with either CPA or LUF6037. Whereas CPA significantly reduced the
number of plasma membrane bound receptors, LUF6037 was without effect, very
similar to a control experiment with the antagonist/inverse agonist DPCPX (4 µM).
The respective percentages of fluorescence retained on the plasma membrane were
38 ± 5%, 91 ± 4%, 80 ± 3% and 85 ± 5% for CPA, DPCX, LUF6037 and the control
situation, respectively. Representative transsections of confocal images are
presented in Figure 6.8.
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Figure 6.7. Percentage
membrane fluorescence on
plasma membranes of CHO
cells stably expressing
human adenosine A1YFP
receptors, after 16 h
exposure to CPA, DPCPX or
LUF6037 at a concentration
of 4 M, respectively.
Figure 6.8. Confocal fluorescent pictures of internalized human adenosine A1YFP receptors in CHO
cells. The cells were incubated for 16 hours with CPA, DPCPX or LUF6037, each at a concentration of
4 M. Pictures were taken from a representative transsection of the cell .
Apparently, LUF6037 is able to inhibit cAMP production as effectively as the full
agonist CPA, but differs from CPA with respect to its sensitivity to PD81,723 and its
ability to induce receptor internalization.
Discussion
Fuelled by a number of patent disclosures2,3, we recently synthesized LUF6037. This
compound is structurally unrelated to the endogenous ligand adenosine, the most
striking feature being the absence of a ribose moiety, which had always been thought
to be responsible for ‘agonistic’ behaviour and activation of the receptor17,18. In this
study, LUF6037 was tested on its ability to bind, activate and induce internalization of
the adenosine A1 receptor.
Affinity of LUF6037 for the human adenosine A1 receptor
Previously we reported on a structural analogue of LUF6037, LUF58316. LUF5831
recognized a single state/site of the human adenosine A1 receptor and was a partial
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agonist. In line with the full agonism displayed by LUF6037 in the cAMP experiments
(see below), LUF6037 recognized two states of the receptor, a high and a low affinity
state just like the reference full agonist CPA. However, LUF6037 was almost 100-fold
more potent than CPA, one of the typical high affinity reference agonists in this
research field.
Effect of the allosteric modulator PD81,723 on the affinity of LUF6037
PD81,723 has been classified as an allosteric enhancer as it increases the affinity of
CPA for the human adenosine A1 receptor 10,13,15,19. More precisely, addition of this
allosteric enhancer at a concentration of 10 M resulted in a leftward shift of the
[3H]DPCPX displacement curve affecting the low, but not the high affinity state/site of
the receptor6.
On the contrary, PD81,723 did not have an allosteric effect on LUF6037. The affinity
of LUF6037 was not affected by the presence of PD81,723, indicating that the
change in receptor conformation induced by PD81,723 is unable to enhance the
binding of this non-adenosine compound to the human adenosine A1 receptor. One
explanation could be that the non-adenosine ligands bind to a different binding site,
insensitive to PD81,723, since the binding of the partial agonist LUF5831 was not
sensitive to PD81,723 either6. The ability of the non-adenosine ligands to displace
[3H]DPCPX binding, just like the adenosine derivatives, suggests however that these
ligands share – at least partly – the same binding site. These findings also show the
general importance of defining the object of allosteric enhancement. In this case,
PD81,723 is an allosteric enhancer of CPA binding, not of LUF6037 binding, despite
the agonistic nature of both CPA and LUF6037.
Effect of temperature on affinity of the affinity of LUF6037
Thermodynamic experiments can be used to characterize ligand binding at GPCRs20;
for review see Borea et al.21. In these studies interaction of an agonist with the
adenosine A1 receptor appeared entropy driven whereas the binding of antagonist
was essentially enthalpy driven. Partial agonists display intermediate behaviour both
for adenosine derivates 14,21,22 and for the non-adenosine ligand LUF58316. Based on
these criteria LUF6037 should be classified as a full agonist as the thermodynamic
experiments at 25 ºC and 0 ºC demonstrated that the interaction with the high affinity
state is fully entropy driven. Indeed the interaction of LUF6037 largely mimics CPA
with respect to interaction with both the low and high affinity sites, although the ΔHo
(enthalpy) values are quite different.
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Efficacy of LUF6037
LUF6037 was tested on its ability to activate the human adenosine A1 receptor. The
second messenger cAMP was used as a read-out to determine the efficacy of
LUF6037. In line with the displacement experiments and the thermodynamic
analysis, LUF6037 was a very potent full agonist for the human adenosine A1
receptor with a picomolar EC50 value, closely mimicking the value of Ki,H obtained in
the radioligand binding studies. Its effect at a single concentration of 30 nM could be
reversed with the antagonist/inverse agonist DPCPX (100 nM), suggesting a
competitive interaction between the two ligands.
Internalization of the human adenosine A1 receptor by LUF6037
Stimulation of GPCRs with agonists often results in internalization of the receptor. In
this process, the receptors are transported from the plasma membrane to endosomal
compartments, thereby contributing to desensitization, a loss of functional
response23. Several studies have confirmed that treatment with the agonist R-PIA, an
adenosine derivative, induces internalization of the adenosine A1 receptor 24,25,26.
Upon stimulation a decrease in number of membrane-bound receptors was found,
but an increase of adenosine A1 receptors in light vesicles, indicating that
internalization was the underlying process of the desensitization of the receptor24.
Recently, we engineered a yellow fluorescent protein (YFP) to the C-terminus of the
human adenosine A1 receptor. By making the receptor fluorescent we could easily
detect and quantify internalization with confocal microscopy. In that study CPA dose-
dependently promoted internalization of the human adenosine A1 receptor upon
incubation during at least 16 hrs. Moreover, addition of 10 M PD81,723 did not
accelerate the process of internalization, but rather lowered the minimal
concentration of CPA needed to induce internalization10.
Since LUF6037 behaved as a full agonist in the radioligand binding as well as the
second messenger studies we also evaluated the ability of LUF6037 to induce
internalization of the human adenosine A1YFP receptor. In contrast to CPA, LUF6037
was not able to induce receptor internalization. These findings differ from more
commonly observed results such as reported by Schlag et al.27 in their research on
the 5-HT2C receptor, who observed internalization levels corresponding to agonist
intrinsic activity.
Receptor activation versus internalization
Apparently the high affinity and efficacy displayed by LUF6037 do not necessarily
lead to internalization of receptors after exposure to this ligand. Although LUF6037
acts as a full agonist, effectuating down-stream inhibition of adenylyl cyclase, thereby
decreasing cAMP formation, -arrestins necessary to induce internalization are most
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probably not attracted by the ligand-receptor complex. In that case, the broad
spectrum of signaling molecules recruited upon -arrestin activation as recently
reviewed by Lefkowitz and Shenoy28 will also be by-passed.
Complex signaling behaviour, also coined “collateral efficacy”, in which receptor
activation, phosphorylation and internalization are not always causally related, has
been recently reviewed by Maudsley et al.29 and Kenakin30. For instance agonists
may effectuate receptor phosphorylation but are unable to either activate the second
messenger system or to induce receptor internalization as observed with the
angiotensin analogue [Sar1, Ile4, Ile8]AngII on the wild-type AT1A receptor31.
The opposite may also occur whereby the ligand mediates receptor internalization
without activating the second messenger pathway. Such behaviour was reported for
amino-truncated forms of parathyroid hormone32 as well as for CCK analogues33 that
mediated internalization but not activation of their respective receptors. Keith et al.34
demonstrated that both enkephalins and morphine activate - and -opioid receptors
to inhibit adenylyl cyclase, but only enkephalins are able to induce rapid receptor
internalization. Yu et al.35 subsequently showed that a direct relationship existed
between the efficacy of morphine and its analogues and their ability to induce
phosphorylation and desensitization of the -opioid receptor. The 5-HT2C receptor
provides yet another example, in which the capacity of agonists to elicit
desensitization was not related to their efficacy to activate signaling36.
LUF6037 extends the list of examples of collateral efficacy in which a full agonist
lacks the ability to induce receptor internalization.
In conclusion, a new agonist for the adenosine A1 receptor with a structure
completely different from the classic adenosine-like compounds was
pharmacologically evaluated. This ligand, LUF6037, showed a very high affinity for
the human adenosine A1 receptor, with an affinity far extending beyond that of the
reference full agonist CPA. Remarkably, the allosteric modulator PD81,723 was not
able to enhance the affinity of LUF6037 for the human adenosine A1 receptor.
Whereas the thermodynamic interaction of LUF6037 with the receptor was
characteristic of a full agonist and cAMP production could indeed be inhibited as
much as with CPA, LUF6037 was unable to induce internalization of the human
adenosine A1YFP receptor. This finding, together with the inefficacy of PD81,723,
suggest that LUF6037 interacts with the receptor binding pocket in a partially
different way from the known adenosine-like agonists. The data show the first proof
of separation between activation and internalization of the adenosine A1 receptor by
a full agonist with 100-fold higher affinity and 35-fold greater potency with respect to
the reference agonist CPA. The ability of LUF6037 to fully activate the receptor
without inducing internalization is a novel example of collateral efficacy. This
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behaviour may be therapeutically advantageous as drug resistance due to receptor
internalization, as seen with traditional full agonists, might be avoided.
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Chapter 7
[3H]LUF5834, a new non-adenosine radioligand for
the adenosine A1 receptor, revealing 3 binding
sites for DPCPX on the A1 receptor
Recently, non-adenosine ligands for the adenosine receptors were synthesized. One
of these ligands, LUF5834, a high affinity full agonist for the A1 receptor, was
radioactively labeled. Here we report on the characterization of [3H]LUF5834 as a
new radioligand for the A1 receptor. Radioligand binding studies were performed in
the absence and presence of the allosteric enhancer PD81,723 and GTP on CHO
cells stably expressing the A1 receptor. [3H]LUF5834 recognized two binding sites in
kinetic and saturation studies. Kd-values of 0.16 ± 0.07 nM and 1.69 ± 0.05 nM were
determined. This new radioligand [3H]LUF5834 recognized the same number of
receptors as [3H]DPCPX. Surprisingly, unlabeled LUF5834 showed a one site
displacement curve with an IC50-value of 5.4 1.3 nM. PD81,723 (10 M) and GTP
(1mM) were not able to shift its affinity. CPA yielded a two site displacement curve
with IC50-values of 4.8 1.9 nM and 339150 nM, respectively. PD81,723 was able
to increase only the IC50,low-value of CPA. GTP did not affect the IC50-values, but
lowered the fraction of receptors in the high affinity state. DPCPX showed a three site
displacement curve with IC50-values of 1.2 1.4 pM, 0.26 0.24 nM and 127 44
nM respectively. PD81,723 decreased all affinities, GTP on the other hand only
shifted the percentages of receptors in the direction of the high affinity states. In
conclusion, [3H]LUF5834 recognizes two binding sites with very high affinity.
Moreover, the displacement of [3H]LUF5834 by DPCPX reveals not two, but three
binding sites.
Based upon Klaasse EC, Chang LCW, de Vries H, de Grip WJ, IJzerman AP,
Beukers MW. Manuscript in preparation.
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Introduction
Recently, Rosentreter et al.1,2 patented a new class of adenosine receptor ligands,
the 2-amino-4-(3,4 substituted phenyl)-6-(2-hydroxyethylsulfanyl)-pyridin-3,5-
dicarbonitriles. This class shows no structural similarity to adenosine, the
endogenous ligand for the adenosine receptors. However, it was observed that
several compounds of this class display a significant affinity and efficacy towards
different adenosine receptor subtypes1-4. Until then, only modified analogues of
adenosine substituted at different positions had been introduced as potent and
selective ligands for the adenosine receptors. Especially substitutions at the N6- and
C2 positions of adenosine yielded potent adenosine A1 agonists, e.g. N6-
cyclopentyladenosine (CPA), N6-2-chloro-cyclopentyladenosine (CCPA) and N6-
cyclohexyladenosine (CHA)5.
One of the new, non-adenosine compounds, LUF5831, appeared to be a partial
agonist with an affinity of 18 1 nM for the adenosine A1 receptor6. From this study it
also appeared that allosteric modulators such as PD81,723 and GTP seem to have
no or much less effect on the binding of LUF5831 than they have on the binding of
the traditional adenosine derivative CPA6. Another non-adenosine compound,
LUF5834, was characterized as a full agonist for the human adenosine A1 receptor
with a very high affinity, comparable to the Ki, high-value of CPA, and as a partial
agonist for the A2B receptor with high affinity3. For these reasons, LUF5834 was
chosen as the non-ribose ligand to radioactively label with 3H.
In this study, we describe the characterization of the new, non-adenosine agonist
radioligand for the human adenosine A1 receptor. Displacement experiments were
performed, and the effect of PD81,723 and GTP on the displacement of a non-
adenosine-like agonist (LUF5834), adenosine-like agonist (CPA), and an inverse
agonist (DPCPX) was studied (see Figure 7.1 for the chemical structures of the
compounds). Surprisingly, [3H]LUF5834 revealed three binding sites in the
displacement with DPCPX. Finally, the influence of G proteins on the different affinity
states of the receptor was studied using Sf9 Insect cell homogenates, expressing the
human adenosine A1his10 receptor but lacking functionally active endogenous Gi
proteins.
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Figure 7.1. Structures of LUF5834, CPA and DPCPX.
Methods
Cell culture
Chinese hamster ovary (CHO) cells stably expressing the human adenosine A1
receptor were cultured in a 1:1 mixture of Dulbecco’s modified Eagle’s medium
(DMEM) and Ham’s F12 medium containing 10% newborn calf serum, 50 µg/mL
streptomycin, 50 IU/mL penicillin and 0.2 mg/mL neomycin (G418), respectively. The
cells were maintained in a humidified atmosphere at 37 ºC and 5% CO2, and
subcultured twice weekly (ratio 1:20).
Spodoptera frugiperda (Sf9) cells were cultured in Insect Xpress medium containing
50 µg/mL streptomycin and 50 IU/mL penicillin at 27 ºC. The cells were subcultured
twice weekly (1:5). Confluent Sf9 Insect cells were infected with baculovirus,
containing the human adenosine A1his10 construct. Six to seven days post infection,
the infected Sf9 Insect cells expressing the human adenosine A1his10 receptor were
harvested by centrifugation (5 min, 1300 rpm) and the cell pellets were stored at – 80
ºC.
Membrane preparation
Membranes of CHO cells stably expressing the human adenosine A1 receptor were
prepared as previously described7. Membrane protein concentrations were measured
using the BCA (bicinchonic acid) method with BSA as a standard8.
Radioligand-binding assays
Membrane aliquots containing 10 g (CHOhA1-wt) protein were incubated in a total
volume of 400 l of 50 mM Tris-HCl, 0.1% CHAPS, ADA (1U/mL) pH 7.4, at 25 ºC
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for 60 min in the absence or presence of 1 mM GTP or 10 M PD81,723.
Displacement experiments were performed using 24 concentrations of cold ligand in
the presence of 2.6 nM [3H]LUF5834. Nonspecific binding was determined in the
presence of 10 M CPA and represented approximately 10% of the total binding.
Saturation experiments were carried out using nine to 21 different concentrations of
[3H]LUF5834, [3H]DPCPX or [3H]LUF5834/[3H]DPCPX ranging from 0.1 to 12 nM. In
kinetic studies, the association of the radioligand [3H]LUF5834 (2.6 nM) was initiated
by addition of the membrane preparation (10 g) to the radioligand. To study the
dissociation of [3H]LUF5834, membranes were preincubated with [3H]LUF5834 (2.6
nM) at 25 ºC for 60 min. Dissociation of [3H]LUF5834 was then initiated by the
addition of LUF5834 (1 M), DPCPX (1 M) or CPA (10 M). Incubations were
terminated by dilution with ice-cold 50 mM Tris-HCl buffer. Separation of bound from
free radioligand was performed by rapid filtration through Whatman GF/C filters using
a Brandel harvester. Filters where subsequently washed three times with ice-cold
buffer, or six times for saturation experiments. Filter-bound radioactivity was
measured by scintillation spectrometry (Tri-Carb 2900TR, Perkin Elmer) after addition
of 3.5 mL Packard Emulsifier Safe. Experiments were performed at least in triplicate,
unless otherwise stated.
Data analysis
Data of radioligand binding experiments were analyzed using the non-linear
regression curve fitting program Prism v. 4.0.2 (GraphPad, San Diego, CA, USA). kon
and koff values were obtained by computer analysis of the association and
dissociation data. Both association and dissociation experiments showed a two site
binding profile for [3H]LUF5834.
Saturation curves were fitted to one and two state/site binding models. For
[3H]DPCPX and [3H]DPCPX/[3H]LUF5834, a one site binding curve was favoured.
For [3H]LUF5834 saturation however, a two site binding hyperbola was preferred.
Radioligand displacement curves were fitted to one, two and three state/site binding
models. The LUF5834 displacement curve was best fitted to a one state/site binding
model, CPA data were best fitted to a two state/site binding model. For DPCPX
however, a three state/site binding model was preferred. IC50-values were taken
instead of calculated Ki-values, since we did not attempt to attribute Kd-values to
each affinity state, especially in the case of the three site binding model.
Three site equation
Since the datapoints of the DPCPX displacement curves did not fit a two site
displacement curve very well, a three site competition equation was incorporated in
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Prism to check whether the datapoints would fit better to a three site model.
Analogous to two site competition, a three site competition equation was written:
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with Y: the binding of the radioligand, and X: the log concentration of unlabeled
(competing) ligand. Fraction 1 is the fraction of all sites that have affinity 1, and the
same applies to fractions 2 and 3. Log IC50,1, Log IC50,2 and Log IC50,3 are the Log
IC50-values for the three sites.
Materials
N6-cyclopentyladenosine (CPA) was obtained from Research Biochemicals Inc.
(Natick, MA, U.S.A.). 1,3-dipropyl-8-cyclopentylxanthine (DPCPX), bovine serum
albumin (BSA) and 3-[(3-Cholamidopropyl)dimethylammonio]-1-propanesulfonate
(CHAPS) were from Sigma (St. Louis MO, U.S.A.). Adenosine deaminase (ADA) was
purchased from Roche Biochemicals (Mannheim, Germany) and Bicinchonic acid
(BCA) protein assay reagent was obtained from Pierce Chemical Company
(Rockford, IL, U.S.A.). [3H] 1,3-dipropyl-8-cyclopentylxanthine ([3H]DPCPX -specific
activity 124 Ci/mmol) was purchased from NEN (Du Pont Nemours, ‘s
Hertogenbosch, The Netherlands). [3H] 2-amino-4-(4-hydroxyphenyl)-6-(1H-imidazol-
2ylmethylsulfanyl)-pyridine-3,5-dicarbonitrile ([3H]LUF5834 – specific activity 25
Ci/mmol) was labeled by Sibtech, Inc. (Newington, CT, U.S.A.). The radiolabeled
ligand was purified over a Kromasil C18 column with a gradient of 10% to 50%
MeCN/H2O/0.1% TFA. TLC on SiO2 was developed with CH2Cl2:MeOH:NH4OH
(10:1.5:0.25). TLC on C18 was developed with MeOH:0.1M NH4OAc pH 3.5 (3:1).
G418 (neomycin) was obtained from Stratagene (Cedar Creek, U.S.A.). Guanosine
triphosphate (GTP) was purchased from Acros Organics (Geel, Belgium). (2-Amino-
4,5-dimethyl-3-thienyl)-[3-(trifluoromethyl)phenyl]methanone (PD81,723) and
LUF5834 were synthesized in our laboratory as described by Van der Klein et al.9
and Chang et al.4, respectively. Chinese hamster ovary (CHO) cells stably
expressing the human adenosine A1 receptor were obtained from A. Townsend –
Nicholson10. Sf9 insect cells were obtained from BD-Biosciences (Alphen aan den
Rijn, the Netherlands). Insect Xpress Protein Free Insect Cell Growth Media were
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obtained from Cambrex (Verviers, Belgium), Dulbecco’s Modified Eagle’s Medium
and F-12 Ham medium were purchased from Sigma Aldrich (Zwijndrecht, the
Netherlands). All other chemicals were of analytical grade and obtained from
standard commercial sources.
Results
Radioligand-binding assay
As a starting point for the set up of a radioligand binding assay for [3H]LUF5834, the
radioligand-binding assay for [3H]DPCPX was taken. CHOhA1-wt membrane protein
(10 g) was incubated in a total volume of 400 l Tris-HCl buffer, 50 mM, pH 7.4 as
described in the Methods section. On control CHO-K1 cell membranes, [3H]LUF5834
did not display any specific binding. To maximize the window of specific binding to
the CHOhA1-wt membranes, the following parameters were varied: GF/B vs GF/C
glass fiber filters, with or without pretreatment of the filters with 0.25% polyethylene
imine (pei) for 1 hour. The effect of addition of 0.1% CHPAS or 0.1% BSA to the
assay buffer was also verified. It appeared that GF/B and GF/C filters performed
equally well; only the addition of 0.1% CHAPS increased the window of specific
binding significantly (results not shown). It was therefore decided to use the
radioligand-binding assay of [3H]DPCPX plus 0.1% CHAPS added to the assay
buffer. The samples were harvested over GF/C filters.
Kinetics of [3H]LUF5834
To characterize the new, non-adenosine radioligand [3H]LUF5834, kinetic association
and dissociation experiments on membranes of CHO cells stably expressing the wt
human adenosine A1 receptor were performed.
Association of [3H]LUF5834 reached a plateau in 30 min and appeared to be biphasic
(Figure 7.2A). From these experiments, the kon values and half lives were determined
(Table 7.1). The kon,1 value was 2.01 0.26 nM-1 min-1 and kon,2 value was 0.12 
0.03 nM-1 min-1. The corresponding half lives were 0.35 0.04 min and 6.01 1.33
min.
Dissociation of [3H]LUF5834 was achieved by adding CPA (10 M) or LUF5834 (1
M), see Figure 7.2B. In both cases, the dissociation of [3H]LUF5834 appeared to be
biphasic. Full dissociation, i.e. to levels of non-specific binding, was reached within
60 minutes. In table 7.1, the radioligand half-life and koff values are represented.
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Figure 7.2. Association of [3H]LUF5834 (A) to and dissociation of [3H]LUF5834 (B) from the wt human
adenosine A1 receptor stably expressed on CHO cell membranes. Dissociation of [
3H]LUF5834 was
achieved by adding CPA (10 M,●) or LUF5834 (1 M,■). Experiments were performed three times,
curves from a representative experiment performed in duplicate are shown.
Table 7.1. Association and dissociation kinetic parameters (± s.e.m.) of [3H]LUF5834 binding to wt
human adenosine A1 receptors. Dissociation was induced with either CPA (10 M) or LUF5834 (1
M). Significant differences between ligands are marked with an asterisk. Values are means (s.e.m.)
of three separate assays each performed in duplicate.
Association
t1/2, 1 (min) t1/2, 2 (min) kon,1 (nM
-1 min-1) kon,2 (nM-1 min-1)
[3H]LUF5834 0.350.04 6.011.33 2.010.26 0.120.03
Dissociation
t1/2,1 (min) t1/2,2 (min) koff,1 (min
-1) koff,2 (min-1)
CPA 0.350.21 8.50.60 2.601.64 0.0880.006
LUF5834 0.500.13 11.85.55 1.430.37 0.0660.031
As expected, the half lives for the two states were the same independent of the use
of CPA or LUF5834 as the displacing ligand. Since these studies provide insight in
ligand binding rather than activation, we cannot specify whether the two sites
represent two states i.e. G protein dependent affinities or two different binding sites.
The half lives for the high affinity states/sites, were 0.35 0.21 min and 0.50 0.13
min (CPA and LUF5834, respectively). The half lives for the low affinity states/sites,
were 8.5 0.60 min vs 11.8 5.55 min. From the kon- and koff values, kinetic Kd
values were calculated according to the formula: Kd = koff / kon. This yielded a kinetic
Kd,1 value of 0.71 nM and Kd,2 value of 0.55 nM.
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Saturation
Saturation experiments were performed with [3H]LUF5834 on membranes of CHO
cells stably expressing the wt adenosine A1 receptor (Figure 7.3). The binding of
[3H]LUF5834 was saturable and best characterized by a two-site model with a Kd,1
value of 0.16 0.07 nM and a Kd,2 value of 1.690.05 nM. Given the large s.e.m. of
the koff,2 value of LUF5834, the calculated kinetic Kd values are in the same range as
the Kd values determined in the equilibrium saturation studies.
Figure 7.3. Equilibrium
saturation curve of [3H]LUF5834
on wt human adenosine A1
receptor stably expressed on
CHO cell membranes, total
binding (▲), specific binding (■),
non-specific binding (●).
Experiments were performed
three times, curves from a
representative experiment
performed in duplicate are
shown.
The corresponding Bmax values were 1.68 0.05 pmol/mg (Bmax,1) and 7.82 0.84
pmol/mg (Bmax,2), respectively, yielding a total receptor density of 9.50 pmol/mg
(Table 7.2). The non-specific binding accounted for approximately 10% of the total
binding. In addition, saturation experiments with [3H]DPCPX and a combination of
[3H]LUF5834/[3H]DPCPX were performed to show that both radioligands share the
same binding site on the receptor (Figure 7.4). The differences in dpm values can be
explained by the fact that [3H]DPCPX has a five-fold higher specific activity than
[3H]LUF5834. These saturation curves fitted best to a one-site model, with Kd values
of 2.87 1.03 nM and an apparent “mixed” Kd value of 2.30 0.48 nM for the
combined ([3H]LUF5834/[3H]DPCPX) saturation, respectively. The calculated Bmax
values were 12.8 1.7 pmol/mg and 13.2 1.1 pmol/mg respectively, comparable to
the Bmax value found with [3H]LUF5834 saturation alone.
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Figure 7.4. Saturation
curves of [3H]LUF5834 (■),
[3H]DPCPX (▲), or a 
combination of
[3H]LUF5834/[3H]DPCPX (♦) 
on wt human adenosine A1
receptor stably expressed
on CHO cell membranes.
Experiments were
performed three times,
curves from a representative
experiment performed in
duplicate are shown.
Table 7.2. Kd-values (± s.e.m.) of [
3H]LUF5834, [3H]DPCPX and an apparent ‘mixed’ Kd-value for the
combination of [3H]LUF5834/ [3H]DPCPX for the wt human adenosine A1 receptor, stably expressed in
CHO cell membranes. Corresponding Bmax-values are also presented. Values are means (s.e.m.) of
three separate assays each performed in duplicate.
Kd (nM) Kd,1 (nM) Kd,2 (nM) Bmax Bmax,1 Bmax,2
(pmol/mg) (pmol/mg) (pmol/mg)
[3H]LUF5834 0.160.07 1.690.05 1.680.05 7.820.84
[3H]DPCPX 2.871.03 12.81.7
[3H]LUF5834/
[3H]DPCPX 2.300.48 13.21.1
Displacement of [3H]LUF5834
To determine the affinity of CPA, DPCPX and LUF5834, displacement experiments
were performed with the new radioligand [3H]LUF5834 on membranes of CHO cells
stably expressing the wt human adenosine A1 receptor (see Figure 7.5). LUF5834
recognized only one binding state/site with an IC50-value of 5.4 1.3 nM. CPA
identified two binding states/sites with IC50-values of 4.8 1.9 nM and 339 150 nM
for the high and low affinity sites, respectively (see Table 7.3). DPCPX on the other
hand recognized three binding states/sites, one with picomolar affinity (1.2 1.4 pM),
and the other two with nanomolar affinity (0.26 0.24 nM and 127 44 nM),
respectively.
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Figure 7.5. Displacement of
[3H]LUF5834 by LUF5834 from
the wt human adenosine A1
receptor stably expressed on
CHO cell membranes, in the
absence (○) or presence (∆) of 
1 mM GTP, or in the presence
of 10 M PD81,723 (□). 
Experiments were performed
three times, curves from a
representative experiment
performed in duplicate are
shown.
Figure 7.6. Displacement of
[3H]LUF5834 by CPA from the
wt human adenosine A1
receptor stably expressed on
CHO cell membranes, in the
absence (○) or presence (∆) of 
1 mM GTP, or in the presence
of 10 M PD81,723 (□). 
Experiments were performed
three times, curves from a
representative experiment
performed in duplicate are
shown.
Figure 7.7. Displacement of
[3H]LUF5834 by DPCPX from
the wt human adenosine A1
receptor stably expressed on
CHO cell membranes, in the
absence (○) or presence (∆) of 
1 mM GTP, or in the presence
of 10 M PD81,723 (□). 
Experiments were performed
three times, curves from a
representative experiment
performed in duplicate are
shown.
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Table 7.3. Affinities of LUF5834, CPA and DPCPX for the wt human adenosine A1 receptor in the
absence or presence of either 10 M PD81,723 or 1 mM GTP, expressed as IC50-values (± s.e.m.).
Significant differences with respect to the control values are marked with an asterisk. Values are
means (s.e.m.) of three separate assays each performed in duplicate, unless indicated otherwise.
IC50,high 2 IC50,high 1 IC50,low Fraction Fraction Fraction
(pM) (nM) (nM) in% in% in%
LUF5834 5.4 ± 1.3
LUF5834 + GTP 7.2 ± 0.8
LUF5834 + PD 6.3 / 4.5a
CPA 4.8 ± 1.9 339 ± 150 56 ± 6 44 ± 6
CPA + GTP 7.7 ± 2.9 440 ± 67 22 ± 5*** 78 ± 5
CPA + PD 2.5 ± 0.8 36 ± 15* 51 ± 14 49 ± 6
DPCPX 1.2 ± 1.4 0.26 ± 0.24 127 ± 44 23 ± 13 29 ± 8 48 ± 11
DPCPX + GTP 2.6 ± 2.2 3.7 ± 1.4 * 120 ± 22 38 ± 4 51 ± 4* 11 ± 3**
DPCPX + PD 9.2 ± 3.4* 8.9 ± 7.2 573 ± 91** 22 ± 10 29 ± 11 49 ± 8
***: P < 0.0001, **: P < 0.005, *: P < 0.05, a n=2
Effects of the allosteric modulator PD81,723 and GTP
Radioligand binding experiments were performed in the absence and presence of 1
mM GTP or 10 M of the allosteric modulator PD81,723 (see Figures 7.5-7.7 and
Table 7.3). In contrast to CPA and DPCPX, LUF5834 was virtually insensitive to both
GTP and PD81,723. The IC50-values of LUF5834 in the presence of GTP and
PD81,723 were 7.2 ± 0.8 nM and 6.3/4.5 nM, respectively, almost identical to the
control value of 5.41.3 nM.
Addition of 1 mM GTP did not affect the affinity of CPA for either the high or low
affinity states/sites. The IC50,high value was 4.8 1.9 nM vs 7.7 2.9 nM in the
absence and presence of GTP, whereas the IC50,low value was 339 150 nM vs 440
67 nM, respectively. In contrast, the percentage receptors in the high affinity state
decreased from 56 6% to 22 5% in the presence of 1 mM GTP.
Addition of 10 M PD81,723 significantly lowered the IC50,low value to 36 15 nM,
whereas the IC50,high value remained unaltered, 2.5 0.8 nM. The percentage
receptors in the high affinity state was not affected by PD81,723 (51 14%).
Like CPA, the affinities of DPCPX were not much affected by the addition of GTP.
The IC50,low-value and IC50,high 2 values remained unaltered 127 44 nM vs 120 22
nM and 1.2 1.4 nM to 2.6 2.2 nM, respectively and the IC50,high1 value increased
from 0.26 0.24 nM to 3.7 1.4 nM (P<0.05). In contrast, GTP did increase the
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percentage receptors in the two high affinity states from 23 13% to 38 4% and
from 29 8% to 51 4%, respectively.
Whereas addition of GTP resulted in a shift from low to high affinity states, PD81,723
affected only the IC50-values. PD81,723 increased the IC50,high values to 9.23.4 pM
(P< 0.05) and 8.9 7.2 nM, respectively, and significantly increased the IC50,low
value to 573 91 nM (P<0.005). The percentage receptors in the high affinity states
was unaffected, 22 10% vs 2313% and 2911% vs 29 8%, respectively.
Sf9 insect cell preparation
Displacement studies on a cell preparation of Sf9 insect cells expressing the human
adenosine A1his10 receptor were also performed. [3H]LUF5834 was displaced by
CPA or DPCPX, in the absence or presence of 1 mM GTP (Figure 7.8). In both
cases, the addition of GTP did not shift the displacement curve. The CPA
displacement curve showed only one binding site, with an affinity comparable to the
IC50,low-value found in the displacement experiment performed on wt hA1-CHO
membranes (360 nM vs 339 150 nM, table 7.4). The DPCPX displacement curve
showed two binding sites, with affinities of 36 pM and 21 nM respectively.
Figure 7.8. Displacement of [3H]LUF5834 by CPA (A, ●) or DPCPX (B, ♦) from the human adenosine 
A1his10 receptor expressed on Sf9 membranes, in the absence or presence of 1 mM GTP (○,◊). 
Experiments were performed three times, curves from a representative experiment performed in
duplicate are shown.
0
25
50
75
100
-11 -10 -9 -8 -7 -6 -5 -4
A
Log [CPA] (M)
[3
H
]L
U
F5
83
4
S
pe
ci
fic
bi
nd
in
g
(%
)
0
25
50
75
100 B
-14 -13 -12 -11 -10 -9 -8 -7 -6
Log [DPCPX] (M)
Chapter 7
134
Table 7.4. Affinities of CPA and DPCPX in the absence or presence of 1 mM GTP for the human
adenosine A1His10 receptor expressed in Sf9 Insect cells, expressed as IC50-values. Two experiments
(unless indicated otherwise) were performed, each in duplicate, yielding average IC50 values.
IC50 (nM) IC50,high (pM) IC50,low (nM) Fraction 1 (%) Fraction 2 (%)
CPA 360
CPA + GTP 504
DPCPX 31* 21* 48 52
DPCPX + GTP 30 31 50 50
* n=1
Discussion
In this study, the new, non-ribose radioligand [3H]LUF5834 was characterized for its
kinetic, saturation and displacement properties on the human adenosine A1 receptor.
Also the effects of the allosteric modulators PD81,723 and GTP on the displacement
of [3H]LUF5834 were investigated. Finally, displacement studies of [3H]LUF5834 on
Sf9 Insect cell homogenates containing the human adenosine A1 receptor were
performed.
Kinetics of [3H]LUF5834
Since LUF5834 had been shown to be a full agonist in cAMP experiments3, the
association and dissociation kinetics of [3H]LUF5834 are best compared with other
radiolabeled agonists. Characterization of 125I-N6-aminobenzyladenosine ([125I]ABA)
revealed a two site association. A t1/2,1 of 1.85 min and a t1/2,2 of 12.8 min were
reported, five and two times slower, respectively than measured for [3H]LUF583411.
[3H]CCPA and [3H]CHA, on the other hand, showed a one site association only, with
a t1/2 of 2.6 0.3 min12 and a t1/2 value of 57.514.4 min13, respectively.
The t1/2 for the dissociation of [3H]CCPA was reported to be 10.8 2.8 min12, similar
to the t1/2,2 for the dissociation of [3H]LUF5834. This is much faster than the koff
values reported for [3H]CHA, 4.76 0.26 min13. In conclusion, [3H]LUF5834 has
relatively fast kinetics among the agonist radioligands, and showed a two site
association and dissociation profile.
Saturation
In line with the kinetic experiments, [3H]LUF5834 also obeyed a two-site binding
model in the saturation experiments. The Kd,1 value was 0.16 0.07 nM and the Kd,2
value was 1.69 0.05 nM. Other useful radioligands for the adenosine A1 receptor
also display affinities in the low nanomolar range, such as [3H]DPCPX (2.87 1.03
nM, (this study); 3.86 nM14; 1.6 0.1 nM6,13,15; [3H]CCPA (1.8 0.2 nM)15, [125I]ABA,
(Kd,1-value of 0.33 0.16 nM and Kd,2-value of 10 25 nM)11. The Kd-value of the
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new, non-adenosine agonist radioligand [3H]LUF5834 is thus in the same range of
the Kd-values of the traditional agonist and inverse agonist radioligands for the
human adenosine A1 receptor. Additionally, the low non-specific binding of
[3H]LUF5834 makes it a suitable radioligand for binding studies.
The calculated Bmax-values from the saturation curves (Figure 7.4) showed that both
[3H]DPCPX (12.8 1.7 pmol/mg) and [3H]LUF5834 (9.5 0.9 pmol/mg) label
approximately the same number of binding sites, despite the fact that LUF5834 is an
agonist. The calculated Bmax value from the combined [3H]LUF5834/[3H]DPCPX
saturation experiment was 13.2 1.1 pmol/mg, thus, no additional sites appeared
occupied by [3H]LUF5834 in the combined [3H]LUF5834/[3H]DPCPX saturation
experiments. To compare, Kourounakis et al.15 found that [3H]CCPA when compared
to [3H]DPCPX labeled only 20% of the receptor binding sites. A putative explanation
is that agonist radioligands such as [3H]CCPA in low concentrations only label the
receptors in the active, high affinity R* conformation. In contrast, the very high
affinities of [3H]LUF5834 (0.16 nM and 1.69 nM) allow full receptor occupancy in the
concentration range studied (0-12 nM).
Displacement of [3H]LUF5834
The displacement of [3H]LUF5834 by LUF5834 followed a one site model with an
IC50-value of 5.4 ± 1.3 nM, equal to the affinity of LUF5834 displacing [3H]DPCPX as
the radioligand, 2.6 0.3 nM3. The affinity of LUF5834 for the human adenosine A1
receptor is slightly higher, but in the same range as the affinity of its close analogue
LUF5831, 18 1 nM6. The reason that only one Ki value is observed for LUF5834 in
the displacement experiments versus two Kd values in the saturation experiments
may be that the percentage receptors in the high affinity state was rather low (<20%).
In addition, there were many more data points in the saturation curve around the Kd,1
value (10 points between 0 – 1 nM) than in the displacement curve (4 points). The
displacement of [3H]LUF5834 by CPA yielded a two site binding curve with IC50-
values of 4.8 1.9 nM and 339 150 nM, similar to the affinities found in
displacement studies with [3H]DPCPX as a radioligand, 2.2 0.9 nM and 338 24
nM6. LUF5834 thus has an affinity for the human adenosine A1 receptor comparable
to the Ki,high–value of CPA (5.41.3 nM vs 2.20.9 nM).
The displacement curve of DPCPX showed the most striking features. Not two, but
three sites were observed. An IC50,low- value of 127 44 nM, and two IC50,high-values
were determined, one with nanomolar affinity (0.26 0.24 nM) and the other one in
the picomolar range (1.21.4 pM). So far, a Ki, high value of DPCPX with an affinity in
the picomolar range, has never been observed before. Chang et al.4 reported a Ki-
value of 6.1 1.6 nM and de Ligt et al.16 reported a Ki-value of 2.4 0.1 nM for
DPCPX, which is in the same range as the IC50,high 1-value. The percentage receptors
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in the two high affinity states were 2313% and 29 8% respectively, and 4811%
of the receptors were in the low affinity state.
Effect of the allosteric modulator PD81,723 and GTP
Addition of 10 M PD81,723, an allosteric enhancer17,18, resulted in an increase in
the affinity of CPA for the human adenosine A1 receptor6,7,15,19.
On the contrary, PD81,723 did not have an allosteric effect on the displacement of
[3H]LUF5834 by LUF5834. Similar results were previously reported for the
displacement of [3H]DPCPX by a structural analogue of LUF5834, LUF58316. The
affinities of LUF5834 and LUF5831 were apparently not affected by the presence of
PD81,723, indicating that the change in receptor conformation induced by PD81,723
is unable to enhance the binding of these non-adenosine compounds to the human
adenosine A1 receptor. A possible explanation could be that non-adenosine ligands
bind to a different binding site, insensitive to PD81,723. However, the ability of the
non-adenosine ligands to displace [3H]DPCPX binding, just like the adenosine
derivatives, suggests that these ligands share – at least partly – the same binding
site. The presence of 1 mM GTP did not shift the displacement curve of LUF5834
either. Apparently, the affinity of LUF5834 was not affected by the addition of GTP,
which had also been observed for LUF58316. Probably, the non-ribose agonists
LUF5834 and LUF5831 have no prevalence for one of the two receptor
conformations, R or R*.
The addition of 10 M PD81,723 in the [3H]LUF5834/CPA displacement experiments
only affected the IC50,low-value of CPA; a ten-fold leftward shift was observed (339 
150 nM vs 36 15 nM). The percentage receptors in the high affinity state was not
affected by the presence of PD81,723. Heitman et al.6 reported comparable data i.e.
a 3.5-fold leftward shift of the low affinity site for CPA and no effect on the
percentage receptors in the high affinity state. The addition of 1 mM GTP did not alter
the affinities of CPA for the receptor, it only decreased the percentage receptors in
the high affinity state from 56 6% to 22 5%. Heitman et al.6 observed an even
more pronounced effect in the experiments with [3H]DPCPX; the receptors in the high
affinity state were completely shifted to the low affinity state in the presence of 1 mM
GTP, resulting in a one site displacement curve. As can be seen in the CPA curve,
GTP decouples the receptor from its G protein, thereby decreasing the amount of
receptors in the high affinity state (R*).
For all three affinities of DPCPX, the addition of 10 M PD81,723 resulted in a
decrease of affinity; for the IC50, high 2 -value and the IC50,low -value this decrease was
significant. However, the percentage receptors in the different affinity states
remained unaltered.
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In concert with the results obtained for CPA, the affinity of DPCPX for the different
receptor states was not influenced by the addition of 1 mM GTP. The percentage
receptors in the high affinity states, however, were significantly increased.
PD81,723 is usually viewed upon as an allosteric enhancer of agonist binding.
However, our data in concert with the findings of Heitman et al.6 show that PD81,723
is an allosteric enhancer of CPA binding, but not of LUF5834 or LUF5831 binding,
despite the agonistic nature of both CPA and the non-ribose LUF compounds. In
addition, PD81,723 lowered the affinity of the inverse agonist DPCPX for the
receptor. Hence, it is not justified to coin PD81,723 as an allosteric enhancer per se,
as is generally done.
GTP on the other hand, did not affect the affinities of the ligands for the receptor in
any of the cases. It only shifted the equilibrium between the active (R*) and the
inactive (R) state of the receptors. Moreover, according to the results obtained with
the DPCPX displacement experiments, the R-state of the receptor seems to be
divided in two high affinity sites for DPCPX, R1 and R2. The ratio between the two
high affinity sites R1 and R2 is almost 1:1 (2313% vs 29 8%), and increase both
with more or less the same percentage (ca. 20%) upon addition of 1 mM GTP to the
system. These observations point to the fact that these high affinity states may not be
induced by differences in receptor conformation caused by e.g. accessory proteins or
allosteric modulators which would be expected to affect the affinity, but are much
more determined by the interactions between radioligand and/or displacing ligand
and the uncoupled receptor, which may favour or induce certain receptor
conformations. Following these observations, we propose an equilibrium of three
receptor states, differing from the two state (R  R*) model, whereby the inactive,
R state, of the receptor is subdivided in two states, R1 and R2.
2
*
1
...
R
R
R
Effect of G protein
All three states are recognized by the inverse agonist DPCPX, but only two of these
by the agonist ligands. It has been shown before that the Gi-protein is involved in the
active conformation, R*, of the adenosine A1 receptor6,20. Interestingly, Sf9 insect cell
membranes hardly contain G i-protein. Figler et al.21 showed that the addition of both
G i and Gisubunits was necessary to regain the high affinity binding of
recombinant bovine adenosine A1 receptor in these cell membranes. We therefore
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performed displacement experiments on an Sf9 insect cell membrane preparation
expressing the his-tagged human adenosine A1 receptor. The ligand pharmacology
for the tagged receptor is identical to the wt human adenosine A1 receptor (data not
shown).
CPA’s displacement curve was monophasic, and addition of 1 mM GTP had no effect
on CPA’s affinity (504 nM). Obviously, no receptors in the active conformation (R*)
were present in this Sf9 insect cell preparation.
For DPCPX, two rather than three binding sites were found. The R*-conformation,
the low affinity state of the receptor for DPCPX, did not seem to be present in the Sf9
Insect cell preparation. The addition of 1 mM GTP had no effect on the affinity of
DPCPX, again proof of two receptor conformations despite the absence of G
proteins.
Conclusion
In conclusion, a new, non-adenosine, agonist radioligand has been characterized for
the human adenosine A1 receptor. This radioligand, [3H]LUF5834, recognized two
high-affinity binding sites with a mere 10-fold difference in Kd values. Therefore it
occupied all the receptor binding sites present on the cell membrane in saturation
studies, comparable to the high affinity inverse agonist radioligand [3H]DPCPX.
Displacement experiments revealed that LUF5834 is not sensitive to PD81,723 or
GTP addition. In addition, an ‘extra’ third site was revealed in displacement
experiments with the inverse agonist DPCPX. This extra third site represents most
probably a subdivision of the R conformation of the receptor into two additional
states, R1 and R2. Based on these results, an extended receptor equilibrium was
proposed for the different receptor states.
Acknowledgements
Laura Heitman is thanked for helpful discussions during the preparation of this
manuscript.
References
1. Rosentreter U, Kraemer T, Shimada M, Huebsch W, Diedrichs N, Krahn T, Henninger K,
Stasch J-P. Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and their use as
adenosine receptor-selective ligands. WO patent 2003/03008384.
2. Rosentreter U, Kramer T, Shimada M, Hubsch W, Diedrichs N, Krahn T, Henninger K, Stasch
J-P. Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and their use as adenosine
receptor-selective ligands. US patent 2004/0176417.
3. Beukers MW, Chang LC, von Frijtag Drabbe Künzel JK, Mulder-Krieger T, Spanjersberg RF,
Brussee J and IJzerman AP (2004). New, non-adenosine, high-potency agonists for the
human adenosine A2B receptor with an improved selectivity profile compared to the reference
agonist N-ethylcarboxamidoadenosine. J Med Chem 47:3707-3709.
4. Chang LCW, von Frijtag Drabbe Künzel JK, Mulder-Krieger T, Spanjersberg RF, Roerink SF,
van den Hout G, Beukers MW, Brussee J and IJzerman AP (2005). A series of ligands
[3H]LUF5834, a new radioligand for the adenosine A1 receptor
139
displaying a remarkable agonistic-antagonistic profile at the adenosine A1 receptor. J Med
Chem 48:2045-2053.
5. Müller CE (2000). Adenosine receptor ligands-recent developments part I. Agonists. Curr Med
Chem 7:1269-1288.
6. Heitman LH, Mulder-Krieger T, Spanjersberg RF, von Frijtag Drabbe Künzel JK, Dalpiaz A
and IJzerman AP (2006). Allosteric modulation, thermodynamics and binding to wild-type and
mutant (T277A) adenosine A1 receptors of LUF5831, a novel non-adenosine like agonist. Br J
Pharmacol 147:533-541.
7. Klaasse EC, van den Hout G, Roerink SF, de Grip WJ, IJzerman AP and Beukers MW (2005).
Allosteric modulators affect the internalization of human adenosine A1 receptors. Eur J
Pharmacol 522:1-8.
8. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK,
Goeke NM, Olson BJ and Klenk DC (1985). Measurement of protein using bicinchoninic acid.
Anal Biochem 150:76-85.
9. van der Klein PA, Kourounakis AP, IJzerman AP (1999). Allosteric modulation of the
adenosine A1 receptor. Synthesis and biological evaluation of novel 2-amino-3-
benzoylthiophenes as allosteric enhancers of agonist binding. J Med Chem 42:3629-3635.
10. Townsend-Nicholson A and Shine J (1992). Molecular cloning and characterisation of a
human brain A1 adenosine receptor cDNA. Brain Res Mol Brain Res 16:365-370.
11. Figler H, Olsson RA, Linden J (2003). Allosteric enhancers of A1 adenosine receptors increase
receptor-G protein coupling and counteract Guanine nucleotide effects on agonist binding. Mol
Pharmacol 64:1557-1564.
12. Göblyös A, de Vries H, Brussee J, IJzerman AP (2005). Synthesis and biological evaluation of
a new series of 2,3,5-substituted [1,2,4]-thiadiazoles as modulators of adenosine A1 receptors
and their molecular mechanism of action. J Med Chem 48:1145-1151.
13. Dalpiaz A, Pavan B, Ngos FN, Franchetti P, IJzerman AP (2002). Temperature dependence of
the affinity enhancement of selective adenosine A1 receptor agonism: a thermodynamic
analysis. Eur J Pharmacol 448:123-131.
14. Klotz KN, Hessling J, Hegler J, Owman C, Kull B, Fredholm BB and Lohse MJ. (1998).
Comparative pharmacology of human adenosine receptor subtypes - characterization of stably
transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol. 357:1-9.
15. Kourounakis A, Visser C, de Groote M and IJzerman AP (2001). Differential effects of the
allosteric enhancer (2-amino-4,5-dimethyl-trienyl)[3-trifluoromethyl) phenyl]methanone
(PD81,723) on agonist and antagonist binding and function at the human wild-type and a
mutant (T277A) adenosine A1 receptor. Biochem Pharmacol 61:137-144.
16. de Ligt RAF, van der Klein PAM, von Frijtag Drabbe Künzel JK, Lorenzen A, Ait El Maate F,
Fujikawa S, van Westhoven R, van den Hoven T, Brussee J and IJzerman AP (2004).
Synthesis and biological evaluation of disubstituted N6-cyclopentyladenine analogues: the
search for a neutral antagonist with high affinity for the adenosine A1 receptor. Bioorg. Med.
Chem. 12:139-149.
17. Bruns RF and Fergus JH (1990a). Allosteric enhancement of adenosine A1 receptor binding
and function by 2-amino-3-benzoylthiophenes. Mol Pharmacol 38:939-949.
18. Bruns RF, Fergus JH, Coughenour LL, Courtland GG, Pugsley TA, Dodd JH, Tinney FJ
(1990b). Structure-activity relationships for enhancement of adenosine A1 receptor binding by
2-amino-3-benzoylthiophenes. Mol Pharmacol 38:950-958.
19. Musser B, Mudumbi RV, Liu J, Olson RD and Vestal RE (1999). Adenosine A1 receptor-
dependent and -independent effects of the allosteric enhancer PD81,723. J Pharmacol Exp
Ther 288:446-454.
20. Dalpiaz A, Townsend-Nicholson A, Beukers MW, Schofield PR, IJzerman AP (1998).
Thermodynamics of full agonist, partial agonist, and antagonist binding to wild-type and
mutant adenosine A1 receptors. Biochem Pharmacol. 56:1437-1445.
21. Figler RA, SG Graber, MA Lindorfer, H Yasuda, J Linden and JC Garrison (1996).
Reconstitution of recombinant bovine A1 adenosine receptors in Sf9 cell membranes with
recombinant G proteins of defined composition. Mol Pharmacol 50:1587-1595.
Chapter 7
140
Chapter 8
General Discussion,
Conclusions and Perspectives

General Discussion
143
General Discussion, Conclusions and Perspectives
General Conclusions
The research described in this thesis has provided novel data and promoted new
insights in structure activity relationships of the adenosine A1 receptor with respect to
traditional agonists such as CPA and R-PIA as well as new, non-adenosine like
agonists. Ligand binding, second messenger activation and internalization of the
adenosine A1 receptor were studied, and the effect of allosteric modulators such as
PD81,723, sodium ions and GTP on these processes was investigated. Fusion
proteins were used as tools to study inverse agonism, constitutive activity and
internalization of the receptors.
Nine different fusion proteins of human adenosine A1 receptors fused to 351Cys
mutated G iα-subunits were studied. From [35S]GTPS binding experiments, it
appeared that all the A1-Gi fusion proteins tested had a higher basal receptor
activity than the unfused adenosine A1 receptor, thereby providing improved
conditions to observe inverse agonism. Compared to unfused adenosine A1
receptors, the affinity of CPA at wild-type A1-G ifusion proteins (351Cys) increased
more than eightfold, while the affinity of DPCPX did not change significantly.
Furthermore, we showed that the allosteric enhancer of agonist binding, PD81,723,
elicited similar effects on ligand binding; i.e. CPA binding to the A1-G i fusion
proteins was enhanced, whereas the affinity of DPCPX was hardly affected.
Moreover, sodium ions were unable to decrease agonist binding to the majority of the
A1-Giαfusion proteins. Sodium ions act through a highly conserved aspartate residue
in TM helix II, presumably inducing a change in receptor conformation towards the
inactive R state. It may be that the physical connection between receptor and G i-
subunit causes a conformational change, which, in turn, prevents the sodium ions
from binding to the adenosine A1 receptor. Alternatively, sodium ions may promote
the formation of an inactive state (R) of the receptor, which cannot or only partly be
achieved in receptors already fused with a G protein.
Concerning internalization, PD81,723 decreased the threshold of the CPA
concentration necessary to induce internalization of the adenosine A1YFP receptor,
rather than accelerating the slow internalization process. CPA by itself was able to
internalize 25% and 40% of the receptors at a concentration of 400 nM or 4 μM,
respectively. In the presence of 10 μM PD81,723, however, a low level of
internalization was obtained already at 40 nM of CPA, and at 400 nM CPA 59% of
the receptors internalized, an increase of 34%. The allosteric inhibitor SCH-202676
(10 μM) on the other hand effectively prevented CPA-induced internalization of the
receptor. It should however be noted that recent studies revealed that SCH-202676
is not a true allosteric modulator. It acts as an agent which reversibly modifies
sulfhydryl groups of cysteine residues in cell membrane preparations and thus in
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receptors. Addition of either PD81,723 or SCH-
202676 alone had no effect on internalization.
Recently, selective agonists for the human
adenosine A1 receptor with an unusual structure
lacking the ribose moiety of traditional adenosine-
like agonists were synthesized. The affinity of
these 2-amino-4-(3 and/or 4-disubstituted phenyl)-
6-(substituted)sulfanyl-pyridine-3,5-dicarbonitriles
(Figure. 8.1) is determined by the substitution
pattern of the phenyl ring whereas the efficacy is
determined by the substituents on both the phenyl ring and the sulfanyl chain. Di-
methoxyphenyl substituted compounds had very little affinity. The monosubstituted
compounds recognized one binding state/site with higher nanomolar affinity. cAMP
studies revealed an activity profile ranging from partial agonism to partial inverse
agonism. 3,4-Methylenedioxyphenyl-substituted compounds recognized two binding
states/sites with a picomolar affinity for the high affinity site. These compounds were
full agonists that largely superseded the prototypic agonist CPA in affinity and
potency. This is a remarkable new class of agonists for the A1R, since the ribose
group of the adenosine analogues was always thought to be crucial for activation of
the receptor.
One of these non-adenosine compounds, LUF6037, showed a very high affinity for
the human adenosine A1 receptor that extended far beyond that of the reference full
agonist CPA (100-fold higher affinity). Remarkably, the allosteric modulator
PD81,723 was not able to enhance the affinity of LUF6037 for the human adenosine
A1 receptor. Whereas the thermodynamic interaction of LUF6037 with the receptor
was characteristic of a full agonist and cAMP production could indeed be inhibited as
much as with CPA, LUF6037 was unable to induce internalization of the human
adenosine A1YFP receptor. This finding, together with the inefficacy of PD81,723,
suggests that LUF6037 has an at least partially different interaction with the receptor
binding pocket compared to the known adenosine-like agonists. This behaviour of
LUF6037 towards the adenosine A1R is a novel example of collateral efficacy, which
may be therapeutically advantageous in drug resistance due to receptor
internalization, as seen with traditional full agonists.
Finally, LUF5834, one of the non-adenosine agonists was tritiated and [3H]LUF5834
was evaluated as a radioligand for the adenosine A1 receptor. It recognized two high-
affinity binding sites with a mere 10-fold difference in Kd values, occupying all the
receptor binding sites present on the cell membrane. Displacement experiments
revealed that LUF5834 is not sensitive to PD81,723 or GTP addition. Furthermore,
an ‘extra’ third site was revealed in displacement experiments with the inverse
N
CN
SNH
2
NC
*
*
*
Figure 8.1. Core structure of 2-
amino-4-(3 and/or 4-disubstituted
phenyl)-6-(substituted)sulfanyl-
pyridine-3,5-dicarbonitriles. The *
represent the substitution positions.
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agonist DPCPX. This extra third site most probably reflects another representative of
the conformational space of the R state of the receptor. Based on these results, an
extended receptor equilibrium was proposed for the different receptor states.
Perspectives
Allosteric Modulators
In light of the above described findings, it would be very interesting to find out what
mechanism underlies the enhancing effect of PD81,723 on the activity of the
adenosine A1 receptor. PD81,723 is known to act as an allosteric enhancer
specifically enhancing agonist binding to the adenosine A1 receptor1. Batthacharya et
al, recently developed six chimaeras between the A1R and A2AR, dually coupled to
the Giαand Gsαsubunit. Amongst others, the third intracellular loop (3ICL) of the A1R
and A2AR was exchanged, which is responsible for G protein coupling. It appeared
that PD81,723 cannot enhance agonist binding to an A2AR equipped with the 3ICL of
the A1R. In contrast, PD81,723 was able to increase the potency of CPA for the
chimaera between the A1R and the 3ICL of the A2AR. These results indicate that the
recognition site of PD81,723 may likely reside within the transmembrane domain
although an interaction with extracellular loops or intracellular loops other than ICL3
can not be fully excluded. PD81,723 acts in a way that directly stabilizes the receptor
to a conformational state, capable of coupling with Giαand Gsα2. Data from Figler et
al. also suggest that simultaneous binding of orthosteric ligands and allosteric
enhancers convert the A1AR from partly to fully coupled to G proteins and prevents
rapid uncoupling upon binding of GTPγS3. The fact that G iαcoupling is necessary to
observe the effect of the allosteric enhancer PD81,723 on agonist binding is also
supported by Kournounakis et al. They found that a mutation of Thr277 to Ala in the
A1R not only decreased agonist affinity but also inhibited the enhancing effect of
PD81,723. Insensitivity of the A1R mutant T277A to PD81,723 may be linked to the
fact that this mutant appears to be uncoupled from G proteins4. In support of this
theory that coupling to Gi is essential to see the enhancing effects of PD81,723, I
report in this thesis that PD81,723 increased ligand binding to A1-Gi fusion proteins to
the same extent as to wildtype A1R. Thus, the enhancing effect of PD81,723 on
ligand binding to the A1R is probably not due to facilitating interaction with the G
protein, but rather by stabilizing a pro-active state of the receptor. In addition, I report
in this thesis that PD81,723 exerts its action in cooperation with an adenosine-like
agonist, but not with one of the new, nonadenosine-like agonists, lacking a ribose
group. This is in line with the conclusion from this thesis that the new, nonadenosine-
like agonists interact with the receptor binding pocket in a partially different way from
the traditional agonists. Probably, the already very high affinity of the nonadenosine-
like agonists, compared to that of the traditional adenosine derived analogues,
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cannot be significantly further enhanced by the addition of PD81,723. Alternatively,
the interaction of non-ribose compounds with the A1 receptor may be insensitive to
the addition of PD81,723.
Collateral efficacy
The efficacy of a drug is generally determined by the drug's ability to produce a
biological response. In the classical receptor-occupancy theory, the efficacy is
considered an intrinsic property of the ligand/receptor pair, and it is often assumed to
be the same for all the responses evoked by this pair. However, very recently it has
become clear from several studies in the GPCR field that receptor activation is not a
linear sequential process whereby a single receptor activation state triggers all
possible relevant downstream signaling pathways within the cell. Instead, a view of
‘collateral efficacy’, in which ligands can produce various combinations of
downstream signaling effects is presented. In literature, the concept of collateral
efficacy is also known as 'ligand-directed trafficking of receptor signalling' (LDTRS),
'functional selectivity', 'biased agonism', 'ligand-biased efficacy', or 'pluridimensional
efficacy'6-8. The findings in this thesis concerning the new, nonadenosine-like
agonists provide an additional example of collateral efficacy. In this case, both
adenosine and nonadenosine-like agonists are able to bind to the receptor and to
inhibit cAMP production, but a difference occurs in the ability to promote
internalization.
Like the adenosine analogues, some of the nonadenosine-like agonists are full
agonists, displaying even higher affinities than CPA for the A1R and inhibiting the
cAMP production to the same extent as CPA. However, where CPA was able to
induce internalization of the A1YFP receptor, the nonadenosine-like agonists were
completely inactive in this respect. An important next step in this line of research
would be to investigate where in the internalization cascade the effects of the
nonadenosine-like agonists deviate from the adenosine analogues. For example,
upon agonist binding, the extent and sites of phosphorylation of the receptors in
desensitization as a first step to internalization may be examined with help of
western-blotting, pull-down assays and mass spectroscopy. Furthermore,
cotransfection of cells with for instance fluorescently labeled β-arrestin would teach
whether β-arrestin will be recruited upon agonist stimulation.
Identification of new chemical entities
More than 10 selective agonists are currently in clinical trials to treat adenosine
receptor subtype related pathologies, namely cardiac arrhythmias and neuropathic
pain (A1R agonists), myocardial perfusion imaging and anti-inflammatory agents
(A2AR agonists), cardiac ischemia (A2BR agonists), rheumatoid arthritis and colorectal
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cancer (A3R agonists). Until now, only adenosine itself has been approved9.
Therefore, another promising line of research would be to develop selective
nonadenosine-like agonists for all adenosine subtypes, taking into consideration the
concepts of collateral efficacy. The same approach as for the new adenosine A1
ligands can be followed, namely using modeling techniques to retrieve electronic and
spatial properties of the existing ligands for the adenosine receptor subtypes, and
clustering them into a new model. This knowledge-based drug design approach has
proven to be a good starting point for the development of new series of compounds.
In this way, hopefully, a new generation of drugs with unique therapeutic profiles and
a minimum of side effects can be developed to treat diseases in which adenosine
receptors are involved.
Internalization
Especially for the A3R, there is a need to develop new agonists. The A3R is known to
internalize in a matter of minutes10, which is a distinct disadvantage in agonist drug
treatment protocols with the currently available agonist drugs. However, it should be
taken into account that the adenosine A3R may contain a nuclear localization signal
(NLS) which may be responsible for the fast ‘internalization’. New agonists unable to
exploit this property will be very welcome.
In order to facilitate internalization studies of the other adenosine receptor subtypes,
preparation of fluorescently labeled adenosine A2A-, A2B- and A3- receptors will be
useful. Niebauer et al. already equipped the C-terminus of the adenosine A2A
receptor with a GFP tag, resulting in an A2AGFP-receptor that should already be
suitable for such internalization studies11,12. Alternatively, cell surface biotinylation
can also be used to measure receptor expression on the plasma membrane13.
Another way to study aspects of the internalization cascade would be to develop
fluorescent agonists for the adenosine A1R, A2AR, A2BR and A3R. To achieve this,
one has to couple fluorescent probes to agonists while retaining a high affinity, high
efficacy and good selectivity for the above mentioned receptor subtypes. It is
recommended to develop a series of fluorescent agonists for each receptor subtype,
in order to pick the one with the best properties. Another option is to vary the spacer
length between the ligand and the fluorescent tag. However, it has to be taken into
account that at a certain stage of internalization the ligand will dissociate from the
receptor and that only the ligand can be traced. Briddon et al. already developed a
fluorescent antagonist for the adenosine A1R, XAC-BY630, used to quantify ligand-
receptor binding at a single cell level14. With help of Fluorescence Correlation
Spectroscopy (FCS), they were able to quantify the XAC-A1R interactions at the cell
membrane in an area as small as 0.1–0.2 μm2, allowing single ligand-receptor
complexes to be studied. Furthermore, since the detection volume of the FCS can be
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directed to specific areas of the cell membrane, such as caveolae, insight into
differences in ligand-receptor interactions within different membrane domains of the
same cell can be determined.
Receptor activation states
A ground-breaking line of investigation would be to explore the conformational space
of the adenosine A1R population. Saturation- and binding studies with the new,
nonadenosine-like radioligand [3H]LUF5834, using the inverse agonist DPCPX as
displacing ligand, revealed that the A1R population can adopt at least three states.
The inactive state seems to be represented by at least two conformations, R1 and R2.
A third conformation represents a G protein-coupled receptor, R* state. Since there is
only a 10-fold difference in the two Kd-values of [3H]LUF5834, and the Kd-values are
in the nM range, this agonist radioligand is able to label the whole adenosine A1R
population, which is an uncommon feature for an agonist radioligand. Therefore,
follow-up studies exploiting the special properties of this new agonist radioligand may
provide urgently needed deeper insight in the conformational space of a GPCR. For
example, it would be very interesting to study if this feature can be observed using
other inverse agonists or antagonists, or if this is exclusive for DPCPX. To further
explore the composition of the A1R population and the behaviour of [3H]LUF5834,
radioligand binding studies with a range of reference ligands representing full
agonists, partial agonists, neutral antagonists in the presence or absence of different
allosteric modulators (e.g. Na+-ions, amiloride analogues) need to be performed.
Taking recent literature into account, it becomes clear that receptors do not have a
single active state, but can adopt a population of different active states that induce a
variety of responses called ‘collateral efficacy’, depending on the nature of agonist or
allosteric modulator that is bound. The results obtained in this thesis extend these
concepts and suggest that the allosteric enhancer PD81,723 ‘assists’ in promoting
the active conformation of the adenosine A1R, induced by the binding of adenosine
derived agonists. In addition, the new, non-ribose agonists may promote an active
conformation of the A1R, that is subtly different in that it is not susceptible to the
action of PD81,723 and does not trigger an internalization pathway. Remarkably, this
active conformation of the A1R stabilized by these non-ribose agonists seems to
much more subtly modulate adenylyl cyclase activity, in order to explain the wide
variety of inverse agonists, partial agonists and full agonists in a series of 12
compounds with relatively small differences in R-groups. This more ‘active’
conformation may also explain the high affinities observed in this series of
compounds.
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In the future, the development of new compounds for and the mechanism involved in
´receptor-research´ will never be linear again, but will have to consider the concepts
of collateral efficacy.
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Summary
The effect of adenosine on heartbeat and arterial pressure was first described in
1929. Much later, almost 30 years ago, it became clear that certain seven
transmembrane proteins were responsible for this effect of adenosine. These
proteins belong to the large class of G protein-coupled receptors (GPCRs), a protein
class which has proven itself to be very amenable as drug targets. Four GPCRs have
been identified that recognise adenosine. All are expressed throughout the body and
each contains its own specific characteristics concerning ligand binding and signal
transduction. An introduction to the four adenosine receptors subtypes, their history
and cloning, occurrence, functioning, trafficking and therapeutic potential is given in
Chapter 1.
The process of desensitization and internalization of adenosine receptors in cell
systems, tissues and in vivo studies is described in Chapter 2. An overview of the
current literature concerning desensitization and internalization of the adenosine
receptors is given and the regulation of the different subtypes upon agonist binding is
discussed. For instance, the A1R internalizes slowly, showing a typical half-life of
several hours, while the other G i-coupled adenosine receptor (A3R) internalizes in a
matter of minutes. In addition, molecular mechanisms involved in adenosine receptor
desensitization are discussed.
In Chapter 3, human adenosine A1 receptors fused to 351Cys mutated Giα-subunits
are used as tools to study inverse agonism. In addition, the enhancing effect of the
allosteric modulator PD81,723 on agonist affinity is shown. It appeared that the
physical linking of the G i1αsubunit to the adenosine A1R in a 1:1 ratio, resulted in an
eightfold higher affinity of the reference agonist CPA. However, the affinity of the
antagonist DPCPX for the fusion protein was not affected, indicating that G protein-
coupling does not affect antagonist affinity. Although the A1R was precoupled to the
G iα-subunit, thereby shifting the receptor equilibrium to the high affinity state,
PD81,723 was still able to increase the affinity of CPA for the fusion proteins. Again,
the affinity of DPCPX for the fusion proteins was hardly affected. Na+-ions, acting as
allosteric inhibitors, were unable to decrease agonist binding to the A1-G i1α fusion
proteins, presumably because they exhibit their effect through uncoupling of the R-G
complex. Exceptions were the 351Pro and 351Arg A1-Gifusion proteins for which Na+-
ions did decrease the affinity of CPA. One may speculate that the side-chain
characteristics of these amino acids (ring structure and positive charge respectively)
may alter the conformation of the G iprotein and with it the conformation of the
fusion protein as a whole. [35S]GTPγS binding experiments showed that all A1-Gi1α
fusion proteins tested had a higher basal receptor activity, thereby providing
improved conditions to observe inverse agonism. It was also found that maximal
receptor (de)activation depended on the amino acid at position 351 of the G i1α–
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subunit. Especially the 351Cys and 351Ile mutants can be used as research tools to
investigate inverse agonism, due to their increased readout window in [35S]GTPγS 
binding experiments.
The influence of allosteric modulators on the internalization of the A1R is detailed in
Chapter 4. For that purpose, the adenosine A1R was equipped with a C-terminal
yellow fluorescent protein tag, resulting in an A1YFP receptor. The adenosine A1R
appears to internalize very slowly, a matter of hours. Upon long-term exposure (16
h), CPA was able to internalize 25% and 40% of the receptors at a concentration of
400 nM or 4μM, respectively. However, in the presence of PD81,723 a slight amount
of internalization was already obtained at 40 nM of CPA, and at 400 nM CPA 59% of
the receptors internalized, an increase of 34%. SCH-202676 on the other hand
effectively prevented CPA-induced internalization of the receptor. Recent
investigations, however, have shown that the action of SCH-202676 is irreversible
and the result of a reaction with among others cysteine residues in a protein. These
properties render SCH-202676 unsuitable as an allosteric inhibitor. Addition of either
PD81,723 or SCH-202676 alone had no effect on internalization. PD81,723 was not
able to accelerate the internalization process it was, however, able to reduce the
threshold agonist concentration at which internalization takes place.
Recently, a series of selective agonists for human adenosine A1 receptors with an
unusual structure lacking the ribose moiety of traditional adenosine-like agonists
were synthesized. The synthesis, affinity and activity of twelve of these non-ribose
ligands, all 2-amino-4-(3 and/or 4-disubstituted phenyl)-6-(substituted)sulfanyl-
pyridine-3,5-dicarbonitriles, are described in Chapter 5. Substitution at the phenyl
ring mostly dictated affinity, whereas the substitution pattern at the sulfanyl position
appeared to rather govern intrinsic activity. cAMP studies revealed that this series of
compounds contains inverse agonists, partial agonists and very potent full agonists.
It is quite remarkable to find such a great variety in potency in such a small series of
compounds. From these series, the 3,4-methylenedioxyphenyl substituted
compounds recognized two binding states/sites with a picomolar affinity for the high
affinity site. These compounds were full agonists that largely superseded the
prototypic agonist N6-cyclopentyladenosine (CPA) in affinity and potency.
Chapter 6 evaluates the characteristics of LUF6037 a representative of these 3,4-
methylenedioxyphenyl substituted compounds. LUF6037 recognized two binding
states/sites on the human adenosine A1 receptor with picomolar and nanomolar
affinity, both much higher than the reference agonist CPA. Just like CPA, LUF6037
was able to inhibit the cAMP production, although again with a much lower EC50
value (picomolar range) than CPA (nanomolar range). In addition, thermodynamic
radioligand binding experiments also classified LUF6037 as a full agonist. However,
the allosteric enhancer PD81,723 did not influence the interaction of LUF6037 with
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the receptor whereas the interaction of CPA with the receptor was affected.
Furthermore, LUF6037 did not induce internalization whereas CPA was able to
induce dose-dependent internalization of the adenosine A1 receptor. Taking these
results together, LUF6037 is a new, high affinity agonist that due the absence of
internalization inducing properties can be preferred over classical agonists like CPA
in drug treatment.
One of the other non-ribose agonists with high affinity for the A1R, LUF5834, was
chosen to be radioactively labelled. Chapter 7 describes the evaluation of
[3H]LUF5834 as a new agonist radioligand. It appeared that [3H]LUF5834 recognizes
two high-affinity binding sites with only a small difference in Kd values, occupying all
the receptor binding sites present on the cell membrane. This is a remarkable feature
for an agonist radioligand, resembling the properties of the inverse agonist/antagonist
[3H]DPCPX. Displacement experiments revealed that LUF5834 is insensitive to
PD81,723 or GTP. In addition, an ‘extra’ third site was revealed in displacement
experiments with the inverse agonist DPCPX. This extra third site represents most
probably a subdivision of the R conformation of the receptor, here named R1 and R2.
Based on these results, an extended receptor equilibrium was proposed for the
different receptor states.
Finally, in Chapter 8, general conclusions about the research described in this thesis
are drawn. These are followed by some future perspectives and suggestions for
research to be pursued, based on the interesting results obtained from this work.
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Samenvatting
Het effect van adenosine op de hartslag en bloeddruk werd voor het eerst
beschreven in 1929. Veel later, bijna 30 jaar geleden, werd duidelijk dat bepaalde
eiwitten die bestaan uit zeven transmembraan domeinen verantwoordelijk waren
voor dit effect van adenosine. Deze eiwitten behoren tot de G eiwit-gekoppelde
receptoren (GPCRs), een klasse eiwitten die zichzelf bewezen heeft als zeer
geschikte aangrijpingspunten voor geneesmiddelen. Vier GPCRs die adenosine
herkennen, zijn geïdentificeerd. Zij worden alle verspreid in het lichaam tot expressie
gebracht, en elk subtype bezit zijn eigen karakteristieken met betrekking tot ligand
binding en signaal transductie. Een introductie tot de vier adenosine receptor
subtypes, hun geschiedenis en klonering, hun voorkomen, functioneren, beweging
door de cel en therapeutische mogelijkheden wordt beschreven in Hoofdstuk 1.
Het desensitisatie- en internalisatieproces van adenosinereceptoren in celsystemen,
weefsels en in vivo studies wordt beschreven in Hoofdstuk 2. Een overzicht van de
huidige literatuur met betrekking tot desensitisatie en internalisatie van
adenosinereceptoren wordt gegeven, en de regulatie van de verschillende subtypes
na agonist binding wordt besproken. De adenosine A1 receptor (A1R) internaliseert
bijvoorbeeld langzaam, met een halfwaarde tijd van een paar uur, terwijl de andere
G i-gekoppelde receptor (A3R) internaliseert in een tijdsbestek van een paar minuten.
Tevens worden de moleculaire mechanismen die betrokken zijn bij de desensitisatie
van adenosinereceptoren besproken.
In Hoofdstuk 3 worden fusie-eiwitten tussen de adenosine A1 receptor van de mens
en 351Cys gemuteerde Giα-subunits gebruikt om invers agonisme te bestuderen.
Tevens wordt het faciliterende effect van de allostere modulator PD81,723 op de
affiniteit van de agonist aangetoond. Het bleek dat de fysieke koppeling van de Gi1α
subunit aan de adenosine A1R in een 1:1 verhouding resulteert in een 8 maal hogere
affiniteit van de referentie agonist CPA. De affiniteit van de antagonist DPCPX voor
het fusie-eiwit werd echter niet beïnvloed, wat aangeeft dat G-eiwit koppeling geen
invloed heeft op de affiniteit van antagonisten. Hoewel de A1R al gekoppeld was aan
de G i-subunit waardoor het evenwicht verschoven wordt naar de hoge
affiniteitstoestand, was PD81,723 nog steeds in staat om de affiniteit van CPA voor
de fusie-eiwitten te verhogen. Wederom werd de affiniteit van DPCPX voor de fusie-
eiwitten nauwelijks beïnvloed. Na+-ionen die zich gedragen als allostere remmers,
waren niet in staat om de agonist binding aan de A1-Gi1α fusie-eiwitten te
verminderen, waarschijnlijk omdat zij hun effect via ontkoppeling van het R-G
complex bewerkstelligen. Uitzonderingen waren de 351Pro en 351Arg A1-Gi fusie-
eiwitten waar de Na+-ionen de affiniteit van CPA verminderden. Men zou kunnen
speculeren dat de karakteristieken van de zijketens van deze aminozuren
(respectievelijk ringstructuur en positieve lading) de conformatie van het Gieiwit, en
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daarmee de conformatie van het fusie-eiwit als geheel zou kunnen veranderen.
[35S]GTPγS bindingsexperimenten lieten zien dat alle geteste A1-Gi1α fusie-eiwitten
een hogere basale receptor activiteit hadden, waardoor invers agonisme
nauwkeuriger gemeten kan worden. Ook werd gevonden dat de maximale receptor
deactivatie afhing van het aminozuur op positie 351 van het Gi1α–subunit. Vooral de
351Cys en 351Ile mutanten zijn geschikt om invers agonisme te onderzoeken dankzij
hun vergrote uitleesvenster in [35S]GTPγS bindingsexperimenten.
De invloed van allostere modulatoren op de internalisatie van de A1R is uitgewerkt in
Hoofdstuk 4. Voor dat doeleinde werd de adenosine A1R voorzien van een geel
fluorescerende eiwit aan de C-terminus, resulterend in een A1YFP receptor. De
adenosine A1R blijkt heel langzaam te internaliseren, een kwestie van uren.
Gedurende lange termijn blootstelling (16 uur), was CPA in staat om 25% en 40%
van de receptoren te internaliseren bij een concentratie van respectievelijk 400 nM of
4 M. Echter, in de aanwezigheid van PD81,723, werd al enige internalisatie
verkregen bij een concentratie van 40 nM CPA, en bij een concentratie van 400 nM
CPA internaliseerde 59% van de receptoren, een toename van 34%. SCH-202676
daarentegen voorkwam op een effectieve manier de door CPA geïnduceerde
internalisatie van de receptor, geïnduceerd door CPA. Recente onderzoeken hebben
aangetoond dat de werking van SCH-202676 onomkeerbaar is en het resultaat is
van een reactie met onder andere cysteine residuen in een eiwit. Deze
eigenschappen maken SCH-202676 ongeschikt als een allostere remmer.
Toevoeging van enkel PD81,723 of SCH-202676 had geen effect op internalisatie.
PD81,723 was niet in staat om het internalisatie proces te versnellen; maar kon wel
de kritische agonist concentratie waarbij internalisatie plaats vindt, verlagen.
Onlangs is een serie selectieve agonisten voor de adenosine A1 receptor van de
mens gesynthetiseerd met een ongewone structuur waarin de ribose groep van de
traditionele adenosine-achtige liganden ontbreekt. De synthese, affiniteit en activiteit
van twaalf van deze non-ribose liganden, alle behorende tot de 2-amino-4-(3 en/of 4-
gesubstitueerde fenyl)-6-(gesubstitueerde)sulfanyl-pyridine-3,5-dicarbonitrillen,
worden beschreven in Hoofdstuk 5.
Substitutie aan de fenylring dicteert voornamelijk de affiniteit, terwijl het
substitutiepatroon op de sulfanyl positie de intrinsieke activiteit lijkt te bepalen. cAMP
studies brachten aan het licht dat deze serie verbindingen zowel inverse agonisten,
partiële agonisten en zeer potente volle agonisten omvat. Het is nogal opmerkelijk
om zo’n grote variëteit in potentie te vinden in zo’n kleine serie verbindingen. De 3,4-
methyleendioxyfenyl gesubstitueerde verbindingen uit deze serie herkennen twee
bindingstoestanden of –plaatsen met een picomolaire affiniteit voor de hoge
affiniteitsplaats. Deze verbindingen waren volle agonisten die de klassieke agonist
N6-cyclopentyladenosine (CPA) veruit overtreffen in affiniteit en potentie.
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Hoofdstuk 6 evalueert de karakteristieken van LUF6037, een voorbeeld van een
3,4-methyleendioxyfenyl gesubstitueerde verbinding. LUF6037 herkende 2
bindingstoestanden of –plaatsen op de adenosine A1 receptor van de mens met
picomolaire en nanomolaire affiniteiten, beiden veel hoger dan de referentie agonist
CPA. Net als CPA was LUF6037 in staat om de cAMP productie te remmen, en
opnieuw met een veel lagere EC50-waarde (picomolaire schaal) dan CPA
(nanomolaire schaal). Tevens werd LUF6037 in thermodynamische radioligand
bindings experimenten gekarakteriseerd als een volle agonist. De allostere enhancer
PD81,723 beïnvloedde echter de interactie tussen LUF6037 en de receptor niet,
terwijl dat wel het geval was bij de interactie van CPA met de receptor. Verder
induceerde LUF6037 geen internalisatie terwijl CPA wel dosis-afhankelijke
internalisatie van de adenosine A1-receptor veroorzaakte. Samengevat laten deze
resultaten zien dat LUF6037 een nieuwe agonist is met een hoge affiniteit, die door
de afwezigheid van internalisatie-inducerende eigenschappen de voorkeur kan
verdienen ten opzichte van klassieke agonisten zoals CPA.
Een van de andere non-ribose agonisten met een hoge affiniteit voor de A1R,
LUF5834, werd uitgekozen om radioactief te labelen. Hoofdstuk 7 beschrijft de
evaluatie van [3H]LUF5834 als een nieuw agonistisch radioligand. Het bleek dat
[3H]LUF5834 twee hoge-affiniteits bindingsplaatsen herkent, met slechts een klein
verschil in Kd-waarden, waardoor alle receptor bindingsplaatsen op het celmembraan
bezet kunnen worden. Dit is een opmerkelijke eigenschap voor een agonistisch
radioligand, wat overeenkomt met de eigenschappen van het inverse
agonistische/antagonistische radioligand [3H]DPCPX.
Verdringingsexperimenten lieten zien dat LUF5834 ongevoelig is voor de toevoeging
van zowel PD81,723 als GTP. Bovendien werd in verdringingsexperimenten met de
inverse agonist DPCPX een ‘extra’ derde bindingsplaats aangetoond. Deze extra
bindingsplaats vertegenwoordigt hoogstwaarschijnlijk een onderverdeling van de R
conformatie van de receptor, hier R1 en R2 genoemd. Op basis van deze resultaten is
een uitgebreider evenwicht tussen verschillende receptor toestanden gepostuleerd.
Tenslotte worden in Hoofdstuk 8 algemene conclusies getrokken over het
onderzoek dat in dit proefschrift beschreven is. Deze worden gevolgd door
toekomstperspectieven en suggesties voor vervolgonderzoek, die gebaseerd zijn op
de interessante resultaten verkregen uit dit werk.
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Aan het einde van dit proefschrift rest mij nog om een heel aantal mensen te bedanken
zonder wie dit proefschrift niet tot stand was gekomen. Als eerste de mensen van de afdeling
Moleculaire Genetica: Hans, Tineke en Riekje, jullie stonden altijd voor mij klaar als ik met
technische of praktische vragen kwam, ik heb veel van jullie geleerd op het moleculair
biologische vlak. Op de afdeling Toxicology was Hans de Bont altijd stand-by als ik achter de
confocale fluorescentie microscoop zat. Dank voor de introductie in de
fluorescentiemicroscopie en de bijbehorende software. Dank ook aan Gerrit Lodder en zijn
medewerkers voor de gastvrijheid op jullie lab waar ik menig radioligand bindingsexperiment
heb gedaan. Prasad Ratnala is thanked for providing me with Sf9 insect cells, and teaching
me how to culture them. De mensen van het Nijmegen Centre of Molecular life Sciences,
UMC Nijmegen, hebben me de eerste beginselen van het maken van FastBac constructen,
baculovirussen, het infecteren van Sf9 insecten cellen en het opzetten van grote kweken
bijgebracht. Giel en Jenny, bedankt voor jullie advies en praktische hulp wanneer dat nodig
was! Henk, jouw jarenlange lab-ervaring, technisch inzicht en creatieve oplossingen hebben
een grote bijdrage geleverd aan mijn onderzoek. Zonder jouw goedgevulde
gereedschapskist hadden we vast niet zo gemakkelijk de bioreactoren in elkaar geschroefd.
Alle foto’s en handleidingen die je voor de nieuwe apparatuur gemaakt hebt zijn van
onschatbare waarde voor a-technische gebruikers zoals ik! Dat we nog steeds niet weten
waarom de A1-receptor niet functioneel gereconstitueerd kan worden, ligt zeker niet aan jouw
inzet. Verder wil ik graag alle voorgaande en huidige collega’s van de afdeling
Farmacochemie bedanken voor de zeer prettige samenwerking, collegialiteit en lol die we
samen gehad hebben. Niet alleen elkaars cellen doorzetten, de wekelijkse ‘biomeetings’ en
gezamenlijk congresbezoek horen daarbij, maar ook (strand)lablunches, sinterklaasvieringen
en labweekenden vallen wat mij betreft daaronder. Ik heb ervan genoten!
Met name wil ik hier nog mijn (snuffel)stage studenten noemen; Hester, Sophie en Gijs, jullie
hebben allen voor kortere of langere tijd, en op verschillende vlakken, een belangrijke
bijdrage geleverd aan dit proefschrift. Ik vond het in ieder geval heel leerzaam om jullie te
begeleiden bij de ‘eerste stapjes’ in de echte onderzoekswereld, en vond het leuk om jullie
enthousiasme voor het wetenschappelijk onderzoek te zien ontstaan en groeien. Sophie,
ondanks jouw aanvankelijke scepsis om in het wetenschappelijk onderzoek te blijven, vind ik
het superleuk dat je nu ook zélf AIO bent geworden in Utrecht!
De laatste paragraaf is gereserveerd voor de mensen die mijn promovendus-periode van
een wat grotere afstand gevolgd hebben, maar die zeker niet minder geïnteresseerd waren.
Vrienden van de dinnerclub, CJV-vrienden, al 5 jaar onafgebroken elke woensdag dinnerclub
met een mannetje of 12, supergeslaagde vakanties, tripjes, lol en gezelligheid, een lach en
een traan, jullie zorgden voor tijdige ontspanning. Agatha, Astrid, Anneke, Corine, Daphne,
Gijs A., Hendrine, Jan-Willem, Johan-Krijn, Mark, Martin, Peet H., Peet alias ‘VanderO’,
Pieter en Vera, a big Thank You is hier wel op zijn plaats! Ienske en Miranda, al vanaf
respectievelijk de kleuterschool en middelbare school bevriend, keep in touch!
Corine en Johan-Krijn, als zusje en broertje en als mede ‘Leiden University students’ kunnen
jullie je wellicht nog het beste een voorstelling maken van de wetenschappelijke wereld
waarin ik me bevind, en alles wat daarbij komt kijken. Dank voor de broeder- en zusterband,
die is heel bijzonder! Pa en Ma, jullie hebben altijd onvoorwaardelijk in me geloofd, me
gestimuleerd en gesteund in school en studie. Ziehier het resultaat. Jullie zijn niet alleen
‘Gouden Ouders’, maar zeker ook ‘Gouden Grootouders’! Daniël en Ruben mogen zich
bevoorrecht voelen met zulke ‘oppas-opa’s en oma’. En natuurlijk Houtzelf, de andere
oppas-opa. Jouw wekelijkse oppasdag (om half 6 opstaan, de files trotserend) heeft het
mede mogelijk gemaakt dat ik dit werk heb kunnen afronden, dank daarvoor!
Tenslotte, Gijs, waar een 10-weekse stage niet allemaal toe kan leiden…
Elisabeth
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List of Abbreviations
1-AR 1 adrenergic receptor
[3H]cAMP [3H] cyclic adenosine monophosphate
[3H]CHA [3H] N6-cyclohexyladenosine
[3H]DPCPX [3H] 1,3-dipropyl-8-cyclopentylxanthine
[3H]LUF5834 [3H] 2-amino-4-(4-hydroxyphenyl)-6-(1H-imidazol-
2ylmethylsulfanyl)-pyridine-3,5-dicarbonitrile
2HE-NECA 2-hexynyl-5'-N-ethylcarboxamidoadenosine
5-HT Serotonin, 5-hydroxytryptamine
A1R Adenosine A1 receptor
A2AR Adenosine A2A receptor
A2BR Adenosine A2B receptor
A3R Adenosine A3 receptor
ADA Adenosine deaminase
ARNO Arf nucleotide site opener
BCA Bicinchonic acid
BSA Bovine serum albumin
CADO 2-chloroadenosine
CGS21680 2-[4-(2-carboxyethyl)phenethylamino]-5’-N-
ethylcarboxamidoadenosine
CHAPS 3-[(3-Cholamidopropyl)dimethylammonio]-1-propanesulfonate
CHO cells Chinese hamster ovary cells
Cl-IB-MECA 2-chloro-N6-(3-iodobenzyl)adenosine-5’-N-methyluronamide
CPA N6-cyclopentyladenosine
CSC 8-(3-chlorostyryl)caffeine
D1R Dopamine D1 receptor
DEAE Diethylaminoethyl
DMEM Dulbecco’s modified Eagle’s medium
DPCPX 1,3-dipropyl-8-cyclopentylxanthine
GIRK-channels G protein-activated inwardly rectifying K+-channels
GPCR G protein-coupled receptor
GRK G protein-coupled receptor kinase
IB-MECA N6-(3-iodobenzyl)adenosine-5’-N-methyluronamide
Ki,H affinity for the high affinity state/site of the receptor
Ki,L affinity for the low affinity state/site of the receptor
koff Dissociation rate constant (min-1)
kon Association rate constant (nM-1 min-1)
LUF5834 2-amino-4-(4-hydroxyphenyl)-6-(1H-imidazol-2ylmethylsulfanyl)-
pyridine-3,5-dicarbonitrile
LUF6037 2-amino-4-(benzo-[1,3]-dioxol-5-yl)-6-(2-hydroxy-propylsulfanyl)-
pyridin-3,5-dicarbonitrile
MRS 1523 3-propyl-6-ethyl-5-[(ethylthio)carbonyl]-2 phenyl-4-propyl-3-
pyridine carboxylate
MRS 1706 N-(4-acetylphenyl)-2-[4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-
dipropyl-1H-purin-8-yl)phenoxy]acetamide
NECA 5’-N-ethylcarboxamidoadenosine
PD81,723 (2-Amino-4,5-dimethyl-3-thienyl)-[3-
(trifluoromethyl)phenyl]methanone
PKA Protein kinase A
R-PIA (R)-N6-(2-Phenylisopropyl)adenosine
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Sf9 cells Spodoptera frugiperda cells
YFP yellow fluorescent protein
ZM 241385 (4-(2-[7-amino-2-(2-furyl {1,2,4}-triazolo {2,3-a {1,3,5}triazin-5-yl-
aminoethyl)phenol
